checkAd

    Abattis Bioceuticals -- warum nicht - 500 Beiträge pro Seite

    eröffnet am 16.03.14 13:59:39 von
    neuester Beitrag 16.09.18 01:32:17 von
    Beiträge: 355
    ID: 1.192.483
    Aufrufe heute: 0
    Gesamt: 173.830
    Aktive User: 0

    ISIN: CA00258G1037 · WKN: A1XCMU · Symbol: ATTBF
    0,0000
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 15:02:02 Nasdaq OTC

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    3,1100+804,86
    3,1000+90,18
    1,0800+69,01
    4,9300+45,00
    0,9500+34,94
    WertpapierKursPerf. %
    2,1000-18,92
    0,7603-23,97
    5,2550-29,46
    2,0400-35,44
    3,5100-46,00

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 16.03.14 13:59:39
      Beitrag Nr. 1 ()
      warum kennt die keiner
      2 Antworten
      Avatar
      schrieb am 16.03.14 16:12:15
      Beitrag Nr. 2 ()
      Antwort auf Beitrag Nr.: 46.638.913 von Hoffnungstraeger am 16.03.14 13:59:39Hallo,

      was is`n der Grund für den leichten Anstieg ??
      Avatar
      schrieb am 21.03.14 21:01:21
      Beitrag Nr. 3 ()
      Antwort auf Beitrag Nr.: 46.638.913 von Hoffnungstraeger am 16.03.14 13:59:39Du kanntest sie ja selbst bis zuletzt nicht, sonst hättest ja schon längst mal was posten können. Anfang März war hier noch keiner, hab immer geschaut.

      lg tz:eek::eek::eek:
      Avatar
      schrieb am 21.03.14 21:10:40
      Beitrag Nr. 4 ()
      Anfang Januar hab ich mal eine Mail bekommen, da wurde dieser Titel erwähnt.
      Kann aber leider nicht mehr nachvollziehen woher/von wem.

      Dachte noch, so ein Sch...!
      Hab dann auf die Watchliste gestellt und wieder vergessen.
      Erst Anfang März habe ich den Anstieg bemerkt, zu Spät!!!

      Viel Glück noch mit dem Teil.:laugh::laugh::laugh:

      lg tz
      Avatar
      schrieb am 21.03.14 21:25:53
      Beitrag Nr. 5 ()
      warum kennt keiner diese aktie??:laugh:

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 24.03.14 22:03:01
      Beitrag Nr. 6 ()
      Hab die am 16.01. auf Watch gesetzt. Jetzt sehe ich ein Plus von 2871%!!! Wieso das denn? Mit 0,07$ reingenommen....
      1 Antwort
      Avatar
      schrieb am 25.03.14 23:09:16
      Beitrag Nr. 7 ()
      Antwort auf Beitrag Nr.: 46.692.743 von schnorps01 am 24.03.14 22:03:01Salute:

      Am 07.01. mit Kurs von 0,017 habe ich die auf Watchlist eingestellt.
      Ist krass,oder? Wahnsinn!!!

      Naja was solls. Nachtrauern nutzt nichts mehr.
      So ne Gelegenheit bekommste nicht alle Tage.

      lg tz.:eek:
      Avatar
      schrieb am 27.03.14 12:37:42
      Beitrag Nr. 8 ()
      Da diese super-news bislang noch keine Beachtung fanden:

      Press Releases

      Mar 24, 2014
      Canadian Federal Court Judge's MMPR Injunction Very Positive for Abattis.

      Vancouver, BC -- March 24, 2014 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), is pleased to comment on Canadian Federal judge Justice Michael D. Manson's ruling on March 21, 2014.

      A Federal Court judge issued an injunction Friday that exempts currently licensed marijuana users and producers from the incoming Marihuana for Medical Purposes Regulations ("MMPR"), set to take effect on April 1. This means that people with existing Authorization to Possess, Designated-person Production, or Personal-use Production licenses issued under the old rules will still be permitted to possess and/or grow medical marijuana past April 1.

      This recent development is very positive for Abattis and underscores the value and effectiveness of the Company's integrated and diversified business model. Abattis believes this injunction will allow the Company to:

      Accelerate the execution of its business plan;
      Enhance near-term cash flow potential;
      Demonstrate the value of its integrated and diversified "GDERS" business model;
      Further strengthen its position as the leading legal marijuana company; and
      More quickly realize value for shareholders.

      Abattis currently has access to several licenses issued under the Marihuana Medical Access Regulations ("MMAR") that were going to expire April 1. These licenses can now be kept active and potentially transferred to Abattis facilities with pending MMPR license applications enabling the Company to grow and sell medical marijuana sooner than first planned. The Company will also be able to demonstrate the efficiency of the Abattis Biocube Green Grow Systems by utilizing them at these facilities. Additionally, Abattis' newly acquired Natures Juice organic feed products will continue to be consumed by existing growers. Finally, the Company now anticipates a quicker roll out of its Canadian lab and testing facilities as well as its nationwide medical marijuana pharmacy model.

      Abattis' "GDERS" (Grow, Dry, Extract, Refine, Science/Sell) business model was designed to provide the Company and its shareholders with the most diversified exposure to the burgeoning legal marijuana business as possible. While companies focused solely on the production of medical marijuana in Canada will likely be negatively impacted by Friday's ruling, Abattis stands to benefit significantly.

      "It looks like Canada now has two systems operating at a Federal level. This is a best case scenario for Abattis as we had the foresight and good fortune to structure our business in a way that capitalizes on both this new ruling and the MMPR." stated Mike Withrow, CEO of Abattis Bioceuticals Corp. He went on to say, "Abattis was designed to be one of the only companies that can operate across multiple business lines in several international markets and now we can start legally growing in Canada earlier than expected. We have some of the top analysts working with us to ensure safety, consistency and innovation in all of our products."

      About Abattis Bioceuticals Corp.

      Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions. For more information, visit the Company's website at www.abattis.com.

      For further information, contact the Company's CEO, Michael Withrow at:
      (778) 896-6536 or 1-872-701-5589 or at mike.withrow@abattis.com.
      Avatar
      schrieb am 27.03.14 12:46:06
      Beitrag Nr. 9 ()
      ...und noch ein guter Video-Beitrag....Interview mit dem CEO:


      http://vimeo.com/87492300
      Avatar
      schrieb am 28.03.14 16:08:41
      Beitrag Nr. 10 ()
      Jetzt geht's los!

      Kräftiger Anstieg in den USA.

      Deutschland wird nachziehen.

      Die positiven Aussichten für den 01.04. stehen bevor *freu* :D
      Avatar
      schrieb am 28.03.14 17:36:23
      Beitrag Nr. 11 ()
      die:) bringt echt spass
      Avatar
      schrieb am 09.04.14 08:03:55
      Beitrag Nr. 12 ()
      Liebe Formusgäste, da hier ja bislang noch recht wenig Beteiligung vorherrscht, möchte ich auf die amerikanische Seite verweisen und die dort regen Beiträge:

      http://investorshub.advfn.com/Abattis-Bioceuticals-Corp-ATTB…

      Die Aktie sollte nun durchstarten
      Avatar
      schrieb am 11.04.14 18:20:34
      Beitrag Nr. 13 ()
      Avatar
      schrieb am 14.04.14 17:07:30
      Beitrag Nr. 14 ()
      Avatar
      schrieb am 10.06.14 12:15:38
      Beitrag Nr. 15 ()
      1 Antwort
      Avatar
      schrieb am 30.06.14 17:30:33
      Beitrag Nr. 16 ()
      Antwort auf Beitrag Nr.: 47.129.724 von Maschiman am 10.06.14 12:15:38Die Aktie scheint wieder an Fahrt aufzunehmen ...
      Meiner Meinung nach ist jetzt ein guter Zeitpunkt einzusteigen.

      Eine wichtige Informationsquelle für alle bei Abattis Bioceuticals Corp. (ATTBF) investierten ist der Twitter-Account von Abattis
      Link: https://twitter.com/Abattis

      Avatar
      schrieb am 30.06.14 17:42:18
      Beitrag Nr. 17 ()
      Industry Spotlight - Medicinal Marijuana and Canadian Capital Markets
      Newsletter - June 24, 2014 Edition
      (Abattis Bioceuticals Corp. (ATTBF) führt die im folgendem Artikel beschriebene 'Gruppe B' an.)

      Link: http://foundationmarkets.com/index.php?option=com_content&vi…
      Avatar
      schrieb am 01.07.14 23:00:32
      Beitrag Nr. 18 ()
      Ich denke auch, dass wir nun wieder zu alten Höhen (2$) und zu neuen aufbrechen könnten.

      Lasst uns die daumen drücken.

      Ansonsten ist folgendes Board sehr lebhaft:

      http://investorshub.advfn.com/Abattis-Bioceuticals-Corp-ATTB…
      Avatar
      schrieb am 01.07.14 23:05:48
      Beitrag Nr. 19 ()
      Mein Tipp zu den positiven letzten Tagen ist, das wahrscheinlich nun die Lizenzen für ATTBF erteilt werden könnten.
      Avatar
      schrieb am 02.07.14 13:02:00
      Beitrag Nr. 20 ()
      Abattis Bioceuticals Mentioned as Top Cannabis Pick

      Link: http://www.cannabisfn.com/abattis-bioceuticals-mentioned-as-…

      Link: http://www.cannabisfn.com/mdc/abattis-bioceuticals-corp/



      For more information, visit the Company’s website at www.abattis.com.
      Avatar
      schrieb am 03.07.14 09:57:25
      Beitrag Nr. 21 ()
      Correction To Earlier News:
      Abattis Names Brazos Minshew The Next President Of Biocell

      " ... The word APPLICATION was mistakenly omitted. Investors should not trade on any expectation or belief that Biocell Labs has an MMPR license ... "

      Quelle: http://finance.yahoo.com/news/correction-earlier-news-abatti…
      1 Antwort
      Avatar
      schrieb am 03.07.14 16:43:12
      Beitrag Nr. 22 ()
      Antwort auf Beitrag Nr.: 47.252.256 von webmimi am 03.07.14 09:57:25Abattis (ATTBF) Names Brazos Minshew The Next President Of Biocell
      Vancouver, BC / ACCESSWIRE / July 02, 2014

      Link: http://online.wsj.com/article/PR-CO-20140702-911286.html#

      Weitere Links zur Person Brazos Minshew:
      https://www.facebook.com/brazos.minshew

      Avatar
      schrieb am 03.07.14 16:50:56
      Beitrag Nr. 23 ()
      Wie der Staat Millionen mit Drogen verdienen kann
      3. Juli 2014, 16:06 Uhr
      Die Legalisierung von Cannabis ist das Ende des Abendlandes - unkten jedenfalls die Gegner der Freigabe im US-Bundessstaat Colorado. Nun, ein halbes Jahr später, herrscht dort eitel Sonnenschein ...

      Link: http://www.stern.de/politik/ausland/nachricht-nach-zahlen-wi…
      Avatar
      schrieb am 05.07.14 21:53:42
      Beitrag Nr. 24 ()
      :eek: ... NEWS werden über den Abattis-Twitter-Account für übermorgen, Montag den 7. Juli angekündigt :

      Abattis Bioceuticals‏@Abattis - 07:05 - 5. Juli 2014
      Abattis Bioceuticals@Abattis@picksharkattack@curiousbuild
      "... first news coming on Monday stage 1 then QX Shortly after that ..."


      Quelle: https://twitter.com/Abattis/status/485424256793063424

      Avatar
      schrieb am 05.07.14 21:56:46
      Beitrag Nr. 25 ()
      Abattis annouces Phytalab CSO presents at 24th annual ICRS meeting in Italy
      Jul 03, 2014 - OTC Disclosure & News Service

      Link: http://www.otcmarkets.com/stock/ATTBF/news?id=83979
      Avatar
      schrieb am 06.07.14 20:59:53
      Beitrag Nr. 26 ()
      Bin gespannt auf den morgigen Tag und die Nachrichten die da kommen werden !

      Siehe auch:
      https://twitter.com/Abattis/status/485424256793063424



      Abattis Bioceuticals - Corporate Presentation:

      http://www.abattis.com/s/presentations.asp

      http://www.abattis.com/i/pdf/Abattis-May-2014.pdf
      Avatar
      schrieb am 07.07.14 14:23:18
      Beitrag Nr. 27 ()
      CANNABIS ANBAU IN EUROPA! (DOKU 2014)

      Avatar
      schrieb am 07.07.14 21:59:43
      Beitrag Nr. 28 ()
      Heute 12,xx % in den Staaten.
      Seit Tagen sehen wir kräftiges grün.

      Gerüchte von 1$ und mehr zum WE werden laut.

      Es tut sich was und mit Glück explodiert der Kurs alsbald. :)
      1 Antwort
      Avatar
      schrieb am 08.07.14 12:55:39
      Beitrag Nr. 29 ()
      Antwort auf Beitrag Nr.: 47.273.886 von Maschiman am 07.07.14 21:59:43Maschiman, das würde mich nicht wundern ... !
      Nach der Legalisierung von Marihuana in Colorado und Washington State (erlaubter, freier Verkauf von Marihuana in zertifizierten und staatl. kontrollierten Geschäften) haben weiter 23 US-Bundesstaaten es vorerst für die ausschliesslich medizinische Anwendung erlaubt - man spricht hier über das sog. MMJ = "Medical Marijuana".
      Weitere Bundesstaaten streben, wie bereits Colorado und Washington State, eine totale Legalisierung an.
      Zu diesen Anwärtern gehören Alaska, Oregon und der District of Columbia.
      Andere Staaten werden wohl bald zu den MMJ-Staaten dazu kommen, nämlich Florida und New York.
      Das bedeutet also, dass es in absehbarer Zeit in 5 US-Bundesstaaten möglich sein wird völlig frei und legal Marihuana zu kaufen und in knapp der Hälfte aller US-Bundesstaaten das "Medical Marijuana" als legales Medikament zugelassen sein wird.
      Der MMJ-Zug nimmt deutlich an Fahrt auf. Das grosse Geschäft mit dieser einmaligen Pflanze hat definitiv begonnen ... :) ...

      Who's Next? Pot Changes Won't Stop With Washington
      abc-news - SALEM, Ore. — Jul 8, 2014, 2:17 AM ET
      Link: http://abcnews.go.com/US/wireStory/pot-stop-washington-24461…
      Avatar
      schrieb am 11.07.14 13:11:27
      Beitrag Nr. 30 ()
      :eek::eek::eek: RIESENMONSTER NEWS :eek::eek::eek:
      ABATTIS WURDE UPGELISTET UND WIRD JETZT AUF DER OTCQX INTERNATIONAL GEHANDELT !!!

      Damit setzt sich diese Firma klar von vielen anderen Marihuana-Stocks ab !!!
      Die Abattis Bioceuticals Corp. spielt jetzt in der gleichen Liga wie adidas, DANONE, Deutsche Telekom usw... !!!


      Quelle:
      http://www.otcmarkets.com/stock/ATTBF/quote


      Zur Erklärung was OTCQX International bedeutet:

      The Best Marketplace with Qualified Companies

      The OTCQX® marketplace offers the best informed and most efficient trading for U.S. and global companies. To qualify for the OTCQX marketplace, companies must meet high financial standards, be current in their disclosure, and be sponsored by a professional third-party advisor. OTCQX ensures that investors have the information necessary to intelligently analyze, value and trade securities.

      Who Should Join OTCQX International?

      Reserved for global companies to trade their ADRs or foreign ordinary securities listed on a qualified non-U.S. stock exchange, OTCQX International allows companies to establish a secondary marketplace for U.S. investors but without the duplicative regulatory requirements of a U.S. exchange listing. Companies on OTCQX may use their home country disclosure in English in lieu of SEC reporting. This requirement helps ensure that only the most shareholder-focused companies already approved by a qualified international stock exchange's listing process are eligible.

      All companies appoint a qualified, third-party investment bank or attorney Principal American Liaison (PAL) sponsor to help with the admission process, post disclosure in English, and act as a trusted resource for all their investor information needs and U.S. market protocols.

      Keeping Good Companies in Good Company

      The OTCQX marketplace serves the unique needs of some of the world’s most successful, liquid, and recognized companies. Companies on OTCQX signal to investors that they are committed to maintaining high quality financial and operating standards.

      OTCQX: ADDYY
      OTCQX: COSWF
      OTCQX: DANOY
      OTCQX: DTEGY
      OTCQX: RHHBY

      Company Benefits on the OTCQX Marketplace

      Accepts home-country reporting in lieu of SEC reporting
      Provides an efficient and cost-effective alternative to NYSE or NASDAQ for publicly traded companies
      Reaches a larger group of U.S. institutional investors who can buy OTCQX securities through the broker of their choice
      Ensures that company disclosure is readily available in the U.S. to investors
      Facilitates increased liquidity
      Identifies the most reputable companies to help investors make informed trading decisions
      Key Highlights About the OTCQX Marketplace*

      300+ world-class companies
      $1.7 Trillion in market capitalization
      $29.5 Billion in annual dollar volume
      $78 Million in average annual dollar volume per security
      *As of December 31, 2013

      Trade Through OTC Link® ATS – The system of choice

      OTC Link® ATS is an SEC registered Alternative Trading System for broker-dealer subscribers to provide investors with an electronic trading experience nearly identical to that of trading a security on NYSE or NASDAQ. OTC Link® ATS directly links a diverse network of leading U.S. broker-dealers that provide liquidity and execution services for a wide spectrum of U.S. and global securities. Its real-time price transparency and connectivity offers broker-dealers control of trades and choice of counterparties so that they can efficiently provide best execution, attract order flow, and comply with FINRA and SEC regulations.

      In addition, investors in all OTCQX companies may view the full market-depth of their stock free of charge on www.otcmarkets.com through the Real-Time Level 2 Quote Display Service.

      OTC Link® ATS is operated by OTC Link LLC, a FINRA member broker-dealer and wholly owned subsidiary of OTC Markets Group Inc.

      Next: OTCQX International Qualification Standards»
      Avatar
      schrieb am 11.07.14 18:49:55
      Beitrag Nr. 31 ()
      Das waren dann die Anzeichen der letzten Tage ;)
      Jetzt geht es endlich richtig los. :)
      Avatar
      schrieb am 12.07.14 14:13:06
      Beitrag Nr. 32 ()
      9 STATES Which Will Probably LEGALIZE MARIJUANA This Year
      Link: http://www.secretsofthefed.com/9-states-will-probably-legali…
      Avatar
      schrieb am 15.07.14 17:11:49
      Beitrag Nr. 33 ()
      Avatar
      schrieb am 17.07.14 14:54:08
      Beitrag Nr. 34 ()
      Keine Sorge vor den kleinen Rücksetzern. Langfristig muss es einfach uuup gehen. :)
      Avatar
      schrieb am 17.07.14 16:19:57
      Beitrag Nr. 35 ()
      :look: Twitter-News:
      Abattis Bioceuticals‏@Abattis
      Biocube Walls Being Received at Abattis Squamish BC Facility
      Link: https://twitter.com/Abattis/status/489770067899719680/photo/…
      Avatar
      schrieb am 22.07.14 10:41:17
      Beitrag Nr. 36 ()
      wir haben es bald geschafft aus der pump&dump Schiene heraus zu kommen. Bei dem Erhalt der Lizenzen wird der Kurs lediglich up gehen.
      1 Antwort
      Avatar
      schrieb am 23.07.14 12:55:09
      Beitrag Nr. 37 ()
      Abattis Announces Grant of Stock Options

      Vancouver, BC / ACCESSWIRE / July 22, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATTBF) (CSE:ATT), the Company is pleased to announce that, in compliance with the Company's option plan, the Company has granted 2,438,100 incentive stock options to certain of its directors, officers and consultants, with each option being exercisable into a common share of Abattis at $0.64 per share for a period of five years.

      Link: http://finance.yahoo.com/news/abattis-announces-grant-stock-…
      Avatar
      schrieb am 23.07.14 13:25:50
      Beitrag Nr. 38 ()
      Antwort auf Beitrag Nr.: 47.349.866 von Maschiman am 22.07.14 10:41:17Ganz Deiner Meinung ! Ich glaube auch dass die Aktie schon bald bei 1 $ stehen wird :yawn:


      Avatar
      schrieb am 24.07.14 16:56:54
      Beitrag Nr. 39 ()
      NEU - Abattis Bioceuticals (ATTBF) auf stockwiki.org

      Link: http://stockwiki.org/index.php/ATTBF




      Quelle:
      http://stockwiki.org
      https://twitter.com/Stock_Wiki
      Avatar
      schrieb am 24.07.14 17:13:55
      Beitrag Nr. 40 ()
      NEU - Abattis Bioceuticals (ATTBF) aufschlussreiches Informationsvideo





      Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) capitalizing on the growing trend toward marijuana legalization in the US and Canada by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and marketing support to licensed growers.

      Abattis Bioceuticals Corp. is a fully integrated bioceutical company that cultivates, extracts, develops and markets proprietary, natural health and wellness products derived from Cannabis that address unmet health and wellness needs of its customers through targeted nutritional and medicinal support.
      Abbattis is a publicly traded company listed on the US OTC under ticker (ATTBF) and on the Canadian CSE under symbol (ATT).

      To learn more about Abattis, please visit the Company's website at:

      http://www.abattis.com
      http://www.abattis.com/s/news.asp
      http://www.abattis.com/s/our_companies.asp
      http://www.abattis.com/s/our_partners.asp
      http://www.abattis.com/s/gders.asp
      Avatar
      schrieb am 25.07.14 13:29:54
      Beitrag Nr. 41 ()
      There Is No Doubting The Health Benefits of Cannabis

      Interessant und sehenswert !
      Link: http://www.frequency.com/video/there-is-no-doubting-health-b…
      Avatar
      schrieb am 28.07.14 12:02:40
      Beitrag Nr. 42 ()
      New York Times für Cannabis-Freigabe

      "Pass me the paper" bekommt an diesem Wochenende eine ganz andere Bedeutung. Denn die Leser der "New York Times" dürften nicht schlecht gestaunt haben, dass das Blatt die Legalisierung von Marihuana fordert - mit Verweis auf die Geschichte ...

      Link: http://www.n-tv.de/panorama/New-York-Times-fuer-Cannabis-Fre…

      Avatar
      schrieb am 28.07.14 12:09:13
      Beitrag Nr. 43 ()
      The Public Lightens Up About Weed
      By Juliet Lapidos - JULY 26, 2014 - The New York Times

      Link: http://www.nytimes.com/2014/07/27/opinion/sunday/high-time-t…

      Avatar
      schrieb am 28.07.14 12:27:59
      Beitrag Nr. 44 ()
      PART 1.1 - Let States Decide on Marijuana
      By David Firestone - JULY 26, 2014 - The New York Times

      Link: http://www.nytimes.com/2014/07/27/opinion/sunday/high-time-l…



      PART 1.2 - Repeal Prohibition, Again
      By THE EDITORIAL BOARD - JULY 26, 2014 - The New York Times

      http://www.nytimes.com/interactive/2014/07/27/opinion/sunday…






      Fortsetzungen werden folgen:
      PART 2 - Criminal Justice - July 29, 2014
      PART 3 - History - July 30, 2014
      PART 4 - Health - Aug. 1, 2014
      PART 5 - Track Records - Aug. 3, 2014
      PART 6 - Regulation - Aug. 5, 2014
      Avatar
      schrieb am 30.07.14 16:39:29
      Beitrag Nr. 45 ()
      Interview mit Frau Dr. Michele Sexton.
      Dr. Sexton ist die Gründerin von Phytalab, das erste Canabis-Analyse-Labor in Washington State.
      Die Firma Phytalab gehört zu 51 % Abattis und ist Teil der Firmenstrategie in möglichst vielen Bereichen des neuen MMJ-Marktes zu agieren (sh. auch http://www.abattis.com/s/our_partners.asp ).

      Link: http://thehash.org/2014/07/dr-michele-sexton/

      Avatar
      schrieb am 31.07.14 11:17:05
      Beitrag Nr. 46 ()
      Bin hier auch rein und hoffe auf eine gute entwicklung.
      1 Antwort
      Avatar
      schrieb am 31.07.14 15:55:47
      Beitrag Nr. 47 ()
      Antwort auf Beitrag Nr.: 47.405.888 von Piet_Houston am 31.07.14 11:17:05Und mit Dir kam auch schon zugleich eine gute Nachricht "ins Haus geflattert" :yawn:

      Abattis (ATTBF) Sub-Licenses Vertical Grow Systems to Biocube
      Vancouver, BC / ACCESSWIRE / July 31, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), today announced that it has entered into a sub-licensing agreement with its subsidiary, Biocube Green Grow Systems Corp. ("Biocube"), for the non-exclusive use of Vertical Design Ltd.'s ("VDL") vertical growing systems for which Abattis owns certain exclusive worldwide rights.

      Link: http://online.wsj.com/article/PR-CO-20140731-911363.html#



      Siehe auch: http://www.cannabisfn.com/abattis-bioceuticals-full-spectrum…
      und: http://www.abattis.com/s/our_companies.asp
      Avatar
      schrieb am 31.07.14 19:32:52
      Beitrag Nr. 48 ()
      Lach.....wenn sich gute Nachrichten durch mich auch in steigende Kurse verwandeln, dann kann ja nichts schief gehen :-)
      Avatar
      schrieb am 01.08.14 03:09:09
      Beitrag Nr. 49 ()
      Wo bleiben die neuen MMJ-Lizenzen ?

      Sehr interessante Podcast-Interviews mit den MMPR Beratern (Marihuana for Medical Purposes Regulations) George Routhier und Ivan Ross. Beide Berater helfen und begleiten Firmen beim Prozess der Antragstellung etc.
      George Routhier (sh. Interview Nr. 1) spricht von bereits über 700 Antragstellern (sh. 02:01).
      Er meint das Health Canada in den letzten 60 Tagen erst 1 neuen Antrag bewilligt hat (sh. 02:32) :eek: und das in diesem Jahr insgesamt nur etwa 25 bis 30 weitere Antragsteller eine Lizenz erhalten werden (sh. 14:24) !
      Somit liegen die Chancen der Antragsteller noch in diesem Jahr eine Lizenz zu ergattern bei etwa 1 : 25 :rolleyes: !

      Where’s The Canadian Medical Marijuana Licenses ?
      July 31, 2014 | midasletter.com

      Link: http://www.midasletter.com/2014/07/wheres-canadian-medical-m…

      Avatar
      schrieb am 01.08.14 11:04:23
      Beitrag Nr. 50 ()
      Warum gehts gen Süden bei den doch recht positiven News?
      Avatar
      schrieb am 01.08.14 14:03:32
      Beitrag Nr. 51 ()
      Avatar
      schrieb am 05.08.14 11:45:31
      Beitrag Nr. 52 ()
      Avatar
      schrieb am 05.08.14 16:24:26
      Beitrag Nr. 53 ()
      1 Antwort
      Avatar
      schrieb am 05.08.14 18:33:16
      Beitrag Nr. 54 ()
      Antwort auf Beitrag Nr.: 47.435.590 von Maschiman am 05.08.14 16:24:26Ja, das ist eine super news !

      Abattis Enters Into US$5 Million Standby Equity Purchase Agreement with Kodiak Capital Group, LLC
      Vancouver, BC / ACCESSWIRE / August 5, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX:ATTBF - News) (CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, including medical marihuana, announced that it has entered into a US$5 million standby equity financing agreement with Kodiak Capital Group, LLC, a Newport Beach, CA-based institutional investor. The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC") covering the Abattis shares that may be issued to Kodiak under this financing. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of one year to sell up to US$5 million of common shares to Kodiak.

      Link: http://www.abattis.com/s/news.asp?ReportID=667972
      Avatar
      schrieb am 06.08.14 11:16:59
      Beitrag Nr. 55 ()
      Super News und de Kurs rauscht gen Norden :-(
      Avatar
      schrieb am 06.08.14 16:18:44
      Beitrag Nr. 56 ()
      Der Kurs folgt augenscheinlich keinen rationalen Gesetzen.
      jedoch liegt er aktuell bei +10%.
      Wenn es nach oben geht, dann setze ich darauf, dass es einem Raketenstart gleichen wird.
      Avatar
      schrieb am 09.08.14 14:25:37
      Beitrag Nr. 57 ()
      Abattis Appoints Jason Anderson as VP of Finance

      Vancouver, BC / TNW-ACCESSWIRE / August 8, 2014 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services to medicinal markets in North American, today announced the appointment of Jason Anderson, CA, CFA as Vice President of Finance.

      Linkt: http://thenewswire.ca/archives?tnwarchive2=release_id%3D1292…
      Avatar
      schrieb am 09.08.14 14:27:05
      Beitrag Nr. 58 ()
      The Abattis Report - August 2014

      Avatar
      schrieb am 13.08.14 15:47:28
      Beitrag Nr. 59 ()
      Nagelt mich nicht darauf fest, aber ich glaube, dass jetzt der perfekte Kurs zum Nachkaufen ist.
      Avatar
      schrieb am 14.08.14 14:18:25
      Beitrag Nr. 60 ()
      twitter-accounts von Abattis und PHYTALAB

      Link: https://twitter.com/Abattis

      Link: https://twitter.com/phytaLab

      Avatar
      schrieb am 14.08.14 15:31:13
      Beitrag Nr. 61 ()
      Abattis Announces Grant of Stock Options

      Vancouver, BC / ACCESSWIRE / August 13, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX:ATTBF - News) (CSE:ATT), the Company is pleased to announce that, in compliance with the Company's option plan, the Company has granted 455,000 incentive stock options to certain of its directors, officers and consultants, with each option being exercisable into a common share of Abattis at $0.43 per share for a period of five years.

      Link: https://ca.finance.yahoo.com/news/abattis-announces-grant-st…
      Avatar
      schrieb am 14.08.14 20:19:03
      Beitrag Nr. 62 ()
      Medical Marijuana Update: Going deeper on AFI (Affinor Growers) and ATT (Abattis)

      Link: http://www.stockhouse.com/news/newswire/2014/08/13/medical-m…

      Avatar
      schrieb am 18.08.14 17:24:26
      Beitrag Nr. 63 ()
      5 States (And One City) Ready to Legalize Marijuana
      AUGUST 17, 2014
      Here are six states that are the closest to legalizing marijuana for recreational use in the near future, hot on the heels of Washington and Colorado.

      Link: http://wallstcheatsheet.com/politics/5-states-and-one-city-r…
      Avatar
      schrieb am 19.08.14 16:39:21
      Beitrag Nr. 64 ()
      Leafly State of the Leaf Cannabis Infographic

      Link: http://www.leafly.com/news/headlines/leafly-state-of-the-lea…

      Avatar
      schrieb am 20.08.14 02:27:29
      Beitrag Nr. 65 ()
      weedco Power Rankings - :look: - Abattis auf dem 4. Platz

      4. ABATTIS BIOCEUTICALS (CSE:C.ATT, Stock Forum): Abattis has been pretty quiet over the last few months after a rip-roaring $2+ start to proceedings, and that’s seen their share price settle at around $0.50 five months later. Abattis is my vertical integration play of choice, as they have so many moving parts, you almost feel like at least one of those has to pop as a genuine profitmaker. Between Biocube Grow Systems, Phytalab, iJuana Cannabis, Experion Technologies, Biocell Labs, Instant Payment Systems, North American BioExtracts and Northern Vine, the catch for Abattis will be getting all the parts to work well together and not just bleed capital. That said, they’ve got plenty of assets that can be flipped for cash when and if needed. I’ve touted them as a legitimacy play for a long time and I’m sensing activity on the horizon. Time to watch hard.

      Link: http://www.stockhouse.com/news/newswire/2014/08/19/medical-m…
      Avatar
      schrieb am 20.08.14 14:10:50
      Beitrag Nr. 66 ()
      Avatar
      schrieb am 24.08.14 21:17:35
      Beitrag Nr. 67 ()
      Buying ATTBF stock (Abattis Bioceuticals) before the reversal?
      The charts are speaking

      August 15, 2014 - 420 Stock Talk - ATTBF

      Technical analysis is one of those touchy subjects that can get you in trouble if you don’t plan your buying or trading carefully. That’s especially true when dealing with marijuana penny stocks.

      But every candlestick tells a story, even with highly volatile stocks. Let us not forget that. And there may be a couple good omens for current ATTBF stock holders and for investors sitting on the sidelines wondering when they should take a long position in Abattis Bioceuticals.

      Link: http://www.420stocktalk.com/buying-attbf-stock-abattis-bioce…

      Let’s go to the charts for some insight, shall we?

      Avatar
      schrieb am 28.08.14 16:47:50
      Beitrag Nr. 68 ()
      :eek:
      Habe diese Nachricht soeben gelesen ...
      Link: https://twitter.com/SmokingAlpha
      1 Antwort
      Avatar
      schrieb am 29.08.14 12:39:39
      Beitrag Nr. 69 ()
      Antwort auf Beitrag Nr.: 47.636.040 von webmimi am 28.08.14 16:47:50420 Investor Conversation with Dr. Michelle Sexton

      Abattis Bioceuticals (ATTBF) owns a 51% stake in Washington-based PhytaLab, which is awaiting certification approval (on a provisional basis). Dr. Michelle Sexton is the CSO and acting CEO of PhytaLab. The conversation covered Dr Sexton's background, the nature of PhytaLab, how Dr. Sexton connected with Abattis and the nature of their partnership, the certification process, the competitive landscape and the issues surrounding geographic expansion. The conversation was about 17 minutes.
      For more info on PhytaLab: http://phytalab.com/

      Link: http://marketfy.com/content/54674-420-investor-conversation-with-dr-michelle-sexton
      Link: https://twitter.com/Abattis

      Avatar
      schrieb am 02.09.14 01:08:51
      Beitrag Nr. 70 ()
      The Abattis Report - August 2, 2014




      The Abattis Report - August 22, 2014

      Avatar
      schrieb am 04.09.14 17:16:41
      Beitrag Nr. 71 ()
      "…in March of last year Canadian company Abattis announced plans
      to bring a CBD-infused kombucha drink to market."


      Siehe dazu folgende Links:
      http://www.foodpolitics.com/2014/09/industrial-hemp-squishy-…
      http://www.huffingtonpost.com/2014/09/03/drinkable-marijuana…
      http://www.fooddrink-magazine.com/index.php/articles/produce…
      Avatar
      schrieb am 08.09.14 16:49:20
      Beitrag Nr. 72 ()
      :rolleyes: :yawn: :eek: :D:p :laugh: !!! NEWS OUT !!! :rolleyes: :yawn: :eek: :D:p :laugh:

      Sep 08, 2014
      Abattis' Phytalab Receives Cannabis Lab Certification In Washington

      Vancouver, BC – September 8th, 2014 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, today announced that Phytalytics LLC. ("Phytalab.com"), its 51% controlled US subsidiary, has received provisional certification from the Washington State Liquor Control Board. This milestone enables the lab to legally offer service to the new legal Cannabis industry.

      Link: http://www.abattis.com/s/news.asp?ReportID=673154



      About www.Phytalab.com

      Phytalab is PhytaLAB is the original Washington Cannabis testing facility setting the standard for Good Laboratory Practice in the Cannabis industry. We come to this industry with extensive herbal product experience. We offer a range of services for growers, producer/processors and retail facilities and provide data on which to base informed business decisions. Our background in Botanical Medicine puts us first when you are looking for help in product development for specific plant chemotypes and standardization for reproducibility and efficacy. PhytaLAB offers consulting services to both business and regulatory entities. We can help with questions around methods, safety, packaging and labeling, and more. Please contact us for our unrivaled expertise.
      Avatar
      schrieb am 08.09.14 17:31:38
      Beitrag Nr. 73 ()
      Hier der Link zur facebookseite von PhytaLab:

      https://www.facebook.com/pages/PhytaLab-Cannabis-Laboratory/…
      Avatar
      schrieb am 09.09.14 00:14:05
      Beitrag Nr. 74 ()
      Medical Marijuana Update
      Chris Parry, Stockhouse.com



      ... In happier news, I'm hearing a lot of online talk that Abattis Bioceuticals (CSE:C.ATT, Stock Forum) has a license announcement coming soon. You sometimes here this kind of talk and it can quickly take a life of its own online, where rumour is enough to get some in a buying state of mind. But I have to say I've heard from people who are connected to the company that their gears are well and truly turning right now. I don’t know specifics, but I know management is very smiley right now.

      UPDATE: Abattis’ Phytalab unit just announced it has lab certification in Washington State to provide cannabis analysis laboratory services to the industry. Stock up 5.5%.

      Abattis CEO Mike Withrow said in a news release, "This is one more milestone the team has achieved in building our overall plan. In addition to revenue, having a licensed lab will serve as a core competency in the Abattis group of companies that collects and stores a bank of tissue culture and logs invaluable data that can be repurposed within the Abattis group of companies and with strategic partners licensed to work with cannabis."

      Abattis had the early run in the stage 1 weed explosion early this year, but drifted when it went through a period of quiet solidification while other companies started making grand promises of world domination.

      If you look deeply at the extensive vertical integration lineup that Abattis has put together, it's a compelling story. Certainly still in my top 5. And this is a great demonstration of their plan in action ...

      Link: http://www.stockhouse.com/news/newswire/2014/09/08/medical-m…
      Avatar
      schrieb am 17.09.14 09:53:57
      Beitrag Nr. 75 ()
      ... man hört dass neben den 13 bereits lizensierten MMJ (Medical Marijuana) produzierenden Firmen weitere 9 Betriebe von Health Canada eine Lizenz bekommen haben - siehe auch Texteinblendung im folgendem Video auf 01:35

      Link: http://www.bnn.ca/Video/player.aspx?vid=441534

      Abattis (ATTBF) hat mit 3 potentiellen Kandidaten Verbindungen (Beteiligungen). Ich hoffe natürlich sehr das wenigstens einer davon unter diesen 9 ist ;)

      Biocube owns exclusive worldwide rights to proprietary building materials and controlled cultivation environments.
      iJuana Cannabis Inc. is a brand of the company and has prepared an MMPR application on a 6.5 acre site with 27,000 sq ft of growing space.
      Experion is a licensed producer of medical cannabis under Canada's MMAR and is seeking an MMPR.
      Avatar
      schrieb am 18.09.14 11:58:50
      Beitrag Nr. 76 ()
      Ich hoffe, dass der Kurs jetzt seinen Boden gefunden hat und die m.M. goldenen Aussichten für ATTBF nun wieder alte Höhen erreichen und darüber hinaus.

      Lege heute nochmal nach.
      Avatar
      schrieb am 22.09.14 17:29:28
      Beitrag Nr. 77 ()
      Abattis Announces Appointment Guy Dancosse, Q.C. to Board of Directors
      Link: http://finance.yahoo.com/news/abattis-announces-appointment-…
      Avatar
      schrieb am 22.09.14 17:35:20
      Beitrag Nr. 78 ()


      Medical Marijuana Update:
      The Undervalued Seven



      Chris Parry, Stockhouse.com

      Abattis Bioceuticals (CSE:C.ATT, Stock Forum): Just got out of a meeting with the Abattis guys, and though they’ve been in my top 5 most favoured weedcos for most of this year, they really surprised me with their plans for true vertical integration. In short, Abattis is a weed incubator (hey, can I get one of those for home?), with seven full or partial subsidiaries in a variety of stages of the seed to sale cycle. I feel like each part of that entity deserves its own deep dive, so I’m going to keep talking to them and, if I can clear some schedule time and if they can finish doing due diligence on something they’re working on right now, we’d be talking about an eight-part series over eight weeks, which is indicative of how complex this story is – and indicative of how undervalued it is.

      Link: http://www.stockhouse.com/news/newswire/2014/09/18/medical-m…
      4 Antworten
      Avatar
      schrieb am 22.09.14 18:41:44
      Beitrag Nr. 79 ()
      The Abattis Report - September 16, 2014 - Interview mit Frau Dr. Michelle Sexton von PhytaLab





      Dr. Sexton ist die Gründerin von PhytaLab, das erste Canabis-Analyse-Labor in Washington State.
      Die Firma PhytaLab gehört zu 51 % Abattis und ist Teil der Firmenstrategie in möglichst vielen Bereichen des neuen MMJ-Marktes zu agieren (sh. auch http://www.abattis.com/s/our_partners.asp ).

      Sh. auch Beitrag Nr. 72 (47.723.967) vom 08.09.2014: http://www.wallstreet-online.de/diskussion/1192483-71-80/

      www.Phytalab.com
      Avatar
      schrieb am 23.09.14 01:05:47
      Beitrag Nr. 80 ()
      Abattis Bioceuticals Corp. ATTBF auf www.marihuana-aktien.de
      Link:
      http://www.marihuana-aktien.de/abattis-bioceuticals-ord-attb…
      ebenso interessant ...
      Link: http://www.marihuana-aktien.de/puffer/
      Avatar
      schrieb am 23.09.14 13:15:13
      Beitrag Nr. 81 ()
      Medical Marijuana Delays Explained
      Brian Wagner - CEO, NHP Consulting Inc.

      "... I feel that we are going to start seeing a lot more applications leave the queue,
      for better or worse, over the next 4 months."


      Links:
      http://www.nhpconsulting.ca/blog/medical-marijuana-delays-ex…
      http://www.nhpconsulting.ca
      https://twitter.com/NHPConsulting
      Avatar
      schrieb am 29.09.14 10:03:40
      Beitrag Nr. 82 ()
      Stehen in dieser Woche großartige News an?
      1 Antwort
      Avatar
      schrieb am 06.10.14 16:55:04
      Beitrag Nr. 83 ()
      Antwort auf Beitrag Nr.: 47.896.727 von Maschiman am 29.09.14 10:03:40Man munkelt so ... :confused:

      "... CAN’T SHARE DETAILS BUT SOMETHING’S COMING FOR:
      Abattis. Bedrocan. Vodis. Organigram. Wildflower. Naturally Splendid. Papuan Precious Metals. Highmark. ..."

      Link: http://www.stockhouse.com/news/newswire/2014/10/01/medical-m…
      Avatar
      schrieb am 08.10.14 22:35:55
      Beitrag Nr. 84 ()
      NEWS !!!



      Abattis Announces Zoning Approval on the Experion MMPR Application

      Oct 08, 2014
      Vancouver, BC -- October 8, 2014 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that through its wholly owned subsidiary, Northern Vine Canada Inc. ("Northern Vine"), Experion Biotechnologies Inc. ("Experion") has received a written update from the Fraser Valley Regional District on the amended zoning regulations for its property which has now been approved for... "the use of cultivation, growth, storage, or distribution, testing, or research, of marijuana for medical purposes as lawfully permitted and authorized under the applicable federal or provincial law."

      Link: http://www.abattis.com/s/news.asp?ReportID=677852
      Avatar
      schrieb am 09.10.14 14:29:00
      Beitrag Nr. 85 ()
      Avatar
      schrieb am 11.10.14 14:58:31
      Beitrag Nr. 86 ()
      White House Strategizing National Marijuana Legalization in Summer of 2015 :eek:

      "... According to several sources inside the White House, President Obama instructed his staff over the weekend to begin plotting out a course for the nationwide legalization of both medical and recreational marijuana, cleaning up federal statutes, demobilizing the DEA from going after marijuana offenders, and incentivizing states to legalize the popular controlled substance. Obama’s alleged goal is to have marijuana legalized, at least at the federal level, in the summer of 2015,
      and insiders say Obama is perfectly poised to get it done ..."


      Link: http://nationalreport.net/white-house-strategizing-national-…
      Avatar
      schrieb am 11.10.14 17:31:39
      Beitrag Nr. 87 ()
      Avatar
      schrieb am 15.10.14 19:55:44
      Beitrag Nr. 88 ()
      Das BIOCUBE SYSTEM von Abattis Bioceuticals (ATTBF) - die Zukunft einer nachhaltigen Landwirtschaft ?
      The Abattis Bioceuticals Biocube System – the Future of Sustainable Farming ?
      the alternative consumer - October 13, 2014



      " ... The “Biocube” is essentially a controlled cultivation micro-environment, integrating lighting, climate control, anti-mildew, anti-odor and dissolved oxygen water systems in a shell structure similar to that of a large shipping container. Abattis has exclusive rights to a proprietary magnesium oxide building material similar in appearance to common drywall, called MgO Board™, that demonstrates enhanced fireproofing, waterproofing, antimicrobial and antibacterial qualities while serving as particularly durable, yet recyclable interior walls for the Biocube. Abattis also obtained licensing rights to revolutionary growing technologies from TerraSphere Systems, based in Boston, MA, that employ vertically stacked grow plots with an autonomous hydroponic nutrient delivery system; organic, nutrient-rich fertilizer solution mixtures that Abattis, too, wholly owns ... "

      Link: http://www.alternativeconsumer.com/2014/10/13/the-abattis-bi…

      Siehe auch Meldung vom 10. Juni 2014 - Link: http://weedtv.com/abattis-acquires-16200-square-foot-growing…
      Avatar
      schrieb am 16.10.14 20:56:19
      Beitrag Nr. 89 ()
      ABATTIS ANNOUNCES NEW INVESTOR RELATIONS APPOINTMENT
      Vancouver, BC – October 17, 2014 -­‐ Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-­‐similar compounds, patented equipment and consulting services to medicinal markets in North America, today announced that they have entered into an Investor Relations Consulting Agreement with Satvir (Saf) Dhillon.

      Link: http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocument…
      Avatar
      schrieb am 03.11.14 18:53:42
      Beitrag Nr. 90 ()
      Abattis Files for Injunctive Relief in Washington State and Claims Damages Against Affinor Growers, Inc.
      :eek:
      Vancouver, BC - October 24, 2014 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), wishes to advise its shareholders that it has today, in U.S. Federal court in Washington State, filed suit for damages and injunctive relief against prior employees of PhytaLab (Dr. Kaleb Lund and Ms. Lauren Hilty), a former business associate (James Baxter), a competitor (Affinor Growers, Inc.), its director and former Abattis director (Nick Brusatore) and an employee of Herbal Analytics LLC (Erin Leary).

      Link: http://www.abattis.com/s/news.asp?ReportID=680323
      6 Antworten
      Avatar
      schrieb am 03.11.14 19:02:47
      Beitrag Nr. 91 ()
      November 4 - High on the agenda: marijuana a key issue in 2014 US Midterm elections
      On November 4, several US states will vote on whether to follow the trail blazed by
      Colorado and Washington and relax their marijuana policies.



      Here is a breakdown of what the voters face in the polls:
      http://www.euronews.com/2014/11/03/high-on-the-agenda-mariju…
      3 Antworten
      Avatar
      schrieb am 04.11.14 11:30:09
      Beitrag Nr. 92 ()
      Antwort auf Beitrag Nr.: 48.208.399 von webmimi am 03.11.14 18:53:42
      Abattis (ATTBF) drops on attack by former employees, files lawsuit
      The company, in a statement released after market Friday, said it filed suit for damages and injunctive relief in US Federal Court in Washington State against prior PhytaLab employees Dr. Kaleb Lund and Ms. Lauren Hilty, former business associate James Baxter, rival Affinor Growers, former Abattis director Nick Brusatore and Herbal Analytics employee Erin Leary.

      Link: http://www.proactiveinvestors.com/companies/news/57673/abatt…
      5 Antworten
      Avatar
      schrieb am 04.11.14 13:30:53
      Beitrag Nr. 93 ()
      First Biocube Installation - Abattis Bioceuticals (ATTBF)
      Twitter-News from Abattis Bioceuticals


      Abattis Bioceuticals @Abattis · 28. Okt.
      Abattis CEO Mike Withrow walking tour through first Biocube installation.
      New systems shown. More to come weekly.







      Abattis Bioceuticals ‏@Abattis 17. Juli
      Biocube Walls Being Received at Abattis Squamish BC Facility







      Link: https://twitter.com/Abattis
      8 Antworten
      Avatar
      schrieb am 05.11.14 13:48:18
      Beitrag Nr. 94 ()
      Antwort auf Beitrag Nr.: 48.208.534 von webmimi am 03.11.14 19:02:47
      The marijuana midterms 3 states and DC vote on legalization
      www.vox.com - November 5, 2014
      On November 4, several states radically altered their approaches to a drug once known for Reefer Madness. In Alaska, Oregon, and Washington, DC, voters approved marijuana legalization measures. But in Florida, a medical marijuana amendment fell short of the 60 percent approval it needed to pass under state law. Here's a breakdown of each state's initiative, the latest results, and how the opposing campaigns pushed their messages to voters.

      Link: http://www.vox.com/2014/10/20/6953771/weed-legalization-alas…

      The marijuana midterms
      3 states and DC vote on legalization
      by German Lopez on November 5, 2014
      http://www.vox.com
      2 Antworten
      Avatar
      schrieb am 05.11.14 13:56:24
      Beitrag Nr. 95 ()
      Antwort auf Beitrag Nr.: 48.229.075 von webmimi am 05.11.14 13:48:18
      ... when can you smoke pot legally ?
      Marijuana legalization won in Alaska, DC, and Oregon, but when can you smoke pot legally?
      by German Lopez on November 5, 2014, 4:15 a.m. ET - https://twitter.com/germanrlopez



      Link: http://www.vox.com/2014/11/4/7151203/is-pot-legal-buy-mariju…
      1 Antwort
      Avatar
      schrieb am 05.11.14 18:38:51
      Beitrag Nr. 96 ()
      Antwort auf Beitrag Nr.: 48.229.180 von webmimi am 05.11.14 13:56:24
      Marijuana has gone mainstream
      washingtonpost.com - by Christopher Ingraham November 5 at 11:56 AM

      " ... Voters in Alaska, Oregon and the District approved marijuana legalization measures by comfortable margins on Tuesday ... The victories are significant because they come despite a midterm election holding huge structural advantages for Republicans. Support for marijuana reform is concentrated among the young, but 18 to 29-year-olds made up only 13 percent of the 2014 electorate, compared to 19 percent in 2012. "Now that it's been shown that putting marijuana legalization on the ballot can succeed even in midterms, we can expect to see a huge surge of additional states voting to end prohibition during the 2016 presidential election," Tom Angell of the advocacy group Marijuana Majority said in an email ... "

      Link: http://www.washingtonpost.com/blogs/wonkblog/wp/2014/11/05/i…
      Avatar
      schrieb am 06.11.14 18:14:16
      Beitrag Nr. 97 ()
      More Canadian Medical Marijuana Licenses Before The New Year Rolls Around ?
      Jacob Securities Co-Head of Research Khurram Malik talks about the Canadian Medical Marijuana trade
      from the perspective of an institutional investor.
      " ... James West: Okay. So now, then, what about the idea that Health Canada is actually holding up the issuance of licenses based on waiting for the outcome of the Supreme Court challenge?

      Khurram Malik: I think it’s the other way around. I think it’s in Health Canada’s interest to now think you will see more licenses granted before the court case goes live. It’s in their interest to show that they have provided enough licenses so most of Canada can easily get access to medical marijuana. I think the first 13 are pretty large when you put them all together, but it’ll strengthen their case if they grant a few more. So I would expect to see more before the New Year rolls around ... "


      Link: http://www.midasletter.com/2014/11/tweed-bedrocan-t-bird-pha…

      Interview written by: James West - November 4, 2014
      Posted In: Top Stories - MidasLetter.com - Midas Letter Financial Group Ltd.
      Top-performing Resource, Energy & Technology Investment Picks
      Avatar
      schrieb am 06.11.14 23:54:34
      Beitrag Nr. 98 ()
      Antwort auf Beitrag Nr.: 48.214.621 von webmimi am 04.11.14 11:30:09
      Abattis (ATTBF) goes to war ...


      Medical Marijuana Update:
      GeoNovus in bed with Affinor as Abattis goes to war



      Chris Parry, Stockhouse.com

      " ... I’d been saying for some time that Abattis was likely to sue Affinor, to which Brusatore has always claimed he and C.ATT boss Mike Withrow go way back and are friends and I’m an idiot who didn’t know what he was talking about.
      Yet, Abattis has now filed suit against Affinor, and associated parties, in Washington State, claiming that consultants / management from its Phytolab operation have improperly jumped to an Affinor-backed competitor, with trade secrets and proprietary knowledge.
      I’ve heard informally from those close to Affinor boss Brusatore in the last few days that he’s ‘going to kick the crap’ out of Abattis. I’ve also heard from those close to Abattis that they didn’t want this, but felt Brusatore had ‘crossed a line’ and needed to be shoved back.
      I’ve seen the legal filing. Abattis is claiming damages and an injunction, as well as a jury trial. The complaint alleges one of the consultants working with Phytolab demanded a chunk of shares or he’d lead a walkout and set up a competitor.
      It also claims Brusatore pledged to fund the competitor in an effort to drive down C.ATT stock to the point where he could stage a takeover bid.
      This may sound a little far-fetched, but it would actually be the second time Brusatore had attempted to take over Abattis, if true. He had previously tried from inside the company and, after management blocked his effort, Brusatore told me he dumped his large stake, took his profits, and jumped into Affinor.
      To be fair, it appears to me that Brusatore is a smaller player in this lawsuit than others mentioned. Perhaps he saw an opportunity and went for it. Perhaps he didn’t know his new partners were potentially breaking their contracts. Perhaps that’s being charitable, as Brusatore has a reputation as a corporate bruiser that’s well earned.
      But a court case doesn’t help either side at this time. Affinor stock needs good news to get it back up to where all those equity-financed deals made sense (the court docs allege Affinor gave the defendants C.AFI stock at $0.516, far above the current price). And Abattis needs one of its eight or so verticals to start turning out revenues. At first glance, you’d hope both sides would settle up and move on with their business, but there’s ongoing bad blood between AFI and ATT, and the ongoing prospect of future legal actions over tech might just force both sides to go to the wall on this one ... "


      Link: http://www.stockhouse.com/news/newswire/2014/10/27/medical-m…
      4 Antworten
      Avatar
      schrieb am 07.11.14 00:03:01
      Beitrag Nr. 99 ()
      $50 Billion in Pot Sold Annually Nationwide, Only $2.5 Billion Is Legal
      mainstreet.com - by Juliette Fairley - Nov 6, 2014

      " ... The highest performing biotech publicly traded
      marijuana companies include Abattis (ATTBF) ... "


      Link: http://www.mainstreet.com/article/50-billion-in-pot-sold-ann…
      Avatar
      schrieb am 08.11.14 01:04:02
      Beitrag Nr. 100 ()
      Antwort auf Beitrag Nr.: 48.249.967 von webmimi am 06.11.14 23:54:34
      Abattis Legal Proceedings Update
      Vancouver, BC / ACCESSWIRE / November 7, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX:ATTBF - News) (CSE:ATT), wishes to advise its shareholders that the U.S. Federal Court in Washington State has this morning declined to exercise federal jurisdiction over the Company's recently announced claims. As a preliminary jurisdictional matter, the court indicated that it did not believe it was an appropriate venue for legal proceedings relating to the state's Marijuana industry. While the Court stated that the Company had fought "valiantly" during the hearing in advocating for federal jurisdiction, it also made plain that, unlike other jurisdictions throughout the U.S. which had exercised jurisdiction, it was bound by a prior legal decision from the ninth circuit that narrowed the ability of the Court to exercise federal jurisdiction in a similar case. The Court took the extraordinary step, however, of warning the defendants that it's decision to decline exercising federal jurisdiction should not be considered "a win" as the Company was likely to refile it's allegations in Washington state court. As predicted in the ruling, the Company is in preparations to immediately refile its complaint and seek a temporary restraining order on an emergency basis in Washington state court. Unlike the federal system, Washington state courts generally align more closely with state law on claims based on disputes within the Marijuana industry. The Company will keep shareholders informed as information becomes available throughout the day.

      Link: https://ca.finance.yahoo.com/news/abattis-legal-proceedings-…
      3 Antworten
      Avatar
      schrieb am 10.11.14 16:04:23
      Beitrag Nr. 101 ()
      Antwort auf Beitrag Nr.: 48.261.226 von webmimi am 08.11.14 01:04:02
      Abattis Legal Action Goes From Federal to Washington State Court
      Vancouver, BC / ACCESSWIRE / November 10, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATTBF) (CSE:ATT), wishes to advise its shareholders that end of day Friday November 7th the company filed its suit in King County Superior Court, that it had previously filed in Federal court. It was filed end of day Friday.
      The hearing on it's motion for a temporary restraining order is scheduled Monday at 1:30 pm.

      Now that the company has made its filing in Washington State Court and will have its case heard in a jurisdiction where a decision to issue a temporary restraining order can be made if deemed appropriate by the court.

      Link: http://finance.yahoo.com/news/abattis-legal-action-goes-fede…
      2 Antworten
      Avatar
      schrieb am 11.11.14 16:17:29
      Beitrag Nr. 102 ()
      Medical Pot Growers Stumped by Strict Licensing Process
      Would-be operators grow frustrated, panicked as Health Canada rejects hundreds of applications.
      By Jeremy J. Nuttall, Today, TheTyee.ca

      Link: http://thetyee.ca/News/2014/11/11/Medical-Pot-Grower-Licensi…
      Avatar
      schrieb am 11.11.14 17:55:25
      Beitrag Nr. 103 ()
      Antwort auf Beitrag Nr.: 48.275.044 von webmimi am 10.11.14 16:04:23
      Abattis Obtains Emergency Temporary Restraining Order
      ABATTIS OBTAINS EMERGENCY TEMPORARY RESTRAINING ORDER AGAINST DEFENDANTS IN KING COUNTY, WASHINGTON STATE COURT - COURT SETS "SHOW CAUSE" HEARING AGAINST DEFENDANTS FOR NOVEMBER 24 REGARDING THE IMPOSITION OF A PRELIMINARY INJUNCTION

      Vancouver, BC – September 8, 2014 - Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, wishes to advise its shareholders that late Monday afternoon, the Company obtained a temporary restraining order from the Washington state court in King County against Herbal Analytics, LLC, James Baxter, Kaleb Lund, Lauren Hilty, and Erin Leary (the "HA Defendants"). The Company agreed with the court to defer any action against Affinor Growers, Affinor Growers, LLC and Nicholas Brusatore, personally, until after the conclusion of a "Show Cause" hearing on preliminary injunctive relief. The Show Cause hearing is scheduled for argument on November 24, 2014 at which time all of the defendants must prove why a temporary injunction should not be entered by the court.

      Link: http://www.otcmarkets.com/stock/ATTBF/news?id=91339
      1 Antwort
      Avatar
      schrieb am 12.11.14 01:00:59
      Beitrag Nr. 104 ()
      Abattis Bioceuticals (ATTBF) - Video-Interview mit dem sog. "Wolf of Weed Street"
      youtube.com - November 11, 2014 - Frau Tracy Weslosky, Herausgeberin von InvestorIntel, befragt den in der Cannabis-Investment-Szene zu Ruhm gelangten sogenannten Wolf of Weed Street * zu seinen aktuellen Einschätzungen der Entwicklungen auf dem Markt der Hanf- und Marihuana-Aktien.
      Abattis Bioceuticals (ATTBF) wird (02:00 - 02:30) als eine der Firmen genannt die aktuell auf seiner Hitliste stehen.



      Tracy Weslosky:
      Alright. Well, my audience is going to want to know what publically listed companies are currently on your hot list.

      The Wolf:
      Well, today actually the last week I was looking at Tweed, which is actually, you know, a Canadian company. They've been doing very well. I'm looking at some of the other Canadian companies cause they're not seeing the impact of the elections and the ballots in the States. I'm looking Supreme Pharmaceuticals as one, Abattis, Affinor. I'm just looking at pretty much right now the Canadian companies because they're not being affected by the emotion in the United States right now in the last couple of days. In the United States though I am looking at a couple of plays. I'm looking at Stevia, which is STEV and that's a hemp play. I think hemp is going to be one of those products going into the future that everybody's going to jump on.

      * The mysterious “Wolf of Weed Street.” The Wolf of Weed Street is both a website and a human being, and both entities specialize in evaluating the value of stocks from marijuana-oriented companies.
      Avatar
      schrieb am 13.11.14 11:33:22
      Beitrag Nr. 105 ()
      Bist Du hier alleinunterhalterin webmimi? der kurs fällt stetig tag für tag und es ist noch immer kein boden erreicht. warum soll es sinn machen in diesen wert zu investieren?????

      SirLacoura
      2 Antworten
      Avatar
      schrieb am 13.11.14 11:35:41
      Beitrag Nr. 106 ()
      Datum/Zeit Kurs Währung Volumen Umsatz Währung
      13.11.14 08:00:38 0,091 EUR 0 0 EUR
      12.11.14 08:00:18 0,101 EUR 0 0 EUR
      11.11.14 08:08:32 0,108 EUR 0 0 EUR
      10.11.14 08:12:07 0,115 EUR 0 0 EUR
      07.11.14 08:00:56 0,132 EUR 0 0 EUR
      06.11.14 08:14:24 0,128 EUR 0 0 EUR
      05.11.14 08:18:40 0,164 EUR 0 0 EUR
      04.11.14 08:00:35 0,125 EUR 0 0 EUR
      03.11.14 17:31:56 0,119 EUR 0 0 EUR
      03.11.14 08:00:16 0,133 EUR 0 0 EUR
      31.10.14 08:14:44 0,126 EUR 0 0 EUR
      30.10.14 08:00:15 0,140 EUR 0 0 EUR
      29.10.14 08:00:20 0,146 EUR 0 0 EUR
      28.10.14 08:09:37 0,156 EUR 0 0 EUR
      27.10.14 08:06:40 0,170 EUR 0 0 EUR
      24.10.14 08:43:49 0,227 EUR 5.000 1.135 EUR
      24.10.14 08:01:04 0,181 EUR 0 0 EUR
      23.10.14 08:00:17 0,181 EUR 0 0 EUR
      22.10.14 08:00:21 0,187 EUR 0 0 EUR
      21.10.14 08:08:09 0,171 EUR 0 0 EUR
      20.10.14 08:00:14 0,154 EUR 0 0 EUR
      17.10.14 08:00:22 0,164 EUR 0 0 EUR
      16.10.14 08:00:27 0,154 EUR 0 0 EUR
      15.10.14 08:00:29 0,148 EUR 0 0 EUR
      14.10.14 08:03:03 0,163 EUR 0 0 EUR
      13.10.14 08:13:07 0,164 EUR 0 0 EUR
      10.10.14 13:45:50 0,228 EUR 5.000 1.140 EUR
      10.10.14 08:00:17 0,167 EUR 0 0 EUR
      09.10.14 08:00:20 0,182 EUR 0 0 EUR
      08.10.14 08:15:10 0,175 EUR 0 0 EUR
      07.10.14 08:33:52 0,236 EUR 2.000 472 EUR
      07.10.14 08:00:21 0,190 EUR 0 0 EUR
      1 Antwort
      Avatar
      schrieb am 14.11.14 15:55:41
      Beitrag Nr. 107 ()
      Antwort auf Beitrag Nr.: 48.216.166 von webmimi am 04.11.14 13:30:53
      First Biocube Installation - Abattis Bioceuticals (ATTBF)
      Twitter-News from Abattis Bioceuticals


      Abattis Bioceuticals@Abattis · 13. Nov.
      Biocubes progress update. Holy Basil doing well after 10 days. Capacity is over 1000 plants per cube 280sq ft.



      Link: https://twitter.com/Abattis

      Abattis Bioceuticals@Abattis · 13. Nov.
      Close up of the Holy Basil in the Biocubes . Stack them and 3000 1 gal pots per 280 sq ft.



      Link: https://twitter.com/Abattis
      7 Antworten
      Avatar
      schrieb am 14.11.14 16:23:41
      Beitrag Nr. 108 ()
      Antwort auf Beitrag Nr.: 48.307.723 von sirlacoura am 13.11.14 11:33:22
      Meet The 8 Hottest Publicly Traded Marijuana Companies
      ... dieser Titel bringt es auf den Punkt. Für mich gehört die Abattis Bioceuticals Corp. unter die Marijuan-Aktien die mittel- und langfristig Erfolg haben werden. ATTBF hat ein gutes Geschäftskonzept, dass sich nicht nur um den Anbau der Pflanze dreht (siehe u.a. meine Beiträge der vergangenen Wochen). Es hat genügend Kapital um zu investieren und ein sehr gutes Management. Viele Vorhaben wurden angegangen und verwirklicht s.h. z.B. Phytalab - Link: http://phytalab.com/


      Marijuana is turning into big business. (Photo credit: Wikipedia)

      Meet The 8 Hottest Publicly Traded Marijuana Companies
      Carol Tice - forbes.com - 11/14/2014 @ 8:35AM

      2. Abattis Bioceuticals Corp. (+1,600%) — Hailing from Vancouver, B.C., Abattis provides cultivation systems, extraction equipment, and consulting services to growers. The company raised $3 million in private placements this year, and went on an acquisition spree. Abattis snapped up fertilizer formulas from one company, a majority interest in marijuana testing-lab Phytalytics, and a one-third stake in a payments company. Last month, though, Abattis filed suit against former Phytalytics executives, whom it alleges formed a rival company.

      Link: http://www.forbes.com/sites/caroltice/2014/11/14/meet-the-8-…
      Avatar
      schrieb am 14.11.14 19:33:18
      Beitrag Nr. 109 ()
      Antwort auf Beitrag Nr.: 48.307.753 von sirlacoura am 13.11.14 11:35:41Du kannst auch nicht das Volumen deutscher Handelsplätze heranziehen.
      Der Kurs wird nicht in Deutschland gemacht.

      Setzen! 6!
      Avatar
      schrieb am 17.11.14 13:37:13
      Beitrag Nr. 110 ()
      Aber den Kurs kann ich schon heranziehen, oder???? Und der fällt und fällt und fällt stetig.

      SirLacoura
      Avatar
      schrieb am 17.11.14 16:40:32
      Beitrag Nr. 111 ()
      langfristig gesehen ja, Volumen zieht an. Heute wird es grün.

      es liegt was in der Luft denkt ich. eine gute pr ist tatsächlichauch etwas überfällig.
      was die Lizenzen angeht, denke ich, dass sich das im Q1/15 entscheiden dürfte.
      1 Antwort
      Avatar
      schrieb am 17.11.14 17:34:48
      Beitrag Nr. 112 ()
      Antwort auf Beitrag Nr.: 48.341.446 von Maschiman am 17.11.14 16:40:32Das sehe ich genauso Maschiman !
      Die Aktie wird offensichtlich für einige Investoren wieder interessant.
      Und wenn Abattis Bioceuticals Corp. endlich seine MMJ-Producer-Lizenz von Health Canada bekommen wird, werden wir hier wesentlich bessere Kurse sehen :)
      Avatar
      schrieb am 17.11.14 17:43:37
      Beitrag Nr. 113 ()
      Abattis Names Jaouad Fichtali as Chief Technology Officer

      VANCOUVER, BRITISH COLUMBIA - (Marketwired) - 11/17/14
      Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that Jaouad Fichtali will assume the role of Chief Technology Officer of Abattis effective November 17, 2014.
      Mr. Fichtali joins the team as a leader in his field in taking biotechnology from concept to sustainable commercialization. He is a global Biotech executive whose background includes successful commercialization and improvements to renewable bio-based materials, food ingredients and health and nutrition products. He has successfully driven multimillion-dollar growth. Mr. Fichtali takes ideas from inception to profitable commercialization by creating innovative solutions. He is known as a strategic leader with deep scientific expertise, and comprehensive business acumen.

      Link: http://www.sys-con.com/node/3230652
      1 Antwort
      Avatar
      schrieb am 17.11.14 17:47:58
      Beitrag Nr. 114 ()
      Antwort auf Beitrag Nr.: 48.342.220 von webmimi am 17.11.14 17:43:37
      Patents by Inventor Jaouad Fichtali
      Unter dem Namen dieses neuen Mitarbeiters der Abattis Bioceuticals Corp. (OTCQX: ATTBF)
      ist ein interessantes Patent eingetragen ...

      Link: http://patents.justia.com/inventor/jaouad-fichtali
      Avatar
      schrieb am 19.11.14 13:15:58
      Beitrag Nr. 115 ()
      Die 7 Stufen bis zur MMPR-Lizenzierung durch Health Canada


      Im folgendem Text werden die 7 Verwaltungsschritte beschrieben die erfolgreich bestanden werden müssen, um eine Lizenzierung als Marihuana-Produzent, gemäß den Marijuana for Medical Purposes Regulations (die „MMPR“), zu erhalten:

      Step 1: Preliminary Screening
      When an application is received, it undergoes a preliminary screening for completeness. If an application is not complete, it will be returned. If an application is complete, it will be assigned an application number. The application number means that the application has completed the preliminary screening.

      Step 2: Enhanced Screening
      Once an application has been assigned an application number, it will be moved through screening to ensure: that the location of the proposed site does not pose a risk to public health and safety; that the proposed security measures outlined in the application meet the requirements of the MMPR; and that the person proposed as a quality person has the appropriate credentials to meet the good production requirements of the MMPR. It is the responsibility of the Company to ensure that it is in compliance with all applicable provincial, territorial, and municipal legislation, regulations and bylaws, including zoning restrictions.

      Step 3: Security Clearance
      Once the screening of an application is complete, the security clearance forms for key personnel will be sent for processing. The time required to conduct mandatory security checks varies with each application. It is expected that security clearances will take a minimum of a few months, but can take much longer. Health Canada and the RCMP do not provide updates on the status of security checks. Until such a time as Health Canada receives the results of the security checks, there will be no further communication from Health Canada.

      Step 4: Review
      Once all security clearances are obtained, an application will be thoroughly reviewed to validate the information provided. Given the extensive review process, it is anticipated that the Company will be communicating with the Office of Controlled Substances multiple times as it responds to requests for clarifications to support its application.

      Step 5: Ready to build letter (if required by applicant)
      Once the review of the application has been completed and it is confirmed that all requirements in the MMPR are met, applicants may request that Health Canada issue a "ready to build letter". The "ready to build letter" is a notice informing the Company that, if the licensed producer's site is built to the specifications outlined in the application, the physical security measures would meet the requirements of the MMPR. The "ready to build letter" is not a guarantee that a licence will be issued. The Company must still successfully pass a pre-licence inspection and obtain its security clearances.

      Step 6: Pre-licence inspection
      Upon confirmation from the Company that the site has been fully built and security measures are in place, a pre-licence application will be scheduled. If any deficiencies are identified, they will be communicated to the Company and must be addressed.

      Step 7: Licensing
      Once it has been confirmed through the pre-licence inspection that the Company meets all the requirements of the MMPR, a licence will be issued.

      Link: http://www.marketwatch.com/story/maple-leaf-clarifies-matter…
      Avatar
      schrieb am 19.11.14 17:31:02
      Beitrag Nr. 116 ()
      Antwort auf Beitrag Nr.: 48.307.723 von sirlacoura am 13.11.14 11:33:22
      Abattis Bioceuticals’ Full-Spectrum Seed-to-Sale Aggregator Model
      Hier der link zu einem sehr informativen Artikel der anschaulich die Stärken von Abattis Bioceuticals
      GDERS”-Geschäftsmodel (Grow, Dry, Extract, Refine, Sales/Science/Sustainability) beschreibt ...

      Link: http://www.cannabisfn.com/abattis-bioceuticals-full-spectrum…

      Avatar
      schrieb am 19.11.14 17:48:58
      Beitrag Nr. 117 ()
      Antwort auf Beitrag Nr.: 47.845.058 von webmimi am 22.09.14 17:35:20

      Medical Marijuana Update:
      How America does it and
      why Canada will win



      Chris Parry, Stockhouse.com

      Abattis (CSE:C.ATT, Stock Forum) was the subject of more questions to me from attendees than any other company. There are a lot of folks wondering if their vertical integration pieces fit together, whether there’s activity moving forward, what those pieces do. Here’s the thing: That company was in my top 5 for a lot of this year. The company struggled when a former big shareholder made a run at a takeover before dumping the stock in one big hit. The company struggled to tell its story when the market needed reassurance. The company recently had its lawsuit against Affinor tossed out. And, more recently, the company had dealings with me and others that, frankly, I was disappointed by.
      So when people asked me what I thought of the play over the weekend, and many did, I gave them all the answer that I feel most confident with: A long silence.
      I do believe it’s an undervalued company.
      Let’s see if they can deliver on their promise.


      Link: http://www.stockhouse.com/news/newswire/2014/11/17/medical-m…
      3 Antworten
      Avatar
      schrieb am 21.11.14 16:58:09
      Beitrag Nr. 118 ()
      Abattis Bioceuticals (ATTBF) - Las Vegas Marijuana Conference And Exposition
      Twitter-News from Abattis Bioceuticals


      Abattis Bioceuticals@Abattis - 16:38 - 17. Nov. 2014
      Tweet from CEO Mike Withrow at the Marijuana Conference in Las Vegas
      " Vegas show was packed, well done, many people kept us busy the whole show.
      Great contacts made.
      Industry is here to stay, only get bigger "

      Link: https://twitter.com/Abattis/status/534505775465762816



      Marijuana conference signals emerging pot market




      Some investors are betting that the marijuana is becoming a booming business in the U.S.

      Avatar
      schrieb am 24.11.14 18:20:10
      Beitrag Nr. 119 ()
      Infographic – Medical Marijuana In Canada: One Year Later
      Marked one year since Health Canada stopped accepting new patients into the old MMAR program, compelling them to purchase medical marijuana from a Licensed Producer under the new MMPR regulations.
      Here’s an infographic highlighting some of the developments since then:



      Link: http://blog.liftcannabis.ca/2014/10/02/infographic-medical-m…
      Avatar
      schrieb am 26.11.14 12:45:34
      Beitrag Nr. 120 ()
      Antwort auf Beitrag Nr.: 48.322.474 von webmimi am 14.11.14 15:55:41
      First Biocube Installation - Abattis Bioceuticals (ATTBF)
      Twitter-News from Brayden R. Sutton


      Brayden R. Sutton‏@BraydenSutton · 19. Nov.
      Biocubes progress update.
      The BioCube is alive and well! Awesome to finally see them in action. It's open to the public @Abattis $ATT $ATTBF








      Link: pic.twitter.com/yRkl6L3IzX
      6 Antworten
      Avatar
      schrieb am 26.11.14 13:18:00
      Beitrag Nr. 121 ()
      Chartanalyse - Abattis Bioceuticals (ATTBF)
      Twitter-News from Brayden R. Sutton


      Brayden R. Sutton‏@BraydenSutton · 20. Nov.
      As a fan of this one from day-one, and as a devoted technical analyst;
      I sure hope that this is the bottom for $ATTBF




      Link: https://twitter.com/BraydenSutton/status/535487238084112384/…
      1 Antwort
      Avatar
      schrieb am 27.11.14 18:06:45
      Beitrag Nr. 122 ()
      Antwort auf Beitrag Nr.: 48.419.019 von webmimi am 26.11.14 13:18:00
      What’s to like about ATTBF stock and CEO Mike Withrow?

      If you have to pick just one word to sum up Abattis Bioceuticals Corp. (OTCQX: ATTBF)
      and their relation to the marijuana stock sector, it is without a doubt — DIVERSIFICATION.

      Mike Withrow isn’t simply trying to corner a niche market or throw out broad promises of “growing lots of cannabis” (as sadly many other companies seem to be doing). He’s attempting to build a well-diversified machine, capable of producing multiple revenue streams.
      Their business model is commonly referred to as “GDERS”, and stands for GrowDryExtractRefineScience/Sell.

      As with all companies attempting to capitalize on the cannabis space, the future of Abattis is dependent upon Health Canada granting the much coveted MMPR (Marihuana for Medical Purposes Regulations) license. It’s important to note that if all license applications come to fruition, Abattis isn’t looking at just one license to enable it to grow and distribute cannabis based products — it’s looking at several.

      Yes, several of its subsidiaries have applied for the MMPR, including iJuana Cannabis Inc, as well as BioCell Labs Inc that will be utilizing the PurGenesis facility, and finally Experion, in which Abbatis’ Northern Vine owns a 25% stake. Northern Vine has also applied for a Controlled Substance License.

      Here is a great visual that pieces together the many powerful components that ATTBF plans to integrate into a dominant force of the new cannabis industry . . .


      Abattis isn’t just ahead of the game in terms of paving the way for multiple streams of income, but it’s also leading the way in the sector regarding transparency to its own stockholders. On July 15, ATTBF became the first marijuana stock to qualify for listing on the OTC Market’s prestigious OTCQX tier. The OTCQX achievement is often viewed as a stamp of approval for legitimate penny stocks, because it requires a higher quality of financial reporting. As such, many investors now view ATTBF as a safer investment than many other stocks listed on the OTCQB. This higher status is also commended as a substantial advancement toward being listed on the NASDAQ or NYSE, which opens the doors to a much larger base of investors and even stronger credibility.

      Excessive dilution is also a common fear for any penny stock investor, but it’s been quite comforting to see that Mike Withrow seems intent on keeping dilution to a minimum. With slightly over 63 million shares outstanding, Mike has publicly stated that he does not plan to exceed 100 million shares at any point in the future. No doubt Abattis may find itself requiring additional capital down the road as it refines the business plans, and it’s nice to have a ceiling in mind.

      What are some common Abattis criticisms ?

      There are three points of criticism that ATTBF skeptics tend to discuss, one of which will play the most *important* role in determining the fate of Abattis.

      1. Although ATTBF has a business model involving multiple plans and potential streams of revenue, some believe this could actually prevent the company from focusing on developing the most profitable of their businesses. In other words, they worry that Abattis could become a jack-of-all-trades but master of none, and open the doors a little wider to competitors.

      2. No major revenue streams at this time. As with any business, no matter how convincing or exciting the possibilties for the future may seem, it’s nothing but a “plan” until the money starts flowing in. Of course, this is the case with the majority of marijuana stocks and a substantial reason the entire sector is considered extremely risky.

      3. Waiting on the license(s) — and this is the most important issue holding many investors back at the moment. Without the MMPR licenses being issued by Health Canada, Abattis is nothing more than a collection of subsidiaries with some very cool technology. CEO Mike Withrow’s commitment to assembling a Grade-A set of directors and scientists would suggest the company firmly believes that receiving the licenses isn’t some near hopeless daydream, but instead it is a highly anticipated event. Even so, governments and their approval processes are not known for being “timely”.


      Link: http://www.420stocktalk.com/marijuana-stocks/attbf-abattis-b…
      Avatar
      schrieb am 28.11.14 13:32:07
      Beitrag Nr. 123 ()
      Ein schöner Zuwachs :D
      2 Antworten
      Avatar
      schrieb am 28.11.14 15:55:37
      Beitrag Nr. 124 ()
      Antwort auf Beitrag Nr.: 48.442.623 von Maschiman am 28.11.14 13:32:07
      TOP MOMENTUM GAINER: ABATTIS BIOCEUTICALS
      Bin ja auch fleissig am Kaufen :laugh:

      TOP MOMENTUM GAINER: ABATTIS BIOCEUTICALS (CNSX: ATT) SOARS 43% IN 2-DAYS
      26 Nov, 2014 - smallcappower.com

      Shares of Abattis Bioceuticals Corp (CNSX: ATT), engaged in cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, recorded over 19.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands.
      ATT was the top performer in the Canadian healthcare sector after gaining 19.4% and closed at C$0.22 Tuesday, while recording significant trading volumes of 288,378 shares. During the past 5-trading sessions, ATT gained 26.5% with daily average trading volumes of 224,039 shares, while the stock fell by 24.6% during the past one month with daily average trading volumes of 231,562 shares. The stock is up 975.0% year-to-date.

      Links:
      http://www.smallcappower.com/posts/top-momentum-gainer-26-11…
      https://twitter.com/Abattis/status/537605277319585792
      Avatar
      schrieb am 28.11.14 16:51:43
      Beitrag Nr. 125 ()
      Antwort auf Beitrag Nr.: 48.442.623 von Maschiman am 28.11.14 13:32:07
      Black Friday Goes Green !
      marijuanastocks.com - Marijuana Trends & Articles - Nov 26, 2014

      You’ve probably heard about Black Friday since the end of summer. It’s one of the biggest “shopping holidays” of the year but there’s something way different this year than any year in the history of Black Friday …
      MARIJUANA IS LEGAL ! (well, in some states). In a recent post in the Denver Gazette, marijuana retailers in Colorado are going after holiday shoppers using traditional Black Friday campaigns ...

      Link: http://marijuanastocks.com/black-friday-goes-green-blackfrid…

      Avatar
      schrieb am 02.12.14 13:20:14
      Beitrag Nr. 126 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) @ The Best Marketplace OTCQX®
      Abattis @ OTCQX®
      Link: i]http://www.otcmarkets.com/stock/ATTBF/quote/[/i]

      OTC Markets Group organizes securities into the OTCQX®, OTCQB® and OTC Pink® tiered marketplaces.
      The marketplace on which a company trades reflects the integrity of its operations, its level of disclosure, and its degree of investor engagement.


      The Best Marketplace

      Designed for investor-focused companies that meet high financial standards, are current in their disclosure and receive third party advisory. The companies found on OTCQX are distinguished by the excellence of their operations and diligence with which they convey their qualifications.

      To view the full list of world-class OTCQX companies click here ...
      Link: http://www.otcmarkets.com/research/otcqx-company-list
      Avatar
      schrieb am 02.12.14 18:05:15
      Beitrag Nr. 127 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - We are painting the country green ...
      Abattis Bioceuticals retweetete - Kristie@CannablissRadio


      Kristie@CannablissRadio · 29. Nov.
      We are painting the country green in a great way. Excited for the future. #LegalizeIt



      Link: https://twitter.com/CannablissRadio/status/53874503753049292…

      Abattis Bioceuticals Corp. (OTCQX: ATTBF) bei Twitter: https://twitter.com/abattis
      Avatar
      schrieb am 05.12.14 13:04:10
      Beitrag Nr. 128 ()
      Antwort auf Beitrag Nr.: 48.362.452 von webmimi am 19.11.14 17:48:58
      Abattis Bioceuticals (OTCQX: ATTBF) - Rumour and innuendo: Medical Marijuana edition


      Medical Marijuana Update:
      Rumour and innuendo



      Chris Parry, Stockhouse.com

      Abattis Bioceuticals (CSE:C.ATT, Stock Forum): For a company that has so many pieces to explain, the good folks at vertical integrator Abattis have sure been slow explaining them. One of my top 5 weed picks early in the green rush, the stock got slammed when Affinor honcho Nick Brusatore fled the building and dumped into the bid, and it has never recovered since.
      Recent moves to make wins in the legal space (involving, no surprise, Brusatore again) have left investors uneasy, but the company has made a recent renewed IR push to see if it can’t correct the tilt.

      Stock is nearing a 52-week low, volume has dried up, and if there aren’t a couple of Affinor fan shorters out there banging the stock around a little, I’d be very surprised. Market wants revs. It’s in Abattis’ hands now to feed the beast or perish.

      Link: http://www.stockhouse.com/news/newswire/2014/12/04/rumour-an…
      2 Antworten
      Avatar
      schrieb am 08.12.14 23:22:37
      Beitrag Nr. 129 ()
      The Abattis Report - 26. November 2014 - Interview mit Herrn Brazos Minshew Vorsitzender der BioCell Labs Inc.



      Biocell Labs Inc. is a wholly owned subsidiary of Abattis Bioceutical Corp. (OTC: ATTBF) (CSE: ATT) focused on supplying standardized pharmaceutical grade products. The company leases a $13M, 20k square foot a botanical drug facility that it will use to perform quality testing and refining using its proprietary Flash Freeze Extraction ("FFE") and water extraction technologies.
      Currently, the company has 13 proprietary formulations for out-licensing to cosmetic, nutraceutical and pharmaceutical companies.

      Founded in 2010, BioCell Labs is the holder of numerous patented and proprietary products, a Health Canada MMPR license and a nutraceutical production facility. As President of BioCell Labs, Brazos Minshew is tasked with consolidating Intellectual Properties, refining production strategies and creating distribution logistics through aggressive project management.
      See also press release from Jul 02, 2014: http://www.abattis.com/s/news.asp?ReportID=662744

      Links:
      http://www.biocelllabs.com/
      http://www.abattis.com/s/our_companies.asp
      Avatar
      schrieb am 10.12.14 21:47:57
      Beitrag Nr. 130 ()
      Abattis Bioceuticals (OTCQX: ATTBF) - Updates

      In diesem Monat finden in vielen Aktien-Depots "Das grosse Reinemachen" statt - aus steuerlichen Gründen trennen sich die Anleger von ihren Aktien "gerne" mit Verlust. Nach dem Absturz des Marijuana-Index Ende März (http://marijuanaindex.org) dürften diesmal viele Marijuana-Aktien dabei sein. Warten wir also dieses Spektakel ab. Meiner Meinung nach sollte dann auch bei Abattis die Bodenbildung abgeschlossen sein. Natürlich bedarf es aber für einen Stop des Abwärtstrends vor allem guter Nachrichten und Erfolgsmeldungen. Dazu möchte ich folgendes feststellen.
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) ist mehr als nur eine MMJ-Produktions-Firma. Die Firma ist breit aufgestellt und wird auch in anderen Segmenten (siehe wo-Beitrag Nr. 116) alles unternehmen um Punkten zu können. Ich rechne mit kleinen, aber immerhin ersten wichtigen Umsätzen aus ein paar Bereichen - zB. bei BioCube und PhytaLab. Perfekt wäre auch endlich der Erhalt der wichtigen MMPR-Lizenz(en) durch Health Canada. Abattis Bioceuticals hat, wie bekannt, gleich 3 "Pferde" im Rennen ... die Chancen, daß eines davon durch die Zielline prescht stehen meiner Ansicht nach sehr gut. Ich rechne mit dem Erhalt einer MMPR-Lizenz für Frühjahr 2015 - November dieses Jahr wäre mir persönlich natürlich lieber gewesen, daß war wohl aber nischt :(

      Einige kleinere Nachrichten und Geschehnisse der vergangenen Wochen scheinen darauf hin zu deuten, daß man schon bald mit ein paar sehr positiven offiziellen Bekanntmachungen rechnen darf:

      1.) BioCell bringt im Januar 2015 gleich 7 neue BIO-Produkte auf den Markt = siehe Interview mit Brazos Minshew CEO der BioCell Labs Inc.
      Link: https://www.youtube.com/watch?v=6qE-3HAOpTo&feature=youtu.be

      2.) PhytaLab meldet erste kleine Erfolge und Kundenaufträge.
      Links:
      https://twitter.com/phytaLab/status/541880992961921024
      https://www.facebook.com/video.php?v=1001153899901467

      3.) Die funktionierenden BioCubes werden bereits in einer neuen Anlage in der Nähe des Flughafens Vancouver Interessenten präsentiert (siehe wo-Beitrag Nr. 107 und 120). Ein Großauftrag von einem bereits am Markt etablierten Produzenten könnte jeden Moment bekannt gegeben.
      Es ist wichtig und ein Erfolg, daß die Anlage in Betrieb ist, denn im Oktober gingen bei BioCube die Sicherheitsüberprüfungen durch Health Canada erfolgreich über die Bühne (Step 3: Security Clearance - sh. wo-Beitrag Nr. 115).
      Sobald also eine MMPR-Lizenz durch Health Canada erteilt würde, könnten diese z.Zt. reinen BioCube-Verkaufsflächen sofort in eine MMJ-Produktionsanlage umgewandelt werden.
      Link: https://twitter.com/BraydenSutton/status/535191446970978305/…

      4) Auch Experion hat die Sicherheitsüberprüfung durch Health Canada (Step 3: Security Clearance - siehe wo-Beitrag Nr. 115) erfolgreich gemeistert und erhielt zudem einen positiven Planfeststellungsbeschluss (zoning approval). Experion ist für die weiteren Schritte bis zur MMPR bestens aufgestellt - der Erhalt einer Lizenz wäre natürlich auch hier ein großer Erfolg der Abattis Bioceuticals nach vorne katapultieren würde.
      Link: http://www.stockhouse.com/news/press-releases/2014/10/08/aba…
      Avatar
      schrieb am 14.12.14 23:56:43
      Beitrag Nr. 131 ()
      Antwort auf Beitrag Nr.: 48.418.626 von webmimi am 26.11.14 12:45:34
      First Biocube Installation - Abattis Bioceuticals (ATTBF)
      Twitter-News from GrowthStar LED


      GrowthStar LED@GrowthStarLED · 11. Dez.
      Biocubes progress update.
      How to #Grow in small spaces #Verticalfarming, Basil from @Abattis








      Link: https://twitter.com/GrowthStarLED/status/543200632606175232/…
      5 Antworten
      Avatar
      schrieb am 15.12.14 00:04:17
      Beitrag Nr. 132 ()
      Antwort auf Beitrag Nr.: 48.569.852 von webmimi am 14.12.14 23:56:43
      First Biocube Installation - Abattis Bioceuticals (ATTBF)
      Twitter-News from GrowthStar LED


      GrowthStar LED@GrowthStarLED · 1. Dez.
      Biocubes progress update.
      Major #MMJ producer is set to begin HPS vs #LED #Showdown, our @GrowthStarLED lights will be added this week.




      Link: https://twitter.com/GrowthStarLED/status/539553923778883584/…
      4 Antworten
      Avatar
      schrieb am 15.12.14 00:22:05
      Beitrag Nr. 133 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) is set to Present on CannaWebcast.com - December 18th, 2014 !
      Twitter-News from Cannawebcast


      Cannawebcast@CannaWebcast · 12. Dez.
      #Breaking: @Abattis | $ATTBF | Is set to Present on http://CannaWebcast.com #December 18th, 2014! | #Online #GreenRush

      Link: https://twitter.com/CannaWebcast/status/543186489882849280
      1 Antwort
      Avatar
      schrieb am 17.12.14 15:10:19
      Beitrag Nr. 134 ()
      Antwort auf Beitrag Nr.: 48.569.909 von webmimi am 15.12.14 00:22:05
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) CannaWebcast.com-Presentation - Verschoben auf Jan. 2015 !
      Twitter-News from Cannawebcast


      Cannawebcast@CannaWebcast · 16. Dez.
      The #Official Agenda for The #Third #Cannabis #Investor #Webcast | Dec. 18th, 2014! | $MJNE $SRNA $LXRP $AMMJ $ICBU

      Link: https://twitter.com/CannaWebcast/status/545023079752028160/p…
      Avatar
      schrieb am 22.12.14 15:00:26
      Beitrag Nr. 135 ()
      Antwort auf Beitrag Nr.: 48.569.870 von webmimi am 15.12.14 00:04:17
      Are Medical Marijuana Producers Going LED?
      ledhorticulture.com - Dec 21, 2014

      "... We found a legal grower in Canada who is running some serious tests and trials on 4 different LED growlights and running HPS to compare and provide detail analysis.
      This Vancouver producer asked to stay anonymous because of strict new Medical marijuana advertising laws in Canada that require them not to make marijuana products so appealing ..."


      Link: http://www.ledhorticulture.com/are-medical-marijuana-produce…
      Avatar
      schrieb am 22.12.14 15:24:44
      Beitrag Nr. 136 ()
      Antwort auf Beitrag Nr.: 48.569.870 von webmimi am 15.12.14 00:04:17
      Abattis Bioceuticals (ATTBF)
      Twitter-News from curiousbuild


      curiousbuild@curiousbuild · 21. Dez. 2014
      "@GrowthStarLED: @HansGoogleserch you can check out the latest #MCOB LED trials at: https://www.facebook.com/pages/GrowthStar-LED/479827185367848?ref=hl … " $ATTBF



      Link: https://twitter.com/curiousbuild/status/546845936224571392
      2 Antworten
      Avatar
      schrieb am 22.12.14 15:37:51
      Beitrag Nr. 137 ()
      Antwort auf Beitrag Nr.: 48.632.033 von webmimi am 22.12.14 15:24:44Abattis Bioceuticals (ATTBF) - GrowthStar LED




      Link: https://www.facebook.com/pages/GrowthStar-LED/47982718536784…





      Link: http://www.growthstarled.com/
      1 Antwort
      Avatar
      schrieb am 27.12.14 14:31:22
      Beitrag Nr. 138 ()
      Antwort auf Beitrag Nr.: 48.288.940 von webmimi am 11.11.14 17:55:25
      Abattis Bioceuticals Corp. (ATTBF) wins a preliminary injunction against Herbal Analytics (Affinor Growers)
      Veröffentlicht auf scribd.com am 24. Dezember 2014 von: eloise9097
      Zu sehen sind hier die Seiten 8 und 9 v. 9 mit den rechtskräftigen Anordnungen des Gerichts dieser bis zum endgültigen Abschluss des Verfahrens geltenden einstweiligen Verfügung.





      Link: http://de.scribd.com/doc/250930371/Order
      Avatar
      schrieb am 02.01.15 16:28:44
      Beitrag Nr. 139 ()
      Abattis Maintains It Is Still the Worldwide Exclusive Licensee to Certain VDL Technology
      VANCOUVER, BRITISH COLUMBIA - (Marketwired - Dec. 31, 2014) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, wishes to advise its shareholders that contrary to public assertions made by Vertical Designs Ltd. ("VDL"), Abattis does not consider the parties' worldwide exclusive license agreement ("License") terminated. The company maintains that it is still the exclusive worldwide holder of VDL technology for growing plants, plant material and extracts grown and produced for use as ingredients in the pharmaceutical, neutraceutical, cosmetic and wellness markets. Abattis will challenge any and all efforts by VDL to terminate the License.

      Link: http://www.digitaljournal.com/pr/2420665
      Avatar
      schrieb am 07.01.15 17:31:23
      Beitrag Nr. 140 ()
      Antwort auf Beitrag Nr.: 48.498.272 von webmimi am 05.12.14 13:04:10
      Abattis Bioceuticals (OTCQX: ATTBF) - Abattis-Affinor legal update


      Medical Marijuana Update:
      Abattis-Affinor legal update



      Chris Parry, Stockhouse.com

      Abattis Bioceuticals (CSE:C.ATT, Stock Forum): Remember that whole Abattis Bioceuticals / Affinor Growers legal war I said was brewing around mid-2014? The one that Affinor stock holders yelled at me about? The one Affinor (CSE:C.AFI, Stock Forum) boss Nick Brusatore said would never happen? The one they said was all over at the first hurdle in Washington State?
      Oh, it ain’t done. Not by a long shot.
      For the uninitiated, Brusatore licensed his Vertical Designs Ltd vertical farming technology to Abattis Bioceuticals (CSE:C.ATT, Stock Forum) way back when the green rush was just beginning. VDL had emerged as a Brusatore vehicle after he departed from TerraSphere, where he invented that company’s first forays into vertical growing.

      Abattis gave Brusatore a shedload of stock to come on over and be part of their vertical integration play, and he happily accepted, but after an aborted attempt to take over the ship, Brusatore dumped his stock, made a lot of cash, and put it into Affinor where he was given the keys to the executive washroom happily.
      When I talked to Brusatore back in the day about what that meant for the tech VDL had licensed to Abattis, he first told me, “We’ll just talk to them and do a deal if we need to use it.” A few weeks later, he said there was no need for such a deal because, “We changed the tech.”
      Abattis wasn’t having that, but had no reason to complain since Affinor had switched gears from weed to strawberries. But then Affinor started talked to people at PhytaLab, Abattis’ Washington State-based weed lab, and when those people bailed to start their own company, presumably with Affinor backing (and, Abattis says, with PhytaLab trade secrets), Abattis pulled the legal trigger ...

      Link: http://www.stockhouse.com/news/newswire/2015/01/05/medical-m…
      1 Antwort
      Avatar
      schrieb am 16.01.15 13:00:45
      Beitrag Nr. 141 ()
      Abattis Announces a Manufacturing Partnership With Empirical Labs of Ft. Collins, Colorado
      January 15, 2015 23:55 ET

      VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 15, 2015) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK:ATTBF)(CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announces a manufacturing partnership with Empirical Labs of Ft. Collins, Colorado.

      Link: http://www.marketwired.com/press-release/abattis-announces-m…
      1 Antwort
      Avatar
      schrieb am 16.01.15 13:14:10
      Beitrag Nr. 142 ()
      Antwort auf Beitrag Nr.: 48.796.487 von webmimi am 16.01.15 13:00:45
      Abattis (OTCQX: ATTBF) Partnership With Empirical Labs
      This relationship will allow Abattis Bioceuticals Corp. the exclusive license for Cannabidiol rich hemp oil products delivered directly to licensed physicians and dispensaries.



      Empirical Labs is a high quality nutraceutical manufacturing facility located in Fort Collins, CO at the foot of the Rocky Mountains.

      In 1989, Herbalists Kelly and Nazreen Goyen started Empirical Labs. As natural health enthusiasts they used their own experiences in healing to help shape Empirical Labs. Their work towards providing high quality nutraceutical products for doctors and consumers in a timely and professional manner quickly earned them a reputation as having a keen sense of quality when selecting herbs, extracts, vitamins and minerals

      Link: http://www.empirical-labs.com
      Avatar
      schrieb am 23.01.15 18:50:08
      Beitrag Nr. 143 ()
      Abattis (OTCQX: ATTBF) - The Marijuana Market Is Expanding: Here Are A Couple Ways To Get Involved

      By Laura Brodbeck, Benzinga Staff Writer - January 23, 2015 7:28 am

      " Abattis Bioceuticals Corp is a Canadian company that provides growers with the equipment needed to efficiently grow marijuana. Last year, Abattis acquired new fertilizer formulas and a new testing lab after raising $3 million from investors. "

      Link: http://www.benzinga.com/news/15/01/5167781/the-marijuana-mar…
      Avatar
      schrieb am 23.01.15 22:55:58
      Beitrag Nr. 144 ()
      This isn’t a football game. This is an investment - Abattis Bioceuticals Corp. (OTCQX: ATTBF)
      420 Stock Talk ♣ Examining Marijuana Stocks & Investors' Opinions ♣
      January 21, 2015 - 420 Stock Talk - ATTBF


      You Can’t Push Abattis CEO Mike Withrow Around – Lessons From Vertical Designs and Affinor Battle

      If you follow Abattis Bioceuticals closely enough, you may have felt as if you were reading a suspense novel during the month of December and especially after Christmas of 2014.

      Shortly after Abattis was able to successfully add to its legal victories over Herbal Analytics, Affirnor Growers, LLC, Nicholas Brusatore, et al (please see “Abattis Obtains Preliminary Injunction Against Defendants In King County, Washington State Court”: http://www.abattis.com/s/news.asp?ReportID=689317), Vertical Designs Ltd. (VDL) issued a notice that the license with Abattis had been officially terminated due to a breach of the agreement.



      Abattis CEO Mike Withrow didn’t waste any time. The very next day, he issued a statement rejecting the termination notice, claiming that Abattis maintained possession of the license, and suggesting that further legal proceedings against VDL would likely ensue in the near future.

      Most fascinating of all, Mike showed no intentions of holding back his true feelings. He openly criticized the VDL statement as an effort to “retaliate against Abattis and its shareholders” and further described those responsible for the announcement as “schemers”.

      If you visit message boards and other internet media, you’ll find some Abattis (ATTBF) and Affinor (RSSFF) holders bickering back and forth over these issues, almost like a grudge match. Amid the banter, however, you’ll also find some very interesting discussions about Nick Brusatore of Affinor. Some specifically berate Brusatore for playing games and issuing “fluff PR’s” as backlash for Abattis’ victories.

      I remain confident in Abattis Bioceuticals (ATTBF) and here’s why ...

      I’m not about to dive into any legal arguments or make conclusions about the future outcome of any legal battles. I’ll leave that to Abattis management and the courts, as it appears ATTBF already has the upper hand.

      But I will say this. I don’t believe for a split second that Mike Withrow would have been so frank and presented such bold statements on December 31 (2014) about the suspected purpose behind VDL’s statement –unless– he was especially confident that it was true.

      If there was merit to VDL’s claim, December 31st and the following days would most likely have been met with complete silence from Abattis. Mike isn’t the type to call specific attention to a situation while knowing it’s highly likely to blow up in his face a few months down the road.

      This isn’t a football game. This is an investment.

      I’m aware that any CEO can puff out his chest and gather praise and admiration from his stock holders for “looking tough.”

      Bear in mind that there’s a right way and a wrong way to stand up for your company and demonstrate leadership. For example, if you want to see a perfect, recent example of a CEO leading the way to absolute disaster in the marijuana industry, I recommend you research Bill Chaaban of FITX and his arrogant communication style.

      But rest assured that the goal here with Abattis and Mike’s statements isn’t simply to motivate investors to swing their pom-poms and cheer faster. Instead it’s a declaration that Mike understands shareholders’ frustration and he’s not going to tolerate competition and “schemers” that overstep their bounds. Mike clarified his stance while maintaining his professionalism.

      I, for one, am very pleased with the way he handled this situation. It’s made me feel a lot more confident with Mike at the wheel, steering the Abattis ship.

      Link: http://www.420stocktalk.com/you-cant-push-abattis-ceo-mike-w…
      Avatar
      schrieb am 23.01.15 23:34:22
      Beitrag Nr. 145 ()
      Antwort auf Beitrag Nr.: 48.632.174 von webmimi am 22.12.14 15:37:51
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) Already Performing Marijuana Growth Testing with LED Light ?
      420 Stock Talk ♣ Examining Marijuana Stocks & Investors' Opinions ♣
      January 15, 2015 - 420 Stock Talk - ATTBF


      The Abattis (ATTBF) share price has been taking a beating for a long time. To the untrained eye, the company appears to be standing still and not showing any progress.

      The dirty tango between Affinor and Abattis, including some downright suspicious P.R. moves by Affinor, isn’t helping matters either. Would it be any surprise to learn that many investors have been selling out of sheer frustration the past few months?

      Since ATTBF investors are already on edge, I’m not going to build up suspense and start some obnoxious 30 second drumroll. Instead, I’m going to cut to the chase and just explain what I think is… or will officially be… good news.

      I believe Abattis is currently undergoing testing with LED technology –but– they will be unable to announce the success and future implications of the trials for a while, possibly a few more months.

      I’ve gathered a lot of clues from different sources, and some new visual evidence helped confirm by original suspicions.
      Let’s first revisit a twitter picture post made on Nov 19, 2014 by Mr. Brayden Sutton, whom apparently had the pleasure of touring the BioCube and LED light technology.



      Take a minute to note the little details in the room. You’re about to see something very similar again soon.

      Although we could determine that Abattis had created an environment for their technology, no word or follow-up about the testing ever surfaced. Some investors even claimed that upon contacting the company in December, Abattis denied that the testing had even started. The lack of progress disheartened some outspoken investors, but then…

      Not too much later, right before Christmas of 2014, a site known as Led Horticulture posted several pictures about an anonymous LED light test being performed with medical marijuana via GrowthStarLED.

      http://www.ledhorticulture.com/are-medical-marijuana-produce…

      Go ahead and view some of the pictures for the full effect. I thought this picture was the most interesting:



      See the resemblances to the twitter picture posted earlier?

      Yes it’s true that the two pictures would have been taken from completely different angles, and under different lighting effects. It’s not bulletproof evidence by itself, and I won’t argue that.

      One specific and very intriguing section on the LED Horticulture blog post states:

      “This Vancouver producer asked to stay anonymous because of strict new Medical marijuana advertising laws in Canada that require them not to make marijuana products so appealing.”

      For those that don’t know, Abattis is headquartered in Vancouver, BC.

      They also bring up another noteworthy point about advertising.
      Don’t expect Abattis to confirm or deny any of this. Not yet anyway.

      Massive production of marijuana is still a very sensitive topic in both the U.S. and Canada as well. I’m also sure Health Canada is aware and uncomfortable with the fact that many hopeful MMPR licensed growers were having a field day, constantly touting their plans and projections on facebook, twitter and “you name it,” while watching their stock prices soar.

      The last thing Abattis would want to risk is their professional reputation with the Canadian government. I don’t expect any confirmation from Mike Withrow about Abattis testing until they are good and ready. And so it should be.

      If you dumped your ATTBF stock during the final months of 2014 because you grew impatient, waiting for some juicy P.R.,
      I think you’re going to really regret it.
      ATTBF needs to be treated as a long term investment.

      Complicated strategies surround this company and any serious investor hoping to eventually be rewarded will need to show a little endurance.

      Link: http://www.420stocktalk.com/abattis-attbf-already-performing…
      Avatar
      schrieb am 27.01.15 11:01:07
      Beitrag Nr. 146 ()
      Abattis Bioceuticals (OTCQX: ATTBF) - Pot Companies Among Biotechnology Stocks To Watch In 2015

      By Juliette Fairley - mainstreet.com - Jan 26, 2015 - 1:44 PM EST

      Viridian Capital & Research found that the cannabis biotech sector returned 339% in 2014.
      “The biggest hot button issue in pot biotech is when and if these pharmaceutical like pot products will emerge and what standards and guidelines we might see the FDA require,” Greiper told MainStreet.
      The top performing marijuana biotech stock in 2014 was Abattis Bioceuticals (ATTBF) with gains of 850%.

      Abattis works to create medicine for targeted, specific diseases and medical conditions,” said Greiper. “If one of their marijuana drugs gets FDA approval, it will be a huge development and more people will invest.”

      Among concerns in the medical marijuana industry is that biotech companies are creating medicinal formations of different strains that will not be a pharmaceutical grade. Abattis responded by involving the company in testing.

      "Abattis is a majority owner in Phytalytics, which got a provisional license to act as a marijuana laboratory in Washington to improve controls around testing of strains for specific diseases and medical conditions,” said Michael Swartz, analyst with Viridian Capital & Research.

      Link: http://www.mainstreet.com/article/pot-companies-among-biotec…
      Avatar
      schrieb am 27.01.15 11:15:33
      Beitrag Nr. 147 ()
      Abattis (OTCQX: ATTBF) - Will Strong U.S. Dollar Lead To Canadian/U.S. Marijuana Firm Mergers ?
      Seeking Alpha | Jan. 26, 2015 5:10 AM ET | Includes: ATTBF, BAYPD, BNRDF, HMKTF, IMLFF, LGBI, MBOO, MZRRF, OGRMF, REFG, RSSFF, SPRWF, TWMJF, UPOT

      Nine Canadian marijuana firms, already accessing U.S. capital markets, are less costly in terms of U.S. dollars.

      Link: http://seekingalpha.com/article/2848636-will-strong-u-s-doll…
      Avatar
      schrieb am 27.01.15 11:56:08
      Beitrag Nr. 148 ()
      Report Predicts 18 States Will Legalize Pot by 2020

      time.com - by Katy Steinmetz - Jan. 26, 2015

      A new report predicts that 18 U.S. states will have legalized recreational marijuana in the next five years, a huge increase from the four states that currently have or are in the process of creating legal markets for pot.

      Link: http://time.com/3682969/pot-legalization-2020/

      The report, set to be released in February from ArcView Market Research, a firm that pairs investors with marijuana-related businesses, was sponsored by marijuana-industry groups and has a prolegalization tone. But their prediction is not simply self-serving optimism.

      Link: http://www.arcviewmarketresearch.com
      Avatar
      schrieb am 27.01.15 15:32:03
      Beitrag Nr. 149 ()
      Abattis (OTCQX: ATTBF) alligns talent and Mike Withrow moves to International Business Advisor
      Vancouver, BC, / ACCESSWIRE / January 27, 2015 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that effective February 1st. Mike Withrow will move from his role as CEO and Chairman to a new position as International Business Advisor where he has identified opportunities in legal jurisdictions that are strategic to Abattis.
      The board is in discussions with its members and will be appointing a new CEO shortly.
      The CEO and Chairman positions will be filled with someone who has good relations with Health Canada and can been seen as a good partner by Health Canada.

      The board thanks Mr. Withrow for his vision in the founding and development of Abattis Bioceuticals Corp., and for the energy he has devoted to bringing the company to a leadership position in the field of botanical medicine analytics and production in the biotech sector. Mr. Withrow will, in his new role as International Business Advisor he will continue to nurture strategic partnerships in select countries that enhance the corporation's activities and maximize value of the Abattis technologies and assets.

      Mr. Withrow was quoted as saying:
      "As a significant shareholder of Abattis, I believe this is the best thing for the company as it moves through its next stage of growth. I look forward to bringing strategic international business partnerships to the company. Now is the time to bring in a CEO who has a proven track record in managing revenue and rapid growth."

      As we align our talent Jaouad Fichtali, who was appointed in the role of Chief Technology Officer (CTO) of Abattis effective November 14, 2014, will be assuming a more focused role as Advisor of Extraction IP effective immediately. This will allow the company to focus on and deploy its extraction technology with foreign partners.

      Link: http://finance.yahoo.com/news/abattis-alligns-talent-mike-wi…
      2 Antworten
      Avatar
      schrieb am 27.01.15 19:55:33
      Beitrag Nr. 150 ()
      Antwort auf Beitrag Nr.: 48.898.031 von webmimi am 27.01.15 15:32:03
      Abattis Names William Fleming as CEO, Mike Withrow to Become International Business Lead

      VANCOUVER, BRITISH COLUMBIA (Marketwired - Jan. 27, 2015)

      Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK:ATTBF)(CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that William (Bill) Fleming, as Chief Executive Officer (CEO) of Abattis Bioceuticals Corp. effective February 1, 2015. He will succeed Mike Withrow, who is resigning his role as CEO and President to become International Business Advisor for Abattis and promote, develops, and manage opportunities for Abattis Bioceuticals Corp.

      Mr. Fleming has founded and served as CEO for a number of entrepreneurial companies and has served with senior executive teams dealing with equity and debt financings. Mr. Fleming has developed corporate strategies for a wide range of companies, from family-owned businesses to multi-national companies. Mr. Fleming is a member of the Qalipu Mi'kmaq First Nation and has provided Advisory Consulting services to Health Canada under the Public Health Information Surveillance program.
      Mr. Fleming is the Founder of Mernova Medicinal Inc., an Aboriginal owned company focused on becoming a Canadian producer of legal marijuana. Mr. Fleming is a graduate of St. Francis Xavier University and a recipient of the Canadian Armed Forces ROTP Scholarship.

      Link: http://www.marketwired.com/press-release/abattis-names-willi…
      1 Antwort
      Avatar
      schrieb am 29.01.15 02:17:14
      Beitrag Nr. 151 ()
      Abattis (OTCQX: ATTBF) Clarifies Previous Disclosure
      Vancouver, BC - January 28, 2015

      Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), announces that, as a result of a review by the British Columbia Securities Commission, it is issuing this news release to clarify its disclosures.

      Link: http://www.abattis.com/s/news.asp?ReportID=692690
      Avatar
      schrieb am 29.01.15 17:54:01
      Beitrag Nr. 152 ()
      Abattis (OTCQX: ATTBF) - Consolidated Financial Statements 2014/2013
      Consolidated Financial Statements
      For the years ended September 30, 2014 and 2013
      (Expressed in Canadian Dollars)

      Link: http://www.sedar.com/GetFile.do?lang=EN&docClass=5&issuerNo=…
      Avatar
      schrieb am 30.01.15 15:15:14
      Beitrag Nr. 153 ()
      Hier kennt der Kurs auch nur eine Richtung....Süd...südlicher....am südlichsten. Ist schon erschreckend wie der Kursabfall in einem Jahr ist....
      2 Antworten
      Avatar
      schrieb am 01.02.15 02:14:12
      Beitrag Nr. 154 ()
      Antwort auf Beitrag Nr.: 48.935.015 von sirlacoura am 30.01.15 15:15:14sirlacoura ... JA es ist deprimierend dabei zuschauen zu müssen. Aber in vielerlei Hinsicht auch verständlich und erklärbar.
      Abattis hat mit den unsäglichen Gerichtsverfahren - s.h. Affinor, Phytalab - keinen guten Start ins neue Jahr hingelegt. Produktankündigungen bez. Empirical Labs wurden für Januar 2015 gemacht. Bis auf eine Meldung der Zusammenarbeit aber nichts konkretes dazu verlautbart.
      Link:
      http://www.abattis.com/s/news.asp?ReportID=691381

      Der Abtritt von Mike Withrow als CEO hat auch einige verunsichert - zumal er im Dezember einen ordentlichen Batzen seiner Aktien verkauft hatte (wie man hört aus steuerlichen Gründen). Aber keine Angst, Mike bleibt der Firma als Manager im International Business Development erhalten - dazu siehe mein nächstes Posting :cool:.

      Wohl jeder Investierte hatte im vergangenem Herbst, spätestens für Ende November 14, damit gerechnet, dass man wenigstens für eine der Firmen "die im Rennen sind" und an denen Abattis beteiligt ist eine MMPR Lizenz erhält.
      Die Rechnung ging nicht auf - die Hoffnung wurde leider nicht erfüllt. :keks:
      Die Prüfungen durch Health Canada dauern immer noch an -
      das bedeutet aber auch, die Chancen sind immer noch gegeben!
      Links:
      http://finance.yahoo.com/news/abattis-acquires-16-200-sq-192…
      http://finance.yahoo.com/news/abattis-announces-zoning-appro…

      Doch wie mittlerweile jedem klar geworden ist, Health Canada arbeitet sehr langsam die Anträge ab - ob das Unfähigkeit, Bürokratie oder gar "politisch gewollt" ist - :mad: - wer weis das schon so genau? Siehe dazu auch folgenden Artikel.
      Link:
      http://www.huffingtonpost.ca/2015/01/28/health-canada-medica…

      Ich persönlich bin davon überzeugt, das Abattis zu einer der vertrauenswürdigsten Unternehmen in der neuen Marihuana-Branche gehört. Das sehen auch Andere (Profis) so - siehe Bewertung / Vertrauensbarometer auf marihuana-aktien.de
      Links:
      http://www.marihuana-aktien.de/abattis-bioceuticals-ord-attb…

      http://www.marihuana-aktien.de/vertrauensbarometer/

      Nicht zuletzt die OTCQX-Uplistung zeigt, Abattis möchte sich berechtigtes Vertrauen verdienen.
      Link:
      http://finance.yahoo.com/news/abattis-makes-history-first-ma…

      Ich rechne mit baldigen, sehr positiven Nachrichten - der Kurs wird sich erholen !
      1 Antwort
      Avatar
      schrieb am 01.02.15 02:38:22
      Beitrag Nr. 155 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Arabidopsis seed harvested from Biocube
      Twitter-News from Abattis Bioceuticals Corp.


      Abattis Bioceuticals@Abattis - 14:41 - 31. Jan. 2015
      We paid $150 g for the Arabidopsis seed used to create 6 lbs of seed. Biocube technology smashed the yeild even the producers get. Amazing!
      Mike Withrow Abattis new International Business Development with 6 lbs of Arabidopsis seed harvested from Biocube

      Link: https://twitter.com/Abattis/status/561653578561880065

      1 Antwort
      Avatar
      schrieb am 01.02.15 02:55:27
      Beitrag Nr. 156 ()
      Antwort auf Beitrag Nr.: 48.945.050 von webmimi am 01.02.15 02:38:22Arabidopsis thaliana als Modellorganismus in der Biologie
      Die Acker-Schmalwand hat für die Landwirtschaft nur die Bedeutung, dass sie als „Unkraut“ gewertet wird, wurde aber bereits in den 1940er Jahren als Modellorganismus in der Genetik etabliert. 1943 wurde von Friedrich Laibach die Möglichkeit beschrieben, Arabidopsis als Modellpflanze einzusetzen. Die Vorteile, die die Pflanze bietet, sind beispielsweise:
      Sie hat ein relativ kleines Genom von 125 Mbp, dessen Sequenzierung im Jahr 2000 abgeschlossen wurde.[3] Das Genom besteht vorwiegend aus codierenden DNA-Sequenzen.
      Sie hat nur fünf Chromosomenpaare (2n = 10), von denen bereits detaillierte Karten erstellt werden konnten.
      Sie hat einen kurzen Generationszyklus von nur acht Wochen (von der Keimung des Samens bis zur Reife der Samen).
      Sie lässt sich auf relativ kleinem Raum einfach kultivieren.
      Es sind bereits viele Mutanten bekannt, die in den Stock-Centern bestellt werden können. Deren Langzeitaufbewahrung als Samen ist ausgesprochen einfach.
      Es können genetische Manipulationen durchgeführt werden, z. B. Transformation durch Agrobacterium tumefaciens.
      Arabidopsis repräsentiert die Physiologie höherer Pflanzen gut (Beispiel Lichtphysiologie).

      Quelle: http://de.wikipedia.org/wiki/Acker-Schmalwand
      Avatar
      schrieb am 01.02.15 20:54:45
      Beitrag Nr. 157 ()
      Antwort auf Beitrag Nr.: 48.945.026 von webmimi am 01.02.15 02:14:12
      Abattis (OTCQX: ATTBF) - Investors Sing The Blues
      420 Stock Talk ♣ Examining Marijuana Stocks & Investors' Opinions ♣
      January 29, 2015 - 420 Stock Talk - ATTBF


      Abattis – ATTBF Investors Sing The Blues As CEO Mike Withrow Unexpectedly Exits The Throne Room

      I’m not a fan of hosting pity parties or erupting with obnoxious levels of optimism to help sugercoat a painful experience.
      The Abattis CEO and former mastermind, Mike Withrow, that many investors came to respect over these past couple years has been replaced with William Fleming. ATTBF fell below 10 cents per share and is sitting deep in the red.
      Financial data was released on 1/28, and aside from a little revenue from Phytalab, the big buck opportunities are yet to be witnessed.

      There it is. That’s the reality. For the longs, this hurts.

      Following these discouraging announcements, many long term ATTBF investors have officially thrown in the towel, washed their portfolio clean of the remaining shares, and made no hesitation in voicing their anger and disappointment.

      Do I blame them? No. I’m also disappointed.

      And for the ATTBF investors acting as if they’re overjoyed that the stock they bought at 20 cents — or 50 cents — or even
      2 dollars — is now sitting between 7 and 10 cents because it provides a new, incredible buying opportunity — let’s get real.
      You may be stocking up right now, but you’re also feeling the pain with everyone else.

      Will I follow the sellers? NO. Not based on these events alone.

      This story has yet to entirely play out, and it’s very easy to lose focus of the long term possibilities, while solely concentrating on the potential catastrophes, when you’re smacked upside the head with multiple disappointments all at once.
      Yes, I have mixed feelings about what transpired in January 2015. Although it’s easy to touch on the negatives, I think we should also carefully take time to reflect on some positives.

      I want to congratulate a rather popular Abattis advocate on both the Investors Hub community and Twitter who goes by
      Shark Attack”. This individual just recently presented an excellent 12 point summary explaining why he remains an ATTBF long on I-Hub, and it’s worth the read for anyone sitting on either side of the fence.
      You can read the official posting here, but I’ve also provided a copy below, since I’ve had a couple of my readers imply that posts often mysteriously disappear on I-Hub.

      Link: http://www.420stocktalk.com/abattis-attbf-investors-sing-blu…

      Originally posted on Thursday, 01/29/15 08:46:54 AM
      Avatar
      schrieb am 03.02.15 10:40:46
      Beitrag Nr. 158 ()
      ATTBF (OTCQX: ATTBF) - MEDICAL MARIJUANA - POSITIVE ENTWICKLUNGEN AUCH IN DEUTSCHLAND
      ntv - Dienstag, 03. Februar 2015 09:42 Uhr Frankfurt

      CSU-Politikerin für Cannabis als Medizin

      "Wir wollen noch dieses Jahr das Gesetz durch den Bundestag bringen, damit es ab nächstem Jahr greift",
      kündigte die Drogenbeauftragte der Bundesregierung, Marlene Mortler, an.

      Cannabis ist die am häufigsten konsumierte illegale Droge in Deutschland - aber auch Basis für Medikamente.
      Den beiden Hauptwirkstoffen Tetrahydrocannabinol (THC) und Cannabidiol (CBD) wird eine krampflösende und schmerzlindernde Wirkung zugeschrieben.

      Link: http://www.n-tv.de/politik/CSU-Politikerin-fuer-Cannabis-als…
      Avatar
      schrieb am 03.02.15 18:32:58
      Beitrag Nr. 159 ()
      Antwort auf Beitrag Nr.: 48.902.162 von webmimi am 27.01.15 19:55:33
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) CEO - Letter to Shareholders

      Avatar
      schrieb am 04.02.15 03:22:59
      Beitrag Nr. 160 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - re-entry initiated on February 2nd 2015
      Brayden Sutton@youtube - Veröffentlicht am 02.02.2015

      One year later and here I am re-entering Abattis at $.13.

      Avatar
      schrieb am 05.02.15 00:53:56
      Beitrag Nr. 161 ()
      Abattis (OTCQX: ATTBF) Enters Into US$25 Million Equity Line Facility Agreement with Dutchess Opportunity Fund
      Marijuana Stocks News - Feb 4, 2015

      VANCOUVER, BRITISH COLUMBIA–(Marketwired – Feb 4, 2015) – Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (ATTBF)(CSE:ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, including medical marihuana, announced that it has entered into a US$25 million equity line facility agreement with Dutchess Opportunity Fund, II, LP, a Delaware Limited Partnership – (“Dutchess”). The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission (“SEC”) covering the Abattis shares that may be issued to Dutchess under this financing. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of three years to sell up to US$25 million of common shares to Dutchess under the terms of the financing agreement, which shares will be issued at the current market price less permitted discounts in effect during such issuances. Proceeds from this transaction will be used to fund the continued development of the Company’s GDERS (grow, dry, extract, refine, sell) strategy spanning the entire industry supply chain from seed to sale.

      Link: http://marijuanastocks.com/attbf-enters-us25-million-equity-…
      Avatar
      schrieb am 06.02.15 00:53:44
      Beitrag Nr. 162 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - On CannaCon Seattle 2015 Exposition

      CannaCon welcomes Abattis to our CannaCon Seattle 2015 Exposition. Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal and adult marijuana markets in North America. http://www.abattis.com/

      Link: https://www.facebook.com/permalink.php?id=381483001995185&st…
      Avatar
      schrieb am 10.02.15 15:18:12
      Beitrag Nr. 163 ()
      Hi und einen guten Tag an alle Abattis Bioceuticals Corp. (OTCQX: ATTBF) Interessierten.
      Ich stelle fest, dass von Tag zu Tag immer mehr Leute diesen thread aufrufen.
      Täglich sind es weit mehr als 500 Personen die hier hereinschauen, mit steigender Tendenz.
      Leider beteiligt sich ganz selten jemand - das finde ich schade :( !
      Ich poste all diese Informationen zu Abattis, weil ich vom Erfolg des Unternehmens sehr überzeugt bin
      und nicht weil ich gerne die Rolle der "Alleinunterhalterin" spiele ...:rolleyes:

      Falls es euch zu anstrengend oder aufwendig ist - das ganze Geschreipsel und Geposte,
      dann stellt doch einfach nur z.B. ein Hurra in den thread :laugh: !
      Grund genug dazu ist auch wieder da ... der chart der letzten Tage sieht doch echt gut aus, oder ?
      Wie hoch wird ATTBF steigen bis sie auf Widerstand stösst - gibt jemand einen Tipp ab ?
      Oder einfach nur ein Hurra ... :kiss:
      In diesem Sinne ...
      Hurra
      webmimi

      Avatar
      schrieb am 11.02.15 00:52:26
      Beitrag Nr. 164 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - A Favourite In The Race For Long Term Sustainability
      investorintel.com - Posted on February 10, 2015 by Dr. Luc Duchesne


      Abattis positions strong in medical and cannabis value-chain with $25M financing
      With $25 M financing Abattis Bioceuticals Corp. (OTCQX: ATTBF | CSE: ATT) is showing the cannabiz world a new integrative business model, making it a favourite in the race for long term sustainability.
      Farming is tough business: while some crafty farmers make money but those who become rich from farming are those who provide goods and services to farmers. Why wouldn’t it be the case in the marijuana business?
      Mind you, a cannabis plant can be worth as much as a thousand bucks because of prohibition, but the same fundamental issues control success: nutrients, pathogens, insects, quality control, and value-added opportunities.

      This is especially true in Canada where the slowness of the Canadian government at granting MMPR licenses has made cannabis investors into disillusion. Canadian would-be growers like drivers driving on reverse on a one-way street: trying to find a way to make things work without looking silly. Fundamentally investing into would-be MMPR growers has become highly risky unless management finds business mitigation risks.

      Such is the case for Abattis and it has the funds to do so.
      With its recent disclosure of $25M in funding Abattis Bioceuticals Corp. is in position to become a leader in the growing, testing, and distribution of medical and adult-use cannabis in North America. Through its network of subsidiaries and partners, the Company is deploying a pioneering GDERS (grow, dry, extract, refine, sell) strategy to span the entire industry supply chain from seed to sale. These subsidiaries and partners specialize in cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services across the continent.

      I like that Abattis is a technology consolidator. There is a real business opportunity by consolidating emerging businesses along the value chain. One of the biggest cannabiz challenge marijuana business is that experts are the small growers with all kinds of processes and remedies that they’ve demonstrated to support their family while worried that the sheriff department would break down the front door in the middle of the night.

      Abattis entered into a US$25 million equity line facility agreement with Dutchess Opportunity Fund, II, LP, a Delaware Limited Partnership – (“Dutchess”). The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission (“SEC”) covering the Abattis shares that may be issued to Dutchess under this financing. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of three years to sell up to US$25 million of common shares to Dutchess under the terms of the financing agreement, which shares will be issued at the current market price less permitted discounts in effect during such issuances.

      According to its quarterly disclosure ending September 30, 2014 the company had generated roughly $25k in revenues in 2013.
      In the short term it will be critical for Abattis to show how it can generate revenues quickly as a result of the deployment of its business plan.

      Link: http://investorintel.com/potash-phosphate-intel/abattis-posi…
      1 Antwort
      Avatar
      schrieb am 11.02.15 01:08:18
      Beitrag Nr. 165 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Biocell Labs Initiates Product Development
      Vancouver, BC - February 10, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that through it's wholly owned subsidiary, Biocell Labs, Inc., a Marketing agenda to deliver Hemp-based nutraceutical supplements to the licensed health care provider marketplace. Currently, the wholly owned subsidiary has 13 proprietary formulations for out-licensing to cosmetic, nutraceutical and pharmaceutical companies.

      Brazos Minshew, president of BioCell Labs, Inc. explains "There are four major pathways for nutraceutical distribution. The top tier is always the professional marketplace, where nutraceutical sales representatives call on licensed healthcare providers and educate them on the medical application of herbal medicines. These products are always governed by Government regulatory agencies, such as Natural Health Products - Canada. The physician or other licensed provider then makes the determination as to whether or not the nutraceutical will benefit the patient."
      Minshew explains that other nutraceutical distribution channels include Direct Response advertising (including internet sales), Direct Sales associations and the Retail marketplace, including brick-and-mortar vitamin stores, pharmacies or dispensaries.
      "Our nutraceutical products are really potent, powerful extracts of classic herbal medicines. For example, Actaea racemosa is known to reduce nerve pain and the pain associated with osteo- and rheumatoid arthritis, as well as anxiety. As such, these formulas may be appropriately applied to improve the health and wellbeing of people suffering from a host of physical and emotional imbalances" Minshew says.

      This announcement follows an agreement reached with Empirical Labs of Ft. Collins, Colorado for the exclusive use of patented liposome technology. "Liposomes are related to transport molecules that dramatically improves nutrient absorption into the cells of humans and animals. This has the effect of making the herbal remedies even more powerful and effective" states Emek Blair, Ph.D. Next steps for BioCell Labs, Inc. and Abattis BioCeuticals Corp. is to license these nutraceuticals through Health Canada's nutraceutical application process, then to craft legally-compliant literature to be used in training the licensed healthcare providers, to partner with a distribution channel and train their sales team, to craft marketing literature and finally to produce the products themselves.
      These products will be available to the public through licensed healthcare providers in Canada and the USA. Product launches are scheduled early in Q2, 2015, "In order to launch our products correctly, the company, rescheduled the launch date to make sure our partners are aligned, so that we can ensure a proper role out in a timely basis"

      Link: http://www.abattis.com/s/news.asp?ReportID=695743
      1 Antwort
      Avatar
      schrieb am 11.02.15 01:22:41
      Beitrag Nr. 166 ()
      Abattis Bioceuticals Corp. (OTCQX:ATTBF) - Abattis Retains J2 Response as a Marketing Partner
      VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 10, 2015) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX:ATTBF) (CSE:ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that Abattis has retained J2Response as a marketing partner.

      After a rigorous search for the right marketing firm for Abattis products, we are pleased to announce selection of J2Response Marketing as our preferred service provider for 2015.


      Link: http://www.stockhouse.com/news/press-releases/2015/02/10/aba…
      Avatar
      schrieb am 12.02.15 16:23:41
      Beitrag Nr. 167 ()
      Antwort auf Beitrag Nr.: 48.718.211 von webmimi am 07.01.15 17:31:23
      Abattis Bioceuticals (OTCQX: ATTBF) - The growing threat of an MMPR class action lawsuit


      Medical Marijuana Update:
      The growing threat of an MMPR class action lawsuit



      Chris Parry, Stockhouse.com

      Link: http://www.stockhouse.com/news/newswire/2015/02/11/medical-m…
      Avatar
      schrieb am 20.02.15 14:26:35
      Beitrag Nr. 168 ()
      Antwort auf Beitrag Nr.: 49.034.888 von webmimi am 11.02.15 00:52:26
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) secures M funding from Dutchess Capital
      InvestorIntel - February 19, 2015 — Tracy Weslosky, Publisher of InvestorIntel speaks to Bill Fleming, CEO and Director of Abattis Bioceuticals Corp. ("Abattis") (CSE: ATT | OTCQX: ATTBF) on the recent US$25 million equity line facility agreement announcement with Dutchess Opportunity Fund, II, LP (“Dutchess”). Further discussions on Abattis initiatives towards investment, incubation and technology partnerships as a fully vertically integrated company in the rapidly expanding botanical drug and product development market.



      Tracy Weslosky: Thank you so much for joining us today and congratulations on your new role as CEO. And, of course, you had really big news last week $25 million dollar line of equity. Can you talk to us about that?

      Bill Fleming: Absolutely. With Abattis we're pretty excited about working with Dutchess. Dutchess is a global investment firm and we've been working with Dutchess now for the last few months to see how we can move forward with them on some of our initiatives. Again, it's an equity line of credit and it's something we have the ability to be able to tap into at the right time. Obviously, as we move forward our company we're pretty excited some strategic opportunities that are out there and deal flow being one of them. That's for sure.

      Tracy Weslosky: Of course, all of the InvestorIntel audiences, I know a lot of us have been scratching our head on the cannabis and medicinal marijuana market. If you could just back us up and explain to our audience who Abattis Bioceuticals is.

      Bill Fleming: Well, as a company today we've got many lines that from a product side, but we're also involved in the investment. We're involved in incubation. We're involved with technology partnerships. We see ourselves as wanting to be a company that's vertically integrated. As we move forward into certain areas we're going to look at new technologies and new companies to either acquire or partner with on a go forward basis.

      Tracy Weslosky: What does that mean for Abattis?

      Bill Fleming: Well, what it means for Abattis is that we've actually got a good portfolio of companies. What we're doing now is we're looking at the realignment of some of these companies to make sure that there's some synergies between them. Ultimately where we see ourselves moving as a company is that we want to move further up the food chain. We see ourselves as moving more into the botanical space. Botanical is what we call the new wave of pharmacy. We see ourselves differentiating ourselves and anyone else that's out there because we have been pretty fortunate in finding some technologies, finding some great people, being able to work with some great financial partners. We foresee ourselves over the next few months as a company that's going to be more strategically aligned to go after the cannabis industry.

      Tracy Weslosky: So I received a lot of phone calls about your company when you received this $25 million dollar line with, who is this company and how did they manage to secure this. Can you talk to me a little bit about this? Does this have to do with management because you do have an impressive executive backgrounds?

      Bill Fleming: A lot of it comes down to relationships. If I was going to give anybody credit it would have to be our chief operating officer, Rene David. Rene's been the guy that's been out there pounding the streets getting the Abattis message out there. Where we are today is basically as a result of his relationships. Obviously, Dutchess is a great company…to view the rest of the interview, click here http://youtu.be/LK2JMSTpwKk
      Disclaimer: Abattis Bioceuticals Corp. is an advertorial member of InvestorIntel.

      Link: http://investorintel.com/potash-phosphate-intel/abattis-secu…
      Avatar
      schrieb am 20.02.15 14:40:06
      Beitrag Nr. 169 ()
      Antwort auf Beitrag Nr.: 49.034.909 von webmimi am 11.02.15 01:08:18
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - BioCell Product Launch at CannaCon and Update
      February 17, 2015 — Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX:ATTBF) (CSE:ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that through it’s wholly owned subsidiary, Biocell Labs, Inc., it will launch it’s first product at Cannacon.

      Cannacon 2015 is being held at Seattle’s Pier 91 Smith Cove Event Center
      on February 19-22, 2015 in Seattle Washington.


      Scheduled to attend is Abattis CFO Rene David, and BioCell Labs President Brazos Minshew. Biocell labs, Inc. is a wholly-owned subsidiary of Abattis Bioceuticals Corp. Michelle’s Sexton’s Phytalab Team will also be attending, Abattis owns a 51% interest in Phytalab LLC, which is a 502 licensed Washington State Testing facility.

      On display at Cannacon will be 8 phytocannabinoid formulas distributed by Abattis Bioceuticals, created by Biocell Labs, manufactured at Nature’s Formulae of Kelowna, BC, and marketed in the USA and Canada by J2Response, Bismarck North Dakota.

      Link: http://www.cnsx.ca/cmsAssets/docs/Filings/2015/2015_02_17_13…
      Avatar
      schrieb am 23.02.15 13:40:39
      Beitrag Nr. 170 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Eindrücke von der CannaCon 2015 Exposition in Seattle



      Phytalab and Abattis Bioceuticals Corp. at CannaCon 2015 in Seattle


      Kyle Shelton of Phytalab, has a back ground of testing experience from tobacco industry.


      Abattis Bioceuticals at CannaCon 2015. Notice the grow tech on display.


      Pi-Technic, Pi-Wall owner/partner in blue, launched Pi-Wall


      Digital shot inside BioCube, solid 8 Pi-Walls & floor model inside, Quotes for two tier 3 producers

      Links:
      https://twitter.com/abattis
      https://twitter.com/picksharkattack
      https://twitter.com/phytaLab
      https://www.facebook.com/CannaConNorthWest?fref=nf
      Avatar
      schrieb am 27.02.15 18:44:38
      Beitrag Nr. 171 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - An Interview with Abattis Bioceuticals
      Equities.com - February 17, 2015 4:30AM
      Building for the Marijuana Industry of Today and Tomorrow
      The marijuana industry is one with great promise… and relative uncertainty.
      Navigating the ever-changing regulatory environment is often fraught with difficulties, making it difficult to do the sort of long-term planning that most businesses rely on.
      However, some companies have found a middle-path, one that leverages the medical benefits of marijuana in entirely legal ways, including some that don’t involve any controlled substances, as well as preparing for a potential future where many of the legal restrictions currently in place are lifted.
      Abattis Bioceuticals (ATTBF) is one such company. Equities.com got a chance to sit down with new CEO William Flemming, CFO/COO Rene David, and President of BioCell labs Brazos Minshew to talk about how Abattis is preparing for the future and the present.

      Link: http://www.equities.com/spotlight/spotlight-companies/buildi…
      Avatar
      schrieb am 03.03.15 20:51:18
      Beitrag Nr. 172 ()
      Abattis Bioceuticals Corp. - Consolidated Financial Statements for the three months ended December 31, 2014
      Letzter Quartalsbericht von Abattis Bioceuticals Corp. (OTCQX: ATTBF) (sh. Interim financial statements/report-English).
      Nach dem Link auf das Feld

      klicken ...
      Link: http://www.sedar.com/DisplayProfile.do?lang=EN&issuerType=03…
      Avatar
      schrieb am 10.03.15 09:22:47
      Beitrag Nr. 173 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Baby Boomers Spend Billions to Stay Young
      VANCOUVER, British Columbia, March 9, 2015 (GLOBE NEWSWIRE) — By Financial Press — According to New York based Transparency Market Research the global nutraceuticals market will reach $204 billion by 2017 – fueled by health obsessed baby-boomers – who still ski and play competitive sports into their 60s and 70s.

      Link: http://marijuanastocks.com/attbf-baby-boomers-spend-billions…
      Avatar
      schrieb am 10.03.15 09:26:26
      Beitrag Nr. 174 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Announces Private Placement
      VANCOUVER, BRITISH COLUMBIA– Marketwired – Mar 9, 2015 – Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (ATTBF)(CSE:ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce a proposed private placement of up to $250,000.

      Link: http://marijuanastocks.com/attbf-announces-private-placement…
      Avatar
      schrieb am 10.03.15 11:20:37
      Beitrag Nr. 175 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - End Of The Federal Prohibition On Medical Marijuana?
      washingtonpost.com - by Niraj Chokshi - March 9 at 7:20 PM - The historic medical marijuana bill a trio of senators plan to unveil on Tuesday has a bit of something for everyone ...
      Link: http://www.washingtonpost.com/blogs/govbeat/wp/2015/03/09/wh…
      Avatar
      schrieb am 10.03.15 12:13:00
      Beitrag Nr. 176 ()
      Ich hadere immer noch mit einem Invest Mimi. Jetzt die KE. Hm....
      1 Antwort
      Avatar
      schrieb am 20.03.15 12:34:05
      Beitrag Nr. 177 ()
      Antwort auf Beitrag Nr.: 49.286.789 von sirlacoura am 10.03.15 12:13:00
      ATTBF - M Funding From Dutchess Capital - D. Leighton Of Dutchess Capital Shares His Views on MJ Investing
      Wenn Du noch nicht investiert bist musst Du doch nicht hadern sirlacoura?
      Schon gelesen(?):

      March 09, 2015 - Interview by Vin Maru from Invest In MJ with Doug Leighton from Dutchess Capital.

      Douglas Leighton is co-founder and a principal partner of Dutchess Capital. He has over two decades of experience in equity trading, investment banking and asset management. While the firm is industry agnostic regarding its selection of investments, Douglas has led Dutchess’ initiative into the legal cannabis sector and is also a member of the firm’s Investment Committee.

      Hello Doug,
      Thank you for taking the time to speak with Invest In MJ.com. As a leader in the Cannabis Industry your insights are appreciated and our readers will benefit from the wealth of knowledge that you share with us.

      IMJ: Tell us a little about yourself and why you became interested in the cannabis industry.

      DL: I have been investing for over 25 years. I initially became interested in the cannabis space when Massachusetts passed their medical cannabis law. My initial reaction was this was going to be a massive industry once people started to realize the true benefits of the plant. The black market for cannabis is a $50 billion business each year, while the legal market is $2.5 billion. The demand exists for this product, it just needs to be serviced legally. That is going to happen over the next several years.

      IMJ: As an investor in the legalized cannabis sector, can you provide us a brief background on your company and what products or services it offers?

      DL: We are a hedge fund that acts as a private equity fund for the cannabis space. For 20 years, we have invested over $2 billion dollars in transactional value in over 400 companies around the globe. We have taken our knowledge and investment experience from the past two decades and are now applying it to the cannabis industry to help small cannabis companies scale. We not only bring capital to the table, but also a wealth of knowledge about how to build businesses. Additionally, we are also helping connect people in the cannabis space and bringing in people outside the industry with strong backgrounds in other business.

      IMJ: Dutchess Capital has successfully funded several different companies in the last year, what attracted you to these deals and why do you feel they will be successful?

      DL: Our first investment was MassRoots, the social network for the cannabis space. It was compelling as it has the ability to scale to great size without large physical assets, infrastructure or massive capital injections. While Google, Facebook and others don’t allow cannabis advertising, this is a perfect spot to drive ad revenue. We also were attracted to Dixie Elixirs and Foria, both companies that have stepped up their marketing and branding to really look like mainstream brands. We think that is where the market is headed. We also like the consulting space. We invested in American Cannabis Company (ticker AMMJ), which provides consulting from inception of an idea to operating the business and also makes and sells their own products as well as others into the space.

      IMJ:
      When evaluating an investment opportunity, what do you specifically look for in a successful candidate to help fund?

      DL: The first thing we look at is the people operating the company. Is it the right person to run the business? Does the business solve a problem? Does the business save time or money? Is it scalable and what is the exit? Is there something unique about the business, are the gross margins enough to grow the business now, and if they are so large, can the company survive when competition begins to enter the space. There are many other metrics we look at, but those are paramount.

      IMJ: List the three most important criteria a company must meet before you proceed in funding them and why are they important?

      DL: 1) Qualified management. A great team can sell a bad product, but a bad team can’t sell a great product. 2) Demand for the product based on solving a problem or saving money. A product will sell if it fits either of those two criteria. 3) Defensible idea or stickiness to the product. A product that no one else has or reoccurring revenue are what we like to see ...

      Link: http://www.investinmj.com/interviews/doug-leighton-of-dutche…
      Avatar
      schrieb am 20.03.15 13:02:44
      Beitrag Nr. 178 ()
      ABATTIS CLOSES THEIR PRIVATE PLACEMENT
      Vancouver, BC - March 19, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, is pleased to announce that further to its news release of March 9, 2015 and amended release dated March 16, 2015, it has now closed the non-brokered private placement of 2,365,072 units for gross proceeds of $307,460.

      Link: http://www.otcmarkets.com/stock/ATTBF/news?id=99869
      Avatar
      schrieb am 16.04.15 21:00:30
      Beitrag Nr. 179 ()
      Abattis Bioceuticals Corp. (ATTBF) und Affinor Growers legen Rechtsstreit in Washington gütlich bei
      10. April 2015 - Die von Abattis im King County im US-Bundesstaat Washington eingereichte Klage gegen Nick Brusatore, Executive Director von Affinor, und Affinor Growers LLC wird fallen gelassen und der Rechtsstreit einvernehmlich beigelegt. Dies lässt die Möglichkeit einer zukünftigen Zusammenarbeit der beiden Unternehmen offen. Beide Parteien sind sich einig, dass die Gerichtsverfahren nicht nur kostspielig und zeitaufwendig waren, sondern auch die Steigerung des Unternehmenswerts beider Parteien beeinträchtigte.

      Die von der Abattis Bioceuticals Corp. (ATTBF) eingereichte Klage gegen Herbal Analytics, LLC, James Baxter, Kaleb Lund, Lauren Hilty, und Erin Leary bleibt davon jedoch unberührt und wird weiterhin aufrecht erhalten.

      Link: http://finance.yahoo.com/news/affinor-growers-abattis-bioceu…
      Avatar
      schrieb am 16.04.15 22:32:19
      Beitrag Nr. 180 ()
      Sag mal Mimi, hat abattis eigentlich eine Lizenz erteilt bekommen bzw beantragt? Wenn ja wann? Und nur für CAN oder auch in den Staaten?
      1 Antwort
      Avatar
      schrieb am 18.04.15 14:34:20
      Beitrag Nr. 181 ()
      Antwort auf Beitrag Nr.: 49.583.867 von sirlacoura am 16.04.15 22:32:19
      Abattis Bioceuticals Corp. (ATTBF) und seine bei Health Canada beantragte MMPR Lizenzen
      Hi sirlacoura, nein die haben noch keine abschliessende Lizenz erteilt bekommen.
      So wie ich allen zugänglichen Infos entnehmen konnte wurden drei Lizenzen beantragt.
      1.) Experion Bio Technologies Inc. application "The British Columbia Application"
      2.) BioCell Labs Inc. application "The Quebec Application"
      3.) iJuana Cannabis Inc. application "The Squamish Application"
      sowie ... "Strategic investments in MMPR applicant True Leaf Medicine Corp."

      Die 7 Prüfungs-Stufen bis zur endgültigen MMPR-Lizenzierung durch Health Canadahabe habe ich in meinem
      Beitrag Nr. 115 (48.359.239) beschrieben.


      Meldung vom 09. Juni 2014:
      Abattis announced that it has leased a 16,200 square foot facility zoned for medical marijuana near Vancouver, B.C. with the potential to expand to up to 254,000 square feet. Abattis Bioceuticals' cultivation partners, Experion, has an additional 4,000 square foot growing facility with 10 acres that could be used to support growth. Currently, the subsidiary is in the late stages of MMPR licensing with Health Canada awaiting inspection and a letter to build. The Biocube environments that will be used in both facilities are designed to produce food and pharma-grade material and prevent the loss of crops due to infestation, mold, and contamination by maintaining separate small controlled environments for specific cannabis strains.
      Additional MMPR licensing applications are pending with the Company's other subsidiaries, including BioCell Labs. Abattis continues to add to the cumulative zoned MM space in Canada with strategic investments in MMPR applicant True Leaf Medicine Corp. Northern Vine Canada Inc., a subsidiary of Abattis, is also in the late stages of its application for a Controlled Substance License, which will enable the company to extract and test compounds in cannabis.
      Link: http://www.abattis.com/s/news.asp?ReportID=657960

      Meldung vom 08. Oktober 2014:
      The company has received many calls from investors and shareholders asking about the status of the three licenses our companies have applied for. We respond on time to each request from Health Canada, who has been very clear and succinct with its requests for clarification on our applications ...
      BioCell Labs Inc. application "The Quebec Application" now is entering the Security Clearances stage. The MMPR application process is an important process for both Health Canada and applicants to go through. The process ensures that only quality operators that meet the strictest of standards are awarded the License to Produce Medical Marijuana and we support this approach.
      Link: http://globenewswire.com/news-release/2014/10/08/671645/1010…

      Information von der Abattis-Internetseite:
      iJuana Inc. is a wholly owned subsidiary of Abattis Bioceuticals Corp. (OTC: ATTBF) (CSE: ATT) that has has leased a 27,000 sq. ft. facility in a pre-appoved zoned area to become a Licensed Producer under Canada's Marihuana for Medical Purposes Regulations ("MMPR"). With operations in Squamish, British Columbia, the company aims to become the licensed cannabis growing arm and consumer-facing entity for Abattis Bioceuticals. The market for medicinal marijuana is estimated to reach $1.3 billion in Canada by 2024, according to estimates made by Health Canada. iJuana owns 75 Natural Health Product Licenses "NPN's" issued by Health Canada.
      Link: http://www.abattis.com/s/our_companies.asp

      Eine zusammenfassende Information zum derzeitigen Status siehe auch Meldung vom 25.03.2015:

      S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports
      Link: http://money.cnn.com/news/newsfeeds/articles/prnewswire/NY64…
      Avatar
      schrieb am 20.04.15 09:25:43
      Beitrag Nr. 182 ()
      Vielen lieben Dank Mimi. Kann nicht ganz genau einschätzen wie hoch hier das Potential ist. Leider ist die Aktie ja mächtig eingebrochen und bewegt sich seit Monaten nur noch seitwärts ohne großes Volumen. Hm...Quo vadis???
      1 Antwort
      Avatar
      schrieb am 20.04.15 20:38:29
      Beitrag Nr. 183 ()
      Antwort auf Beitrag Nr.: 49.599.737 von sirlacoura am 20.04.15 09:25:43;) Dum spiro spero ...
      Fluctuat nec mergitur :cool:
      Avatar
      schrieb am 28.04.15 21:52:48
      Beitrag Nr. 184 ()
      Investor Update for Q2 2015 from Abattis Bioceuticals Corp. (OTCQX:ATTBF)
      Abattis would like to update Investors on work underway at the Company and the status of work under the Company's wholly-owned subsidiaries and partners. The Company is currently:
      Evaluating current assets;
      Awaiting Northern Vine's rebranded websites to go live;
      Expecting Biocell to bring products to the direct sales market;
      Working through the research and development (R&D) at Biocube following a successful growth trial run;
      Holding a future pipeline of product opportunities in IJuana; and
      Assessing the use of the Phytalab business model for deployment into Northern Vine.
      Link: http://www.digitaljournal.com/pr/2535930
      Avatar
      schrieb am 07.05.15 12:31:20
      Beitrag Nr. 185 ()
      Abattis Bioceuticals Corp. (ATTBF) - appoints Hugh Oswald as Investor Relations
      Abattis Bioceuticals Corp.(ATTBF) recently released that Hugh Oswald, will assume the role of Investor Relations of Abattis Bioceuticals Corp. effective April 29, 2015. Hugh brings over 15 years of success in the public and private markets conducting Investor Relations and Direct Marketing. Described as a tenacious and enthusiastic professional with an entrepreneurial spirit who is driven, client focused, reliable, dedicated, ethical and trustworthy with expertise in the best communication practices for issuers. He has helped over 15 companies meet their marketing goals.

      Link: http://www.satprnews.com/2015/05/01/abattis-appoints-hugh-os…
      Avatar
      schrieb am 07.05.15 12:36:04
      Beitrag Nr. 186 ()
      Abattis Bioceuticals Corp. (ATTBF) Names Brazos Minshew Chief Science Officer
      Vancouver, BC - May 6, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets -- some of which will contain cannabinoid compounds, today announced that Brazos Minshew, former Chief Science Officer of TriVita, Inc., former Chief Executive Officer of Therapy Alternatives and Director of Marketing for Tiena Health, will assume the role of Chief Science Officer ("CSO") of Abattis Bioceuticals Corp. effective April 20, 2015.

      Brazos has been consulting for the Company since July 2014 and the Company is pleased to see him assume a larger role. Brazos commented, "By strengthening our scientific base, we look to obtain a leadership position for Abattis in deployment of innovative and breakthrough nutrition products that will improve human health for many years to come."

      Link: http://www.abattis.com/s/news.asp?ReportID=706666
      Avatar
      schrieb am 12.05.15 19:16:29
      Beitrag Nr. 187 ()
      Abattis Bioceuticals Corp. (OTCQX:ATTBF) Selects Ingredient Identity as Global Regulatory Management Partner
      Link: http://www.stockhouse.com/news/press-releases/2015/05/11/aba…
      Avatar
      schrieb am 22.05.15 09:42:02
      Beitrag Nr. 188 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Growing Out of the Changing Landscape
      ihrmagazine.com - by Dale Sproule - April 2015
      On the surface, Canada has a thriving hemp industry – with over twenty large-scale commercial producers currently growing medical marijuana for a customer base of over 35,000 licensed users. And then there are hundreds and hundreds of aspiring “farmers” with dollar signs in their bloodshot eyes – dreaming of getting in early to take advantage of an industry that is clearly poised to become massive.

      Health Canada told the Globe and Mail last summer that they were receiving an average of 25 applications a week (an extremely small percentage of which will ever get licenses to become producers) – and they projected that the number of patients using medical marijuana could easily blossom to over 400,000 within the next ten years.

      Then again, instead of becoming massive, the “industry” could well just sink back into the rocky ground from which it sprung – a crop blighted by a frosty political climate. The only thing that’s truly certain about the marijuana industry is its uncertainty. The Conservative government has made no secret of their antipathy towards the entire sector and no one can deny the stigma from decades of illegality and bad press, still floating in the air like a haze after a memorable and unruly rock festival.

      Medical marijuana producers are continuing to encounter well-documented difficulties marketing their products, with traditional advertising strictly forbidden – as are most other tried and true marketing methods. The industry is heavily regulated and perpetually scrutinized – so even with the experience, facilities, investors, credentials and a winning business plan, a company could end up falling on their face after a single misstep.

      Possibly, the smartest companies and savviest investors are the ones who follow the old adage
      “don’t put all your eggs in one basket.”
      In fact – the varieties of different baskets being created may surprise and delight you.



      Building a Market from the Ground Up

      Vancouver’s Abattis Bioceuticals Corp. has made a point of diversity from the beginning. It developed what it calls “an innovative GDERS (grow, dry, extract, refine, sell) strategy spanning the entire industry supply chain from seed to sale.” By operating a number of subsidiaries and working with a wide range of partners, it has put itself in a position where failure in any one area is extremely unlikely to bring down the entire company – but where profits coming from several different streams at the same time can funnel inward to help support the rest of the infrastructure.

      “At the end of the day, we know that we only have so much bandwidth,” says Abattis CEO, William (Bill) Fleming. “It’s all about understanding what you have now and how you can monetize it. There’s so much shifting sand in the market that you have to be very careful about where you start building your foundations.”

      The company’s current subsidiaries and partnerships include:

      BioCube provides controlled cannabis cultivation environments for high yield marijuana growing; North American Bioextracts Inc. plans to use proprietary extraction technologies to develop customized THC extract oils and CBD extract oils;

      Phytalab performs testing services under Washington State’s Initiative 502;

      Instant Payment Systems enables patients to make payments through electronic means

      And those are just a few of its many arms. The company also has subsidiaries awaiting approval to become licensed producers under Canada’s new Marijuana for Medical Purposes Regulations (“MMPR”) program.

      But with all that going on, Fleming insists “We believe that botanical is the next new wave of pharmacy. Right now within the industry, you look at the big pharmaceutical companies and everything that they’re doing today has been chemically synthesized, so consequently, they haven’t been doing much on the botanical side.”

      One of the best things to come out of the softening of the regulatory environment, is the growing body of pharmaceutical and nutraceutical research that is now able to be done on cannibinoids.

      “Since cannabis has always been a schedule one drug, there hasn’t been much research and development, because you weren’t permitted to do it,” says Fleming. “Even now, in order to really get in and be compliant for doing research and development and building an intellectual property around a cannabis based type platform you have to ensure that you conform to the regulations and guidelines (in whatever part of the world you’re operating). For example, in Canada if you’re going to do any kind of research and development with cannabis based products, then you need to have a controlled substance license.”

      Another of the Abattis subsidiaries – and the one that has been getting the most press for the last six months – is called BioCell Labs Inc. and is involved with research and development of nutraceutical products. They have been developing a line of phytocannabinoid formulas which include ECS Supreme, a functional beverage rich in phytocannabinoids. ECS Supreme is based in Canadian saskatoon berries and contains Abattis’ patented nitric oxide blend. Bio-cell simultaneously introduced seven other condition-specific cannabinoid formulas to address everything from nausea to anxiety to traumatic brain injury.

      There are over 150 compounds – including at least 85 different cannabinoids – which exhibit a vast range of properties and effects – that can be isolated from cannabis – and only one of them is renowned for its psychoactive properties. “But it’s the THC that is the issue,” Fleming admits, “because one of those 150 compounds just happens to be THC.”

      Link: http://www.ihrmagazine.com/retail-opportunities-growing-out-…
      Avatar
      schrieb am 22.05.15 09:58:14
      Beitrag Nr. 189 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Northern Vine Website Update
      Northern Vine Canada has applied for a Controlled Substance License with Health Canada, with an existing cannabis processing, testing, and packaging facility located in Langley, British Columbia. In addition to these services, the company will support its operations by providing analytical services for Licensed Producers and charging a fee to produce a Certificate of Analysis. The firm will also formulate compositions for sprays, creams, and tinctures that it plans to patent.

      The office of Northern Vine Canada Inc. ("NV Canada Inc.") is located at Unit 104 - 9295 198th Street, Langley, BC V1M 3J9.



      Abattis Bioceuticals Corp ("Abattis" or the "Company") acquired NV Canada Inc. in August 2012.
      The assets held under it is comprised of:

      GMP Site License, Building Improvements;
      Soft Gel Manufacturing Line & Packing Line;
      Health Canada Natural Health Product Licenses; and
      Inventory of Finished Products or Raw Materials


      Furthermore, Abattis acquired the assets from Sci-Natural Wellness Corporation ("Sci-Natural") during the same period. Abattis presently owns 16 Natural Health Product Licenses from this transaction.



      Northern Vine Canada will facilitate the availability of high-quality health products in Canada. Our primary focus in this endeavour is to provide quality control laboratory services on raw materials and finished products. Today’s licensed manufacturers are stringently regulated by Health Canada, and we are here to help by providing accurate, rapid, and cost-effective laboratory solutions to mandated quality control requirements.

      Northern Vine Canada Inc. operates a laboratory facility in Langley, BC with a focus on testing natural products, bioceuticals, nutraceuticals, and cosmetics.

      Northern Vine is a cGMP-designed facility, previously housing a small-scale natural health product manufacturer. Northern Vine currently holds 15 natural health product licenses issued by Health Canada under the Natural Health Products Regulations.

      Northern Vine has applied for a controlled substances license (“CSL”) from Health Canada.

      Contact Info
      104-9295 198th Street,
      Langley, BC V1M 3J9 Canada
      E-Mail: northernvinecanada@gmail.com
      Web: www.northernvine.ca
      Avatar
      schrieb am 06.06.15 02:48:25
      Beitrag Nr. 190 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Corporate Presentation - May 2015
      Bridging the gap between pharmaceuticals and nature - Promoting health through natural products
      Corporate Presentation from Abattis Bioceuticals (ATTBF) - Update May 2015

      Link: http://www.abattis.com/i/pdf/Presentation.pdf

      Avatar
      schrieb am 27.06.15 01:43:53
      Beitrag Nr. 191 ()
      Interview mit Bill Fleming, CEO von Abattis Bioceuticals Corp. (CSE: ATT | OTCQX: ATTBF)
      Clausi on Cannabis Industry Infrastructure: Abattis Bioceuticals
      Posted on June 26, 2015 by Peter Clausi - investorintel.com

      Jacob Securities hosted a Canadian Cannabis investor conference this week in Toronto. The MMRP licencees and applicants were well represented there, but so were the “infrastructure” players. Their view of the industry is very different from the producers’ view. Below is a brief Q&A with one such infrastructure participant, Bill Fleming, the CEO of Abattis Bioceuticals Corp. (CSE: ATT | OTCQX: ATTBF).



      In addition to Bill’s comments below, Abattis has a US$25 million equity line facility agreement with Dutchess Opportunity Fund, II, LP, and is actively searching for intelligent cannabis-related investment opportunities.


      Q: What makes Abattis Bioceuticals different from the other market participants?

      A: Abattis is able to provide proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. Abattis also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market.
      Subscribe here to receive free daily InvestorIntel updates
      Sign Up

      Our main differentiator is our people and our strategic partnerships. We have depth in our Board Members and we have some of the best scientific minds working with us in the herbal cannabis field. I’d like to say that we have a first mover advantage in that we are aggressively positioning ourselves to focus on the botanical drug development market which can be a fast track through the FDA approval process. We have the knowledge and intellectual capital to identify opportunity within this emerging industry.

      Q: How was the Jacob Securities conference?

      A: We found it extremely informative. The conference was well attended by the herbal cannabis heavyweights, the timing was perfect as it brought the right stakeholders to the table to share lessons learned, and we heard from industry leaders to gain insight into future growth areas.

      Q: What impressed you the most at the conference?

      A: The vast North American representation and the fact the attendees stayed for the whole event….the speakers were from Canada and the USA and it became apparent that there is no “one solution fits all” for the industry. All companies are experiencing fragmentation with regards to regulatory, finance, and commercial, which leads to investor uncertainty yet excitement. We all seem to be operating in silos without any cohesive fabric. The individual states in the USA are the most difficult as they seem to be levering the herbal cannabis industry as an economic stimulus opportunity to create jobs, and as such are not prepared to tackle the Federal cross-border issues.

      Q: What topic or company do you want to learn more about as a result of the conference?

      A: The biggest thing for me is to have a better legal and commercial understanding of herbal cannabis derivatives and how Abattis can position itself to play in this field. Ultimately, companies will be required to demonstrably show the efficacy of the foods, consistent dosages and clinical studies for pain management. One of the key market areas that was briefly mentioned by one of the attendees is the partnering with USA Tribal Reserves and I’m looking forward to discuss potential relationships in this untouched area.

      Q: Will the Allard decision from Canada’s Federal Court of Appeal have an impact on your business?

      A: Allard or any court decision that better legitimizes or defines the herbal cannabis industry is an advantage to Abattis Bioceuticals. The future is the efficacy and the prescriptive nature of cannabis and we at Abattis through our management and science team understand these guidelines, which will allow us to be one of the lead dogs in the hunt.

      Q: How do you see the edibles market developing in Canada over the next year?

      A: A medicinal user who on average consumes 5-10 grams per day has difficulty in trying to smoke or vapourize the dry bud in one day and therefore must look to alternate ways for ingesting the product. Ultimately, cooking dough manufacturers and others will be producing ready-to-eat cannabis products. This will have a ripple effect into other manufactured goods processes.

      Link: http://investorintel.com/agbusiness-mmj-intel/clausi-on-cann…

      About Peter Clausi
      Mr. Clausi is an experienced investment banker, executive and director. A graduate of Osgoode Hall Law School and called to Ontario's bar in 1990, Mr. Clausi has extensive experience in finance, shareholder rights and corporate growth. Mr. Clausi has been a guest lecturer at three Ontario MBA programs, and was an instructor at the Law Society of Upper Canada's bar admission course for over 10 years. Most recently, he was a speaker at the 2nd Securities Compliance for Mining Conference. He is executive vice-president of corporate affairs and general counsel of GTA Resources and Mining Inc.; an independent director and audit committee member of Baja Mining Corp.; and a past independent director of Aldrin Resources Corp.
      Avatar
      schrieb am 21.07.15 16:34:32
      Beitrag Nr. 192 ()
      Abattis Bioceuticals Corp. (ATTBF) Appoints Hugh Oswald as Investor Relations
      Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (ATTBF) (CSE:ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets – some of which will contain cannabinoid compounds, today announced that Hugh Oswald, will assume the role of Investor Relations of Abattis Bioceuticals Corp. effective April 29, 2015.

      Link: http://www.bestmedicalmarijuanastocks.com/abattis-appoints-h…


      Hugh Oswald - Consultant
      Vancouver, Canada Area, Investment Banking
      Current: TG Residential, WordLogic Corporation, Marifil Mines
      Previous: Ascenta Capital Partners
      Education: University of San Diego School of Business Administration

      Hugh Oswald is a Communications Specialist wirh over 15 years of success in the public and private markets conducting Investor Relations and Direct Marketing. Described as a tenacious and enthusiastic Professional who is driven, client focused, reliable, dedicated, ethical and trustworthy with expertise in the best communication practices for issuers.
      Avatar
      schrieb am 27.08.15 16:09:37
      Beitrag Nr. 193 ()
      Dot.com, Pot.com: We’ve Seen This Movie Before
      "... When the cannabis market rebounds, and it’s inevitable it will, one of our picks for who will be left standing is
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE:ATT). Go through the website and the press releases. You’ll find a strong management team, an experienced board, product diversification, some exposure to the MMPR’s for potential immediate upside if Allard and the election go the right way, a history of accessing capital as needed, and an unwillingness to spend that capital ..."

      Link: http://investorintel.com/agbusiness-mmj-intel/dot-com-pot-co…
      Avatar
      schrieb am 27.08.15 16:21:11
      Beitrag Nr. 194 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) Announces Sale of Hemp Glacier Water at Seattle Hempfest®
      Abattis Bioceuticals Corp., through it’s wholly-owned subsidiaries Abattis Bioceuticals International Corp. and Vergence Visionary Bioceuticals Corp., (the “Company” or “Abattis”) (OTCQX: ATTBF) (CSE: ATT), a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the pharmaceutical, nutraceutical, bioceutical and cosmetic markets – some of which will contain cannabinoid compounds, would like to announce the initial sale of 10,000 units of Glacier Hemp Water produced by Abattis and cobranded for sale with Nana’s Secret Soda of Washington State.

      Link: http://www.abattis.com/s/news.asp?ReportID=719693



      Hemp drink sales at Seattle Hempfest marks an emerging trend

      Link: http://investorintel.com/agbusiness-mmj-intel/hemp-drink-sal…
      Avatar
      schrieb am 30.09.15 01:53:01
      Beitrag Nr. 195 ()
      Hier passiert wohl nichts mehr
      Avatar
      schrieb am 10.10.15 13:58:59
      Beitrag Nr. 196 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Northern Vine Begins Security Build
      October 6, 2015 (Source: Abattis Bioceuticals Corp.) — Northern Vine Canada Inc. (“Northern Vine”), a subsidiary of Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX: ATTBF) (CSE: ATT), would like to announce that work has been initiated to complete the leasehold improvements for Northern Vine in support of its application for a Controlled Substance License.



      Northern Vine has applied for a Controlled Drugs and Substances Dealer’s License. This process includes an in-depth application in accordance with the Narcotic Control Regulations, including:

      Physical security
      Personnel
      Activities & substances
      Record keeping


      The pending Northern Vine application for a Controlled Drugs and Substances Dealer’s License is currently under review. The Company is in the process of completing all leasehold improvements to meet the specified security requirements; once all the outstanding items are complete, we will arrange an inspection to confirm that the security is in compliance with the requirements for Controlled Substances.

      See more at:
      http://www.cnsx.ca/cmsAssets/docs/Filings/2015/2015_10_06_9_…
      Avatar
      schrieb am 20.10.15 20:54:13
      Beitrag Nr. 197 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Wahlsieg für Liberale in Kanada - Cannabis-Legalisierung erwartet
      In Kanada sind die gestern die Parlamentswahlen beendet worden. Aus diesen ging Justin Trudeau als Sieger hervor, der damit Stephen Harper nach rund zehn Jahren im Amt ablöst.
      Trudeau hat sich explizit für die Cannabis-Legalisierung ausgesprochen.



      We will legalize, regulate, and restrict access to marijuana.

      Canada’s current system of marijuana prohibition does not work. It does not prevent young people from using marijuana and too many Canadians end up with criminal records for possessing small amounts of the drug.

      Arresting and prosecuting these offenses is expensive for our criminal justice system. It traps too many Canadians in the criminal justice system for minor, non-violent offenses. At the same time, the proceeds from the illegal drug trade support organized crime and greater threats to public safety, like human trafficking and hard drugs.

      To ensure that we keep marijuana out of the hands of children, and the profits out of the hands of criminals, we will legalize, regulate, and restrict access to marijuana.

      We will remove marijuana consumption and incidental possession from the Criminal Code, and create new, stronger laws to punish more severely those who provide it to minors, those who operate a motor vehicle while under its influence, and those who sell it outside of the new regulatory framework.

      We will create a federal/provincial/territorial task force, and with input from experts in public health, substance abuse, and law enforcement, will design a new system of strict marijuana sales and distribution, with appropriate federal and provincial excise taxes applied.

      Link: https://www.liberal.ca/realchange/marijuana
      1 Antwort
      Avatar
      schrieb am 20.10.15 21:00:56
      Beitrag Nr. 198 ()
      Antwort auf Beitrag Nr.: 50.892.372 von webmimi am 20.10.15 20:54:13
      We will legalize, regulate, and restrict access to marijuana
      Link hier korrekt:
      http://www.liberal.ca/realchange/marijuana/
      Avatar
      schrieb am 21.10.15 13:21:06
      Beitrag Nr. 199 ()
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Liberal Victory Gives a Boost to Canadian Marijuana Stocks
      There is definitely a plus to having a youthful, Liberal-minded Prime Minister in Canada: he is an unabashed supporter of the decriminalization of marijuana. For the Canadian publicly traded companies labouring under the so far unevenly applied Marihuana for Medial Purposes (MMPR) legislation, that fact translates directly into elevated share price performance.

      Link: http://www.midasletter.com/2015/10/liberal-victory-gives-a-b…
      1 Antwort
      Avatar
      schrieb am 08.11.15 15:07:36
      Beitrag Nr. 200 ()
      Antwort auf Beitrag Nr.: 50.897.211 von webmimi am 21.10.15 13:21:06
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Corporate Update
      Vancouver, BC -- November 5, 2015 -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), would like to provide an update to its shareholders. The Company believes a positive new landscape might be on the horizon with the win of Justin Trudeau and his vow to legalize cannabis.

      Link: http://www.abattis.com/s/news.asp?ReportID=729242
      Avatar
      schrieb am 10.02.16 17:41:44
      Beitrag Nr. 201 ()
      neu homepage hat das was zu bedeuten?
      1 Antwort
      Avatar
      schrieb am 18.02.16 17:29:10
      Beitrag Nr. 202 ()
      Antwort auf Beitrag Nr.: 51.711.292 von Sukram123 am 10.02.16 17:41:44
      Abattis Bioceuticals Corp. (OTCQX: ATTBF) - Corporate Update, Product Launch, Licensing And Anual Audit
      Vielleicht möchte man den Image-Schwerpunkt stärker auf die 'natural health (nutraceutical) products' legen und weg vom 'Marihuana' lenken … :rolleyes:

      Link: http://www.abattis.com/#!news/c1cqp
      Avatar
      schrieb am 18.02.16 17:42:04
      Beitrag Nr. 203 ()
      Abattis (OTCQX: ATTBF) is preparing to launch the Company’s NÖXX BOTANICAL BLENDS
      Abattis is preparing to launch the Company’s NÖXX BOTANICAL BLENDS™ line of products in the first quarter of 2016. This launch culminates product development work conducted over the past year. Abattis engaged Ingredient Identity, LLC to perform a claim substantiation review of its products that will be sold in the United States. The review evaluated information found in publicly available literature and scientific studies for each ingredient in Abattis’ formulas and the information is available to the FDA upon their request. These products all contain Abattis’ Phyto[NOS]™ as a key ingredient which was designed to promote the up-regulation of nitric oxide in the body, providing cardiovascular support and creating increased uptake of the medicinal ingredients in the formulae. The first NÖXX Botanical Blends™ product to be sold will be Comfort™, is currently in production.



      Comfort™ is a dietary supplement for the natural relief of occasional pain. Comfort™will be sold direct to consumers online through Vergence Sales and Marketing. Post launch, Management will pursue wholesale distribution opportunities in North America and Asia. The Management Team continues to aggressively pursue strategic downstream partnerships for its formulated product lines.

      Link: http://www.abattis.com/#!CORPORATE-UPDATE-PRODUCT-LAUNCH-LICENSING-AND-ANNUAL-AUDIT/c1k7g/56ba66a80cf2fd311cdcd234
      1 Antwort
      Avatar
      schrieb am 06.04.16 23:22:54
      Beitrag Nr. 204 ()
      Abattis Bioceuticals Corp. (ATTBF) Agrees to License Its NOXX Botanical Blends Products
      VANCOUVER, BC / ACCESSWIRE / April 6, 2016 / Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) ("Abattis') has agreed to enter a licensing arrangement and marketing partnership with Crimson Capital Group ("Crimson") to commercialize Abattis' NÖXX Botanical Blends Products, which contain Abattis' patent-pending Phyto(NOS)™.

      Link: http://finance.yahoo.com/news/abattis-agrees-license-noxx-bo…
      Avatar
      schrieb am 13.04.16 10:59:39
      Beitrag Nr. 205 ()
      Antwort auf Beitrag Nr.: 51.779.797 von webmimi am 18.02.16 17:42:04
      Abattis Receives NPN from Health Canada for Phyto[NOS]™
      April 12, 2016 — Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (“Abattis”) is pleased to announce that it has received a Natural Product Number (“NPN”) approval for Phyto(NOS)TM. This NPN allows Abattis to manufacture and to sell Phyto(NOS) TM in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report necessary for the sale of Phyto(NOS)TM in the United States.
      Link: http://investorintel.com/agbusiness-mmj-news/abattis-receive…
      Avatar
      schrieb am 15.04.16 12:36:36
      Beitrag Nr. 206 ()
      USA: DEA kündigt Stellungnahme zur Umstufung von Cannabis an
      11. April 2016 - Die Drug Enforcement Agency (DEA) hat vor wenigen Tagen angekündigt, noch in der ersten Hälfte des Jahres ihre Empfehlung zur Umstufung von Cannabis zu veröffentlichen. Bislang ist Cannabis zusammen mit Substanzen wie Heroin und LSD als "Schedule 1 Drug" klassifiziert. Deshalb kann Cannabis zum jetzigen Zeitpunkt auf Bundesebene nicht einmal aus medizinischen Gründen verkehrsfähig werden, ganz zu schweigen von der Verwendung zu Entspannungszwecken…



      …Sollte sich die DEA wirklich dazu entscheiden, eine Empfehlung zur Umstufung von Cannabis als "Schedule 2-Drug" auszusprechen, wäre das vor allen Dingen für die 23 Bundesstaaten mit einem medizinischen Cannabisprogramm ein bedeutsamer Schritt. Nicht zuletzt hätte eine Umstufung auch für die vielen Hanfapotheken, die derzeit in Sachen Bundesrecht in einer rechtlichen Grauzone agieren, positive Folgen. Medizinisches Cannabis könnte unter den Auflagen, die viele Abgabestellen ohnehin erfüllen, wie jedes andere medizinische Produkt behandelt werden. Das hieße Rechtssicherheit für Produzenten, Hanfapotheken und Patienten. Die immer noch gefürchteten Durchsuchungen und Schließungen durch die DEA wären ein für allemal passé. Außerdem könnten die gesamte Industrie, die sich rund um die medizinischen Cannabisprogramme etabliert hat, dann, anders als heute, auch legale Bankgeschäfte machen. Derzeit gibt es legales Cannabis, egal ob medizinisch oder zu Entspannungszwecken, lediglich gegen Bares, was im Kreditkartenland USA dazu führt, dass spezielle Sicherheitsunternehmen mit dem Transport beauftragt werden.

      Link: https://hanfverband.de/nachrichten/news/usa-dea-kuendigt-ste…
      Avatar
      schrieb am 18.04.16 15:28:20
      Beitrag Nr. 207 ()
      Abattis Announces Co-Formulation with Vitagum(TM)
      VANCOUVER, BC / ACCESSWIRE / April 18, 2016 / Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB : ATTBF) ("Abattis") through its proposed licensing arrangement with Crimson Capital Group ("Crimson") is pleased to announce that a letter of intent to co-formulate gum products under the brand name Vitagum™ has now been signed.

      Once the arrangement has been approved by the Canadian Stock Exchange (the "CSE"), Abattis and Crimson will finalize plans to co- formulate new gum products containing Phyto(NOS)™.

      Crimson has acquired control of the Canadian distributor of Vitamingum™ products and also owns the trademark rights to Vitagum™. These products contain active ingredients that are developed to be readily released and absorbed as a delicious functional food, snack, or supplement. These ingredients include vitamins, herbals, minerals, and other nutrients that are good for the body and mind, ingredients that have targeted health benefits.
      Siehe Vitamingum™: http://www.chewvitamingum.ca

      In June of 2015, The Pennsylvania State University, Department of Food Science Center for Molecular Toxicology and Carcinogenesis, completed a six-month study and published findings scientifically proving that products such as Vitamingum™ optimize nutrient and medicinal delivery via the oral cavity. Vitamingum™ is proven to release active ingredients within minutes to achieve rapid absorption and bioavailability.

      Link: http://www.stockhouse.com/news/press-releases/2016/04/18/aba…
      Avatar
      schrieb am 25.04.16 19:01:12
      Beitrag Nr. 208 ()
      Abattis Bioceuticals Corp. (ATTBF) Names Michael Yung as Ceo
      Vancouver, British Columbia--(Newsfile Corp. - April 25, 2016) - Abattis Bioceuticals Corp. (OTC PINK: ATTBF) (CSE: ATT), (the "Company" or "Abattis"), today announced that Michael Yung has been named as Chief Executive Officer (CEO) of Abattis Bioceuticals Corp, effective April 18, 2016. He will succeed William (Bill) Fleming, who has resigned his role as CEO and Director to pursue other business interests.

      Link: http://www.stockhouse.com/news/press-releases/2016/04/25/aba…
      1 Antwort
      Avatar
      schrieb am 25.04.16 23:50:18
      Beitrag Nr. 209 ()
      Antwort auf Beitrag Nr.: 52.272.214 von webmimi am 25.04.16 19:01:12
      Michael Yung - New CEO of Abattis Bioceuticals Corp. (ATTBF)

      Link: https://ca.linkedin.com/in/michaelyung1
      Avatar
      schrieb am 13.06.16 22:51:08
      Beitrag Nr. 210 ()
      Goldman Small Cap Research Issues Research Report on Abattis Bioceuticals Corp.
      BALTIMORE, MD / ACCESSWIRE / June 13, 2016 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a research report on Abattis Bioceuticals Corp. (OTC: ATTBF) (CSE: ATT), a specialty biotechnology poised to help transform two fast-growing segments of the health and wellness arenas.
      Link: http://www.goldmanresearch.com/201606131135/Opportunity-Rese…
      Avatar
      schrieb am 17.08.16 16:04:28
      Beitrag Nr. 211 ()
      Kriecht seit geraumer Zeit ziemlich rum. Passiert in dem Unternehmen noch was?
      Avatar
      schrieb am 08.09.16 15:39:42
      Beitrag Nr. 212 ()
      Abattis Bioceuticals Corp. - Consolidated Financial Statements - 06-30-2016
      Abattis Bioceuticals Corp. Condensed Consolidated Interim Statements of Financial Position for the three and nine months ended June 30, 2016
      Link: http://www.sedar.com/GetFile.do?lang=EN&docClass=5&issuerNo=…
      Avatar
      schrieb am 08.09.16 15:53:27
      Beitrag Nr. 213 ()
      Three reasons to invest in Abattis Bioceuticals Corp. stock (ATTBF)
      from Fred Marion - tradingstocks.me - posted on september 8, 2016

      What does Abattis Bioceuticals Corp. (ATTBF) do?
      Abattis Bioceuticals Corp. originally sought to be a vertically-integrated company serving the medical marijuana and natural health products industries. They’ve slowly evolved away from that model to reduce overhead. The company’s now focused on generating revenue from its natural tonics, elixirs and blends, many of which contain its proprietary botanical blend ingredient PhytoNOS. The company’s also seeking a Controlled Substance License (CSL) with Health Canada via subsidiary Northern Vine Labs so it can possess and produce cannabis.

      Three reasons to invest in Abattis Bioceuticals Corp. stock (ATTBF)
      1) Rapid sales growth. ATTBF’s sales grew from $7,720 (CAD) in 2014 to $91,940 (CAD). That’s a gain of more than 1,000 percent. Yes, it’s fairly easy to grow when you’re only doing $7,000 (CAD) in sales per year, but their numbers are at least moving in the right direction. 2016 could be a defining year for the company.

      2) China bound. Last month, Abattis announced a partnership with China’s Jaingsu to export Abattis’ line of Phtnos Superfruit tonics and VitaGum to mainland China.

      3) Diversification. Abattis has its hands in a lot of pots (so to speak). Altogether, the company lists ten subsidiaries:
      Abattis Bioceuticals International Inc.
      - Animo Wellness Corporation
      - BioCell Labs Inc.
      - Biocube Green Grow Systems Corp.
      - iJuana Cannabis Inc.
      - Instant Payment Systems LLC
      - National Access Pharmacy Corp.
      - North American BioExtracts Inc.
      - Northern Vine Canada Inc.
      - Phytalytics LLC


      Link: http://tradingstocks.me/3-reasons-invest-abattis-bioceutical…
      Avatar
      schrieb am 20.09.16 23:26:43
      Beitrag Nr. 214 ()
      Abattis Bioceuticals Corp. +88,70 %
      Abattis Bioceuticals Corp. (ATTBF)
      $ 0.0551 ▲0.0259 (88.70%) :eek: :confused:
      Volume: 1,739,342

      Der gesamte MMJ-Sektor scheint aufzuwachen … :p

      Lizenz? :rolleyes:
      Avatar
      schrieb am 21.09.16 14:39:33
      Beitrag Nr. 215 ()
      Abattis Bioceuticals Corp. (ATTBF) - 19 Canadian Marijuana Stocks
      Ein Blick auf 19 Kanadische Marihuana Aktien …

      Link: http://investingnews.com/daily/resource-investing/agricultur…
      Avatar
      schrieb am 24.09.16 13:17:20
      Beitrag Nr. 216 ()
      Abattis Bioceuticals Corp. (ATTBF) - In the Process of Moving


      Investor Relations New Number 778 883 7869

      Source: http://www.stockhouse.com/companies/bullboard/c.att/abattis-…
      1 Antwort
      Avatar
      schrieb am 29.09.16 12:17:04
      Beitrag Nr. 217 ()
      Abattis Bioceuticals Corp. (ATTBF) - 3rd Quarter Results
      September 28, 2016 | Abattis Bioceuticals Corp | Vancouver, B.C.
      Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), has released its interim Financial Statements and Management’s Discussion & Analysis for the third fiscal quarter ended June 30, 2016.

      The Company recorded a net and comprehensive loss for the three-month period of $359,974 versus $601,094 for June 30, 2015, or ($0.00) per share versus ($0.01). Allowing for non-cash operating expense of $672,703 compared to $1,039,582 for June 30, 2015 the Company’s operational cash flow loss was ($1,557,152) versus a loss of ($2,410,752) for June 30, 2015.

      On a year to date basis The Company recorded a net and comprehensive loss for the year to date of $1,557,152 versus $2,410,782 to June 30, 2015, or ($0.01) per share versus ($0.03). Allowing for non-cash operating expense of $1,580,542 compared to $2,410,782 to June 30, 2015 the Company’s operational cash flow loss was ($0.01) versus a loss of ($0.03) to June 30, 2015.

      Rene David, Abattis’s CFO noted that “Abattis continues to streamline operations and clean up legacy assets. It has allocated operations to prepare for the approval of its Controlled Substance License in Vancouver. The build out of the lab and final inspections have been completed and is preparing promotional efforts once approval is in hand.” Mr. David further noted that: “the medical marijuana patients and public need access to legitimate quality testing and a reliable centre for cannabinoid research. Also, the new Health Canada ACMPR regulations have increased the importance of testing, giving MMAR patients the ability to utilize our lab to confirm the quality, potency and any possible contaminants in their product.”

      Link: http://www.abattis.com/single-post/2016/09/28/ABATTIS-ANNOUN…
      Avatar
      schrieb am 01.10.16 22:54:43
      Beitrag Nr. 218 ()
      Abattis Bioceuticals Corp. (ATTBF) - New Science Advisor and Comptroller Appointment
      VANCOUVER, BC / ACCESSWIRE / September 27, 2016 / Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the "Company" or "Abattis") is pleased to announce the appointment of Dr. Shuang Xie as its newest Science and Technology Advisor. Dr. Xie graduated from Zhejiang University in 1987 and Queen's University in 1993. Dr. Xie has been widely published and holds more than 20 patents. She has assisted companies globally in assessing project risk, securing financing, and has undertaken numerous project management mandates. Dr. Xie is a founding partner of privately-held Efilcon Corp., a leading developer and producer of extraction technologies and systems and has assisted a number of manufacturers to carry out project assessment, financing, extraction equipment set up, and extraction plant construction. She is currently appointed as overseas talent for the Chinese government and an expert consultant for Zhejiang University Innovation Research Institute.

      Link: http://finance.yahoo.com/news/science-advisor-comptroller-ap…
      Avatar
      schrieb am 01.10.16 22:59:34
      Beitrag Nr. 219 ()
      Antwort auf Beitrag Nr.: 53.340.933 von webmimi am 24.09.16 13:17:20
      Abattis Bioceuticals Corp. (ATTBF) - Moved Corporate Headquarters to Administrative Offices in Langley, BC
      " …We also wish to announce that we have moved our corporate headquarters to our administrative offices in Langley, BC. This will put our key resources under one roof while we patiently wait for the approvals of the Northern Vine Laboratories Medical Marihuana Testing Lab, which underwent final inspection in the early summer this year. All deficiencies were completed and we hope to see Northern Vine Labs as one of the only approved labs in BC shortly… "

      Link: http://finance.yahoo.com/news/science-advisor-comptroller-ap…
      Avatar
      schrieb am 04.10.16 09:10:56
      Beitrag Nr. 220 ()
      Abattis Bioceuticals Corp. (ATTBF) - Northern Vine Receives Controlled Substance Licence from Health Canada
      VANCOUVER, BC / ACCESSWIRE / October 3, 2016 / Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the "Company" or "Abattis"), is pleased to announce that Northern Vine has received a letter from Health Canada and a copy of the licence informing that it is now an authorized Licensed Dealer.

      "We wish to congratulate the Northern Vine team on this important milestone for the Company. We have remained patient in obtaining this licence. We persevered and were granted Licence No. 2016/6368 for our Northern Vine facility."

      'The licence allows for the analytical testing of samples of cannabis received from holders of a valid licence issued under the Narcotic Control Regulations, the Access to Cannabis for Medical Purposes Regulators or from an individual authorized by a valid exemption under the Controlled Drugs and Substances Act to provide, deliver, transport or send fresh or dried marihuana or cannabis to licensed dealers for the purposes of analytical testing.'

      "The Northern Vine facility would be one of the only testing facilities in the Lower Mainland of British Columbia and one of 18 in Canada. Abattis is very proud of this accomplishment and is looking forward to moving to the revenue and growth stage of the Company for its investors and stakeholders. We are grateful for the support of the shareholders, staff, board of directors and are excited about the future prospect of Abattis and its related companies," said Rene David, Director of Northern Vine and Individual in Charge of the Premises.

      Further reading on the importance of testing facilities on the quality of medical marihuana please see:
      http://www.theglobeandmail.com/news/national/health-canada-s…

      Katherine Maloney, Qualified Person in Charge at the Northern Vine Canada facility provides the following information. "We can test for any approved patients or licensed producers. We will test for potency, constituency, microbial, foreign matter for dried marijuana and oils. Our license includes research and product development, as well as production of base materials. Northern Vine continues to explore different testing methodologies with BCIT. We intend to expand our list of approved cannabinoids and intend to file an amendment to expand on the list." Northern Vine seeks to become the premier analytical testing laboratory and research and development partner to the legal cannabis industry in Canada. Northern Vine will be known for: neutral, credible and reliable third party testing service, highest quality, accuracy, speed and competitive pricing.
      Avatar
      schrieb am 04.10.16 09:42:39
      Beitrag Nr. 221 ()
      ABATTIS’ (ATTBF) NORTHERN VINE LABS RECEIVES CONTROLLED SUBSTANCE LICENCE
      Link: http://www.abattis.com/news
      Avatar
      schrieb am 05.10.16 16:17:12
      Beitrag Nr. 222 ()
      OMG! Mit dem neuen Vertrag wird es jetzt einen unaufhaltsamen Raketenstart geben! :)
      2 Antworten
      Avatar
      schrieb am 05.10.16 19:08:17
      Beitrag Nr. 223 ()
      Antwort auf Beitrag Nr.: 53.414.286 von Maschiman am 05.10.16 16:17:12Hi Maschinen - Herzlich Willkommen zurück … ;)
      Seit fast 2 Jahren war ich hier so ziemlich allein unterwegs.
      Manchmal wusste ich gar nicht was grausiger war … der Kurs dieser Aktie oder die Stille hier :laugh:
      Avatar
      schrieb am 05.10.16 19:11:27
      Beitrag Nr. 224 ()
      Antwort auf Beitrag Nr.: 53.414.286 von Maschiman am 05.10.16 16:17:12
      Abattis Bioceuticals Corp. (ATTBF) - Signs MOU with Global Damon Pharma of South Korea
      … und schon wieder ein Schmankerl … :lick:

      Vancouver, British Columbia--(Newsfile Corp. - October 5, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis") is pleased to announce that it has entered into a Memorandum of Understanding with Global Damon Pharma ("GDP") of South Korea, to distribute and sell Abattis' proprietary PhytoNOS™ and Sassy™ Tonics in modified formulations. GDP will engage in the research and creation of necessary components for completion of these two products and will negotiate and enter into a formal Exclusive Licensing Agreement to sell and distribute these two products under licence in South Korea.

      GDP will identify, and source, marketing, sales and distribution channels, engage in any risk management programs; and, oversee the compliance of these products within the regulatory framework of the Korean territory. GDP will also retain and liaise with all service providers in the Korean territory and will oversee compliance with revenue objectives and overall performance of the marketing, sales and distribution channels. GDP will provide marketing, sales and distribution reports to Abattis on a quarterly basis as well as submitting payments under any Licensing Agreement. The initial research and feasibility stage of this agreement will expire on or after June 30, 2017 after which Abattis has the option to renew the agreement for 24 months, after which it may enter into a separate services agreement.

      Mr. Sonny Hwang, Vice President of GDP noted that: "GDP also wishes to congratulate Northern Vine, one of Abattis' related companies, on its successful achievement of a Controlled Substance Licence. This access to the R&D of scheduled and regulated ingredients allows GDP to complete formulations efforts in a jurisdiction that it federally legal"

      Link: http://www.stockhouse.com/news/press-releases/2016/10/05/aba…
      Avatar
      schrieb am 14.10.16 13:57:14
      Beitrag Nr. 225 ()
      Abattis Bioceuticals Corp. (ATTBF) - Partnerfirmen Northern Vine Inc. + EXPERION Biotechnologies Inc.
      "On April 10, 2014, the Company through its wholly owned subsidiary, Northern Vine, entered into a share exchange agreement with Experion Biotechnologies Inc. (“Experion”). Experion is incorporated under the laws of British Columbia, Canada and is located in Vancouver, BC. Pursuant to the terms of the agreement, Experion and Northern Vine have exchanged 25% of each parties’ issued and outstanding common shares. The Company maintains a 75% ownership in Northern Vine."

      Link: http://www.sedar.com/GetFile.do?lang=EN&docClass=5&issuerNo=…

      Avatar
      schrieb am 14.10.16 14:27:18
      Beitrag Nr. 226 ()
      Abattis Bioceuticals Corp. (ATTBF) - Northern Vine Inc. Executive Overview
      Northern Vine seeks to become the premier analytical testing laboratory and research and development partner to the legal cannabis industry in Canada. Northern Vine will be known for: neutral, credible and reliable third party testing service, highest quality, accuracy, speed and competitive pricing.





      About Abattis Bioceuticals Corp.
      Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

      About Northern Vine Canada Inc.
      Northern Vine Labs™ is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis.Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the Canadian market.

      Link: http://www.abattis.com/single-post/2016/10/03/ABATTIS’-NORTH…
      Avatar
      schrieb am 17.10.16 17:20:03
      Beitrag Nr. 227 ()
      Abattis Bioceuticals Corp. (ATTBF) - Experion Biotechnologies Prepares for Construction
      VANCOUVER, BC / ACCESSWIRE / October 17, 2016 / Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the "Company" or "Abattis"), announces commencement of construction for the Experion secure, production facility.

      Experion Biotechnologies Inc. is pleased to announce that it has begun the construction process and prepares to break ground for the six-month build-out for its 8,000 square foot, phase one facility. This first phase will provide the operational infrastructure needed to continue forward through the licensing process.



      Experion, a Licensed Producer Applicant, is located one hour east of the heart of downtown Metro Vancouver. Sean MacNeil, of Experion's Communications, says: "Our facility location allows for cost-effective transportation and logistical controls as well as being out of the way from the hustle and bustle of the central business district of the Vancouver, Burnaby and Richmond hubs. We are best positioned to take competitive advantage of our location, and serve as the primary provider of product and starting materials for the industry."

      Experion has taken the communication from the federal government very seriously; implementing its approved design and proprietary operating systems, while raising all necessary funds to complete construction. A fast-track program is now in place to complete the facility during Q1 of 2017.

      Phase Two expansion plans will provide the ability to have a continuous self-supply of product and a fulfillment centre that will be will be second to none. Experion's 10-acres has the capability to have a canopy of approximately 350,000 square feet with access to additional acreage that will allow for perpetual and secure production.

      Link: https://www.yahoo.com/news/abattis-bioceuticals-corp-experio…


      _____________________________________________________________________





      AND is still an additional MMPR licensing application pending with the Company’s other subsidiary BioCell Labs.?

      Link: https://news.lift.co/list-of-approved-lps-under-mmpr/

      Biocell[/url] Labs Inc. is a wholly owned subsidiary focused on supplying standardized pharmaceutical grade products. Currently, the company has 13 proprietary formulations for out-licensing to cosmetic, nutraceutical and pharmaceutical companies. While there is clearly a great deal of value here, if Vergence and NVL thrive, this division could also be a candidate for sale.

      Link: http://www.goldmanresearch.com/201606131135/Opportunity-Rese…
      Avatar
      schrieb am 19.10.16 19:22:40
      Beitrag Nr. 228 ()
      Abattis Bioceuticals Corp. (ATTBF) - A Leader in Canada’s Cannabis Testing Industry
      Canada’s cannabis industry may well be more established than that of the United States, but is lagging behind in one critical area – cannabis testing.
      While many U.S. states require independent lab testing, it was only after concerns were raised recently that the government was not doing enough to prevent unauthorized dispensaries from selling contaminated product, that Canada’s cannabis laws permitted consumers to screen cannabis products for contaminants
      Here is a closer look at the evolution of Canada’s cannabis testing regulations and why Abattis Bioceuticals (OTC: ATTBF) Northern Vine Laboratories is well positioned within this country’s burgeoning market …

      Link: http://www.cannabisfn.com/abattis-attbf-a-leader-in-canadas-…
      Avatar
      schrieb am 20.10.16 12:01:18
      Beitrag Nr. 229 ()
      Abattis Bioceuticals (OTC: ATTBF) - Northern Vine Laboratories Well Positioned
      Here is a closer look at the evolution of Canada’s cannabis testing regulations and why Abattis Bioceuticals (OTC: ATTBF) Northern Vine Laboratories is well positioned within this country’s burgeoning market …



      Link: http://www.cannabisfn.com/abattis-attbf-a-leader-in-canadas-…
      Avatar
      schrieb am 21.10.16 22:24:58
      Beitrag Nr. 230 ()
      Goldman Small Cap Research, Abattis Bioceuticals Corp. - Stock Up Big on Recent News, Greater Gains on Horizon
      ATTBF has jumped to the forefront of the Canadian Cannabis space, a market that should approve recreational sales shortly. Given the history of valuations afforded Cannabis stocks upon receipt of a LP designation, and the proposed valuations of new firms such as Emblem, a LP designation to the Experion subsidiary could be worth tens of millions in market cap to ATTBF, and that excludes the higher value of the NVL business. Thus, we reiterate our Speculative Buy rating.

      Link: http://www.goldmanresearch.com/201610201179/Opportunity-Rese…
      Avatar
      schrieb am 05.11.16 20:40:59
      Beitrag Nr. 231 ()
      Abbatis Bioceuticals (ATTBF) - A Cannabis Company with Leverage
      Abbatis has a diverse pipeline of products. The company has a uniquely diverse corporate structure with five divisions and other large share investment …
      Link: https://www.equities.com/news/abbattis-bio-attbf-a-cannabis-…
      Avatar
      schrieb am 05.11.16 20:42:51
      Beitrag Nr. 232 ()
      Abattis’ Federally Licensed Lab and the Crucial Role It Plays
      Abattis Bioceuticals (OTC: ATTBF) (CSE: ATT) recently announced the receipt of a Controlled Substance Licence from Health Canada for Northern Vine Laboratories, a company in which Abattis has a 75% stake. The Northern Vine lab site is built, security is in place, and all of the government inspections are complete. Once the lab’s equipment is properly calibrated, Northern Vine will be open for business …
      Link: http://www.cannabisfn.com/abattis-federally-licensed-lab-and…
      Avatar
      schrieb am 06.01.17 12:41:03
      Beitrag Nr. 233 ()
      Abattis Bioceuticals’ (ATTBF) Northern Vine Labs Could Benefit from New Rules
      January 4th, 2017 - CFN media group
      Northern Vine Canada Inc., an Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) subsidiary, is one of only 18 laboratories licensed by Health Canada. With new rules set to take effect in the near-term, the company plans to market its testing services to licensed producers and patients to generate significant revenue in 2017 and beyond. These revenues will be used to help finance the company’s move into functional foods and other areas of the market.

      Link: http://www.cannabisfn.com/abattis-bioceuticals-attbf-norther…
      Avatar
      schrieb am 18.01.17 14:21:50
      Beitrag Nr. 234 ()
      Hallöchen, scheint's dass es vorangeht. http://www.stockwatch.com/News/ltem.aspx?bid=Z-C:ATT-2436749. :cool:
      Avatar
      schrieb am 18.01.17 14:34:44
      Beitrag Nr. 235 ()
      Link funzt anscheinend nicht, einfach bei finanznachrichten.de nachschauen. :cool:
      1 Antwort
      Avatar
      schrieb am 13.02.17 19:32:08
      Beitrag Nr. 236 ()
      Antwort auf Beitrag Nr.: 54.109.880 von grayWOLF am 18.01.17 14:34:44Während der Handel in Kanada ruht, schießt der Kurs an der USOTC nach oben, +35 % :)
      Avatar
      schrieb am 13.02.17 19:38:10
      Beitrag Nr. 237 ()
      Abattis Bioceuticals Corp. (ATTBF: OTCQB) - Abattis Addresses Key Shortcomings in Canada’s Cannabis Industry
      Abattis Bioceuticals Corp. (CSE: AT) (OTC: ATTBF) is uniquely positioned to capitalize on Canada’s $22+ billion cannabis industry over the coming years. With the recent recall notices from two licensed producers, pesticide and residue testing has become increasingly important to both companies and consumers. The company’s Northern Vine Laboratories is one of only 18 approved laboratories in the country and could benefit from new upcoming testing regulations.

      Link: http://www.cannabisfn.com/abattis-addresses-key-shortcomings…

      Avatar
      schrieb am 25.02.17 01:51:40
      Beitrag Nr. 238 ()
      Abattis Bioceuticals Corp. (ATTBF: OTCQB) | Annual Report
      Fri, Feb 24, 2017 04:58 – Abattis Bioceuticals Corp. (ATTBF: OTCQB) released their Annual Report concerning Audited Annual Financial Statements – September 30, 2016.

      Link: http://www.otcmarkets.com/financialReportViewer?symbol=ATTBF…
      Avatar
      schrieb am 25.02.17 02:10:51
      Beitrag Nr. 239 ()
      Abattis Bioceuticals Corp. (ATTBF: OTCQB) - Company's Subsidiaries
      Through our divisions Biocell Labs Inc. and Vergence Sales & Marketing Group, we develop and license natural health products and have future plans to expand into the nutraceutical, pharmaceutical and cosmetic markets. The Company has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding natural health product market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions.

      Within our other divisions we have capabilities that support the production and extraction of botanical ingredients for our products; one of which includes cannabis.



      Northern Vine LaboratoriesTM (Northern Vine LabsTM) seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada.

      Executive Overview of Northern Vine LaboratoriesTM (Northern Vine LabsTM):
      media.wix.com/ugd/5c7cae_00f34d52e01d4ac88c2963fb6a0a1439.pd…
      Avatar
      schrieb am 27.03.17 22:33:56
      Beitrag Nr. 240 ()
      LEGISLATION TO LEGALIZE MARIJUANA IN CANADA IS BEING ANNOUNCED NEXT MONTH
      March 27, 2017 l Abattis Bioceuticals Corp. l Vancouver, BC
      Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), and its subsidiary, Northern Vine Labs is anticipating the Liberal government’s upcoming announcement, next month (the week of April 10th), on legislation that will legalize recreational marijuana use across Canada by July 1, 2018.

      As reported by the CBC, Trudeau’s government will follow the recommendations of a federally appointed task force, led by former liberal Justice Minister Anne McLellan, and in doing so, will look to deliver on their controversial campaign promise of introducing legislation by the Spring of 2017.

      Link: https://www.abattis.com/single-post/2017/03/27/LEGISLATION-T…
      Avatar
      schrieb am 04.04.17 14:37:23
      Beitrag Nr. 241 ()
      Why Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) is well positioned
      Canada’s Plans for Near-term Legalization Puts Testing into Focus
      by Ryan Allway

      April 3rd, 2017
      The Canadian government plans to introduce legislation to legalize recreational marijuana in early April and enact it by mid-July, which could open the door to a significantly larger market for cannabis and extracts. In addition, the market for cannabis testing is expected to dramatically expand over the coming years, particularly given the recent issues that the industry has had with contaminated products and recalls.



      In this article, we will take a look at Canada’s plans to introduce the recreational legalization of cannabis on April 10 and why Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) is well positioned to capitalize on the move.

      Upcoming Legalization
      Prime Minister Justin Trudeau promised to introduce legislation to legalize medical and recreational cannabis by the spring of 2017. According to the CBC, the government has plans to introduce legislation by April 10, 2017 and legalize the drug by July 1, 2018. The new rules generally follow the recommendations of the federal task force chaired by Anne McLellan, a former justice minister, which included 80 different recommendations in over 100 pages.

      According to Markets and Markets, the global cannabis testing market is expected to grow at an 11.5% compound annual growth rate to $1.42 billion by 2021. Cannabis laboratories test for potency, purity, and details like terpene counts, which are both required by lawmakers in the U.S. and Canada and demanded by consumers. This is particularly true after a string of pesticide and contamination scandals that led to several pending class action lawsuits.

      Health Canada recently introduced random testing on the 40 licensed producers in the country to address these issues. In addition, the board of the Cannabis Canada Association voted unanimously to implement mandatory product testing among all of its members, which represents 15 of the 40 licensed producers. This testing should screen for contaminants including bacteria, heavy metals, and unapproved pesticides.

      Northern Vine Labs
      Abattis Bioceuticals’ Northern Vine Labs plans to open its doors in April 2017 to serve the rising demand for cannabis testing. The facility will be one of the only testing facilities in the lower mainland of British Columbia and one of just 18 approved facilities in Canada. The company plans on testing for any approved patients or licensed producers for potency, constituency, microbial, foreign matter, and others for dried marijuana, oils and edibles.

      The company recently added Jaclyn Thomson, PhD, and Dr. David Galvez, PhD, to its senior management team and advisory board, respectively. Ms. Thomson will join the team and be responsible for lab operations and testing protocols by leveraging years of experience in lab operations and academia. In prior roles she oversaw quality assurance, scientific, and regulatory consultation and research activities, among other things.

      Dr. Galvez will work with the company to analyze and identify superior strains, extraction methods, and formulations for its programs. Northern Vine Labs’ Controlled Substance License enables proprietary methods and services to be offered to current licensed producers within Canada’s existing Federal regulatory structure. It also offers Northern Vine Labs’ customers, including Abattis, the ability to perform R&D on cannabis and explore unique formulations for licensed producers. Dr. Galvez’s prior roles included Director of Research & Development at ZAG Global where he launched several commercial products.

      Looking Ahead
      Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) is well-positioned within Canada’s burgeoning cannabis testing industry. With the government projected to introduce legislation in April and enact it by mid-July, the market for cannabis testing on the part of licensed producers could be set to rise past $1.4 billion by 2021 with only a handful of companies approved to test the substance so far in Canada.

      With an emphasis on cannabis industry safety and a vision to advance the technology and biosciences markets within the industry, Abattis and Northern Vine have a clear plan of execution outlined for the coming months. Investors may want to take a closer look at the stock ahead of Northern Vine Labs’ opening and the new legislation taking effect.

      Quelle: http://www.cannabisfn.com/canadas-plans-near-term-legalizati…
      Avatar
      schrieb am 05.04.17 15:53:06
      Beitrag Nr. 242 ()
      Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) - Northern Vine Labs are Ready
      Die Northern Vine Laboratorien von Abattis Bioceuticals planen ihre Türen im April 2017 zu öffnen, um für die bestehende und absehbar steigende Nachfrage nach gesetzlich vorgeschriebenen Marihuanatests als Marihuana-Prüflabor zur Verfügung zu stehen. Northern Vine ist das einzige Labor in der Provinz Britisch-Kolumbien und eines von gerade mal 18 staatlich genehmigten und lizensierten Fachlaboren in ganz Kanada.

      Gestern wurde folgender Beitrag mit Foto auf der neuen facebook-Seite von Northern Vine Labs gepostet:
      "We're ready. Coffee time."



      Link: https://www.facebook.com/Northern-Vine-Labs-130932567437601/
      Avatar
      schrieb am 06.04.17 15:24:34
      Beitrag Nr. 243 ()
      Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) - Gets Added to the Marijuana Index by MJIC
      Vancouver, British Columbia - April 6, 2017 - Abattis Bioceuticals Corp., is pleased to announce it has officially been added to The Marijuana Index, within the Biotechnology sector.

      The North American Marijuana Index tracks the leading public cannabis companies operating in the United States and Canada and gives investors up to date, centralized news on the securities deemed to be well positioned within the multi-billion dollar cannabis industry. Selected companies must meet stringent trading guidelines including having a minimum market capitalization of $30 million and daily trading volumes of above $400K.

      "We are delighted to have Abattis added to the The Marijuana Index and look forward to sharing our story with investors closely tracking this exciting sector," stated Abattis CFO, Rene David. "As we approach sector legalization, we'll start to see markets broaden their reach from the closely covered cultivation and growing players to those advancing the technology and biosciences side of the cannabis industry," added Mr. David.


      Abattis' subsidiary Northern Vine Labs is set to open its doors this month and will legally be able to test dried plant products, extracts, derivatives and edibles for licensed producers and patients under the ACMPR regulatory framework. Management will continue to provide timely updates on these developments in the coming weeks.

      Link: http://www.newsfilecorp.com/release/26080#.WOY9FelijlJ
      Avatar
      schrieb am 09.04.17 01:43:21
      Beitrag Nr. 244 ()
      Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) - Chart Analyse vom 07.04.2017
      ATTBF stock chart analysis explained as of 04-07-2017:



      Mehr Infos: https://www.abattis.com/news
      Avatar
      schrieb am 09.04.17 23:31:05
      Beitrag Nr. 245 ()
      Canada Aims to Become the First Developed Country to Legalize Marijuana
      Is this too good to be Trudeau?

      "… This maple leaf could turn green in July 2018
      However, according to senior Canadian government officials speaking on the condition of anonymity, Prime Minister Justin Trudeau and his progressive government are aiming to pass a countrywide legalization of recreational marijuana soon, such that by July 1, 2018, it would be legal for adults to smoke pot.



      This news shouldn't come as a complete shock given that Trudeau has campaigned for the legalization of marijuana in the past. The question marks had always been whether Trudeau had the support of the Canadian government, and what the final bill would look like.

      Per the various sources reporting on the matter, adults ages 21 and up would be allowed to buy recreational cannabis, users would be allowed to possess up to 30 grams (more than one ounce), and households could grow up to four plants at a time. Though some pundits have suggested a higher minimum age limit since brain development continues until age 25, the marijuana task force, which is offering advice to the Canadian government, believes a higher minimum age requirement would preserve black market sales.

      The marijuana task force also suggested that marijuana strains should be taxed based on their potency. Thus, higher potency strains should come with a higher tax rate than weaker strains.

      Lastly, the task force recommends that recreational marijuana not be sold in the same locations as tobacco and/or alcohol. Therefore, cannabis lounges could be set up in Canada, but they would have to be alcohol-free establishments …"

      Link: https://www.fool.com/investing/2017/04/08/canada-aims-to-bec…
      Avatar
      schrieb am 11.04.17 00:07:22
      Beitrag Nr. 246 ()
      Canada looks to legalise recreational use of marijuana
      Canada's government is aiming to pass legislation that will legalize the recreational use of marijuana.

      Avatar
      schrieb am 11.04.17 00:17:03
      Beitrag Nr. 247 ()
      Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) - Abattis Bioceuticals Announces New CEO
      Vancouver, British Columbia (Newsfile Corp. - April 10, 2017) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis"), is pleased to announce the appointment of Robert Abenante as President and Chief Executive Officer of the Company.

      Link: http://www.stockhouse.com/news/press-releases/2017/04/10/aba…
      Avatar
      schrieb am 11.04.17 00:29:54
      Beitrag Nr. 248 ()
      Abattis Bioceuticals Corp. (QB) (ATTBF) - Kurze Chart Analyse - Stand 10.04.2017
      About Abattis Bioceuticals Corp.
      Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.



      About Northern Vine Canada Inc.
      Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.

      About Vergence Visionary Bioceuticals Corp.
      Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis, based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.

      For more information, visit the Company's website at: www.abattis.com.
      Avatar
      schrieb am 12.04.17 11:34:20
      Beitrag Nr. 249 ()
      Abattis Bioceuticals Corp. (ATTBF) Gets A Close Look
      Abattis Bioceuticals Corp (OTCMKTS: ATTBF), the biotechnology company, which invests in agricultural technologies for the legal cannabis industry developing in Canada, is our new profile.

      On April 10, 2017, the company announced that it had appointed a new President and Chief Executive Officer. Investors celebrated the news and the share price rapidly increased by 19%. We believe that this rise may be just the beginning.

      Link: https://www.insiderfinancial.com/abattis-bioceuticals-corp-o…
      Avatar
      schrieb am 13.04.17 15:49:21
      Beitrag Nr. 250 ()
      ACHTUNG Wichtige Bekanntmachung - Government of Canada to make an important announcement
      OTTAWA, April 12, 2017 /CNW/ - The Honourable Jody Wilson-Raybould, Minister of Justice and Attorney General of Canada, the Honourable Jane Philpott, Minister of Health, the Honourable Ralph Goodale, Minister of Public Safety and Emergency Preparedness, and the Honourable Diane Lebouthillier, Minister of National Revenue, along with Parliamentary Secretary Bill Blair, will make an important announcement.

      Link: http://www.ottawacitizen.com/business/cnw/release.html?rkey=…

      Periscope channel for live stream of announcement: www.pscp.tv/HealthCanada

      Facebook channel for live stream of announcement: www.facebook.com/JusticeCanadaEn/

      Avatar
      schrieb am 13.04.17 16:05:39
      Beitrag Nr. 251 ()
      Realtime OTCQB - Abattis Bioceuticals Corp. ATTBF
      Realtimekurse und weitere Infos zur Abattis-Aktie sind hier kostenlos abrufbar:
      http://www.otcmarkets.com/stock/ATTBF/quote
      Avatar
      schrieb am 14.04.17 13:30:20
      Beitrag Nr. 252 ()
      Mit dieser Aktie werden wie viel Freude haben - Gains $$$
      2 Antworten
      Avatar
      schrieb am 14.04.17 13:35:07
      Beitrag Nr. 253 ()
      Mein Persöhnliches Kursziel setze Ich mal auf 3,00 - 4,00 US$+ auf Longfrist innerhalb von max. 2 - 4 Monaten
      Avatar
      schrieb am 14.04.17 13:37:30
      Beitrag Nr. 254 ()
      ATTBF $ BIG NEWS $ Canada announces legislation to legalize marijuana
      MONTREAL — The Canadian government on Thursday announced new legislation legalizing marijuana, fulfilling one of Prime Minister Justin Trudeau’s major campaign promises.

      Canada has anticipated the law will take effect in the summer of 2018. U.S. voters in California, Massachusetts, Maine and Nevada decided last year to approve the use of recreational marijuana, joining Colorado, Washington, Oregon and Alaska. Uruguay is the only nation to legalize recreational pot.

      The new federal laws in Canada will make the possession of small amounts of pot legal throughout the country and will also establish broad guidelines concerning who can grow, sell and buy the drug.

      Canada's federal government set the age at 18, but is allowing each of the provinces to determine if it should be higher. The provinces will also decide how the drug will be sold and distributed. The law also defines the amount of THC in a driver’s blood, as detected by a roadside saliva test, that would be illegal. Marijuana taxes will be announced at a later date.

      Those under 18 found with small amounts of marijuana would not face criminal charges.

      “If your objective is to protect public health and safety and keep cannabis out of the hands of minors, and stop the flow of profits to organized crime, then the law as it stands today has been an abject failure,” Public Safety Minister Ralph Goodale said at a news conference, according to the Associated Press. “Police forces spend between $2 billion and $3 billion every year trying to deal with cannabis, and yet Canadian teenagers are among the heaviest users in the western world … We simply have to do better.”

      Canada legalized marijuana for some medicinal uses in 2001.

      https://www.usatoday.com/story/news/world/2017/04/13/canada-…
      Avatar
      schrieb am 14.04.17 17:16:41
      Beitrag Nr. 255 ()
      Avatar
      schrieb am 14.04.17 17:27:13
      Beitrag Nr. 256 ()
      $ ATTBF: Oh CANADA...:-} Looking for great things now that the CAT is out of the bag..:-}


      The ENTIRE WORLD now knows what's going on...

      CANNABIS Testing companies are GOLD NUGGETS...:-}


      http://420intel.com/regional/canada


      http://www.cnn.com/2017/04/14/americas/canada-justin-trudeau…



      http://www.bbc.com/news/world-us-canada-39569993
      Avatar
      schrieb am 14.04.17 21:53:09
      Beitrag Nr. 257 ()
      We could start by talking about the three huge catalysts which are going to Catapult ATTBF into being a major force in the MMJ sector:


      1 - Northern Vine Labs™, a subsidiary of Abattis, seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada. Northern Vine Labs™ Controlled Substance License enables proprietary methods and services to be offered to current licensed producers within Canada’s existing Federal regulatory structure. It also offers Northern Vine Labs™ customers, including Abattis, the ability to formulate and develop new products containing cannabinoid ingredients in advance of the end to prohibition.

      2 - Vergence Visionary Bioceuticals, a subsidiary of Abattis, is a team of nutraceutical marketing and brand specialists focused on innovative health products to penetrate the fast growing market for natural, safe and effective solutions to two of society’s unresolved and ubiquitous health issues: Pain caused by inflammation and mental ailments common to our modern lifestyle. Vergence is the exclusive exporter of 99.6%, organic and pure CBD Isolate out of Hong Kong and directly to the rest of the world. Vergence is in possession of over 100 Natural Product Numbers (NPN’s) as granted by Health Canada and plans to develop and distribute these products into global markets for end use.

      3 - Raybot Extraction Science Co. is a Cannabinoid and Agtech research and development company possessing intellectual property and machinery for the extraction of cannabis derivatives such as CBD, THC and others. Raybot’s proprietary extraction process revolves around industrial preparative high-performance liquid chromatography separation through patented fillers and solvents to end up with highly isolated extracts of superior quality and lesser cost than that of competitors using CO2. The result is simple, higher purity at a fraction of the cost. Raybot has arranged a proposed licensed for the usage of their procedures to Abattis.

      https://streetregister.com/2017/02/15/the-three-pillars-of-a…
      Avatar
      schrieb am 15.04.17 00:01:55
      Beitrag Nr. 258 ()
      Antwort auf Beitrag Nr.: 54.738.471 von t-haier am 14.04.17 13:30:20
      Welcome +++ Willkommen +++ Bienvenue +++ Bienvenido
      Hi t-haier … das will ich wohl auch meinen :) … schön das ich nach 30 Monaten "Alleinunterhalter" einen Interessierten hier antreffe … ich kam mir schon vor wie Tom Hanks in Cast Away
      1 Antwort
      Avatar
      schrieb am 15.04.17 10:05:02
      Beitrag Nr. 259 ()
      Antwort auf Beitrag Nr.: 54.740.373 von webmimi am 15.04.17 00:01:55Hi webmini, Grüß dich.;)

      Es werden Hier noch viele nachkommen, wenn Sie erstmal merken, wieviel Potential hier wirklich steckt.

      Welcome an Alle
      Avatar
      schrieb am 15.04.17 10:08:35
      Beitrag Nr. 260 ()
      Ab nächste Woche, Dienstag gehts hier Richtig an.:D:D:D:eek::eek::eek:

      Eins kann Ich sagen, Ich kaufe Ich nach.

      Strong Holding and Strong Buying, mit einer <zielsetzung auf 2 - 4 bzw. 6 Mnate Sicht, Mein Target: 3 ,00 - 4,00 US$ +++Sicht.
      1 Antwort
      Avatar
      schrieb am 15.04.17 10:13:02
      Beitrag Nr. 261 ()
      Hab auch schon bei IHUB geschriben: 30 - 40+ Bagger, sprich Potentioal von 3000 - 4000 % +++ ab diesem Kurs, More eyes watching ATTBF $$$

      GLTA

      Grüße TH
      Avatar
      schrieb am 15.04.17 10:23:44
      Beitrag Nr. 262 ()
      Company Website: https://www.abattis.com/ :D:D:D:eek::eek::eek:

      Frohe Ostern und auf ein vorzeitiges grosses Sylvester, und Gains Gains Gains $$$

      GLTA

      TH
      Avatar
      schrieb am 15.04.17 14:28:22
      Beitrag Nr. 263 ()
      Antwort auf Beitrag Nr.: 54.741.000 von t-haier am 15.04.17 10:08:35:eek: Du bist ja wirklich seeehr optimistisch was die zukünftige Kursentwicklung angeht.
      Ich wünsche mir das nach Ostern endlich Berichte, Fotos, etc. zu der angekündigten Eröffnung von Northern Vine Labs veröffentlicht werden und als "Sahnehäubchen" erste Aufträge vermeldet werden - das wäre eine optimale Ausgangslage für Kurssteigerungen. Ich hoffe sehr das Wort gehalten wird und die Eröffnung des Testlabors wie angekündigt im April stattfinden wird - alles andere wäre pures Gift für den Kurs. In der Meldung vom 24 Februar ist von 45 Tagen die Rede … das wäre eigentlich bereits der 10. April gewesen :confused: … rechnet man allerdings reine Arbeitstage (was m.M.n. nicht gemeint war) wäre es erst der 28. April - na ja … wie dem auch sei, auf jeden Fall jetzt im April :rolleyes:
      Meldung vom 24. Februar 2017
      "… Management has been focusing their efforts on their Northern Vine Lab buildout after receiving their controlled substance dealers license ("CSL") in 2016. The lab setup has been expedited and is now approximately 45 days away from opening its doors to licensed producer and MMAR patient customers for cannabis testing and analytics. Issues surrounding quality control and massive cannabis product recalls from licensed producers by Health Canada have recently taken headlines in the press. Northern Vine Labs is strategically positioned in Langley, British Columbia and holds a considerable geographic advantage over their few competitors as the region has many MMAR growers looking to prove their products' quality …"

      Link: http://www.nasdaq.com/press-release/abattis-completes-audit-…
      Avatar
      schrieb am 15.04.17 14:34:25
      Beitrag Nr. 264 ()
      Auch wäre es von Vorteil, wenn endlich die Seite der Vergence Sales and Marketing Group online gehen würde: http://vergencesales.com

      Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis Bioceuticals Corp. based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs.
      Avatar
      schrieb am 15.04.17 14:41:39
      Beitrag Nr. 265 ()
      Abattis Bioceuticals Corp. (ATTBF) - Top 10 most active @CSE_News listed #cannabis #companies on #Twitter
      Top 10 most active @CSE_News listed #cannabis #companies on #Twitter pic.twitter.com/5363Sk5S5M

      Link: https://mobile.twitter.com/VirideIr/status/85260982784724582…

      1 Antwort
      Avatar
      schrieb am 15.04.17 16:27:20
      Beitrag Nr. 266 ()
      Antwort auf Beitrag Nr.: 54.741.759 von webmimi am 15.04.17 14:41:39Toller Links die du da reingestellt hast.

      In ATTBF steckt unglaublich viel Potenzial

      Gruß
      Avatar
      schrieb am 15.04.17 17:23:35
      Beitrag Nr. 267 ()
      ATTBF
      Pretty very Good $$$ ATTBF $$$ :D:D:D:eek::eek::eek:

      Report of the Task Force on Cannabis Legalization and Regulation
      www.healthycanadians.gc.ca/...amework-cadre/index-eng.php#a5.6

      Implementation
      The successful implementation of a regulatory framework for cannabis will take time and require that governments meet a number of challenges with respect to capacity and infrastructure, oversight, co-ordination and communications.

      Capacity: Canada's governments will need to move swiftly to increase or create capacity in many areas relating to the production and sale of cannabis. Success requires federal leadership, co-ordination and investment in research and surveillance, laboratory testing, licensing and regulatory inspection, training for law enforcement and others, and the development of tools to increase capacity ahead of regulation. …

      To this end, the Task Force recommends that the federal government:
      Take a leadership role to ensure that capacity is developed among all levels of government prior to the start of the regulatory regime
      Build capacity in key areas, including laboratory testing, licensing and inspection, and training …

      … Establishing and promoting laboratory standards: Laboratory testing is a cornerstone of some of the health and safety measures proposed in Chapter 2. Specifically, the mandatory product testing recommended by the Task Force is intended to minimize the risk of contaminated products entering the market and to verify the information on labelling, in order to help consumers make informed decisions. Canada is in the fortunate position of having laboratory standards for cannabis as part of the existing medical cannabis program; as noted in Chapter 3, the capacity of this system will need to be adapted to a new regulatory environment and enhanced so that licensed producers can meet new product safety, quality and labelling requirements. The federal government will play a key role in facilitating this enhancement and ensuring it is capable of meeting the needs of the new regime. …

      … Advice to Ministers
      The Task Force recommends that the federal government:
      Take a leadership role to ensure that capacity is developed among all levels of government prior to the start of the regulatory regime
      Build capacity in key areas, including laboratory testing, licensing and inspection, and training
      Build upon existing and new organizations to develop and co-ordinate national research and surveillance activities
      Provide funding for research, surveillance and monitoring activities …

      … Good production practices: In general, ingestible products must meet certain quality standards. In the medical marijuana regime, Health Canada has established product content and production controls that have proven effective in minimizing risks to clients. Similarly, safeguards could be put in place to ensure that marijuana is produced and stored in sanitary and secure conditions. There could be strict security requirements to minimize the possibility of diversion. Controls could be placed on pesticides that can be used, and on microbial and chemical contaminants. Marijuana could also be subject to analytical testing so that those consuming can be reliably advised of its contents, particularly amounts of THC and CBD. …

      … The Cannabis Trade Alliance of Canada, which represents producers, said the new regime should provide for mandatory testing:

      “Mandatory laboratory testing of all cannabis products (potency and contaminants) – a critical step in the seed-to-sale process when considering public health, and should be the main objective in the legalized framework.” …

      Report of the Task Force on Cannabis Legalization and Regulation
      www.healthycanadians.gc.ca/...amework-cadre/index-eng.php#a5.6
      Avatar
      schrieb am 15.04.17 22:02:48
      Beitrag Nr. 268 ()
      Yaeu, Die News übeerschlagen sich eine nach der anderen

      http://www.n-tv.de/politik/Kanada-legalisiert-Haschisch-Kons…
      Avatar
      schrieb am 16.04.17 15:05:01
      Beitrag Nr. 269 ()
      ABATTIS BIOCEUTICALS: Joins an Index and Runs with the Herd

      https://www.abattis.com

      https://marijuanaindex.com/stock-profile/?qm_symbol=ATTBF






      http://oracledispatch.com/2017/04/10/abattis-bioceutica-com-…


      By Jermaine Farmer - April 10, 2017


      ABATTIS BIOCEUTICALS COM NPV (OTCMKTS:ATTBF) is a penny play in the Canadian MMJ space that has been red hot in recent days. As most readers are probably aware – and something we have been talking about quite a bit over the past 3 months – the Canadian government is preparing to officially begin a process of full-scale, nationwide legalization of marijuana for both medical and recreational purposes. We think that is likely helping to fuel gains in ATTBF. However, there are a couple other catalysts.

      Among them is the company’s announcement that it has officially been added to The Marijuana Index, within the Biotechnology sector. According to the release, “the North American Marijuana Index tracks the leading public cannabis companies operating in the United States and Canada and gives investors up to date, centralized news on the securities deemed to be well positioned within the multi-billion dollar cannabis industry. Selected companies must meet stringent trading guidelines including having a minimum market capitalization of $30 million and daily trading volumes of above $400K.”

      ABATTIS BIOCEUTICA COM NPV (OTCMKTS:ATTBF) casts itself as a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana markets in North America.

      In essence, the company develops, licenses, and markets health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets in Canada. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts; and bioceutical marketing services in the area of health products.

      The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corp. in September 2012. Abattis Bioceuticals Corp. was incorporated 1997 and is headquartered in Langley, Canada.

      According to company materials, “Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.”


      As discussed above, ATTBF shares are likely running in part due to the Liberal government’s upcoming announcement, coming today (according to prior announcements), about legislation that will legalize recreational marijuana use across Canada by July 1, 2018. As reported by the CBC, Trudeau’s government will follow the recommendations of a federally appointed task force, led by former liberal Justice Minister Anne McLellan, and in doing so, will look to deliver on their controversial campaign promise of introducing legislation by the Spring of 2017.

      However, as we noted, there are also a few company-specific catalysts to consider. The inclusion in an index of marijuana stocks should not be overlooked. Legitimacy, as we have pointed out recently in other pieces on Oracle Dispatch, is the fundamental objective of companies in the MMJ space at this young stage of the game.

      “We are delighted to have Abattis added to the The Marijuana Index and look forward to sharing our story with investors closely tracking this exciting sector,” stated Abattis CFO, Rene David. “As we approach sector legalization, we’ll start to see markets broaden their reach from the closely covered cultivation and growing players to those advancing the technology and biosciences side of the cannabis industry,” added Mr. David.


      Recent action has seen 79% tacked on to share pricing for the stock in the past month. The situation may be worth watching. ATTBF has evidenced sudden upward volatility on many prior occasions. In addition, the company has witnessed a pop in interest, as transaction volume levels have recently pushed nearly 250% above the average volume levels in play in this stock over the longer term.

      Earning a current market cap value of $33.1M, ATTBF has a store ($460K) of cash on the books, which stands against virtually no total current liabilities. The company is, for all practical purposes, a pre-revenue company at this point, which is important and, at first glance, unexpected. We will update the story again soon as further details emerge.
      Avatar
      schrieb am 17.04.17 13:54:02
      Beitrag Nr. 270 ()
      Ab morgen, Dienstag fängst richtig an $$$, wegen dem Ostermontag in Deutschland, wobei man heute in den USA und Kanada schon handeln kann.
      Avatar
      schrieb am 17.04.17 13:56:34
      Beitrag Nr. 271 ()
      Abattis, mein Favorit, und bleibe bei meinem Target von 2,00 - 4,00 US$ bis zu diesem Sommer 2017

      Schöne Grüße

      GLTA

      TH
      Avatar
      schrieb am 21.04.17 16:36:05
      Beitrag Nr. 272 ()
      Abattis Bioceuticals (ATTBF) - Latest 10 SEDI fillings for ATT
      The latest insider fillings within the last 6 months for ATT - fillings by transaction data:

      Avatar
      schrieb am 25.04.17 21:23:47
      Beitrag Nr. 273 ()
      Abattis Bioceuticals (ATTBF) - Northern Vine Labs™on Health Canada List
      Northern Vine Labs™ has received a Controlled Substance License (CSL) with Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Security inspections are complete and the license is pending. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the Canadian market.

      Northern Vine Labs™ are now on Health Canada list for licensed dealers:
      https://www.canada.ca/en/health-canada/services/list-license…

      Northern Vine Labs™ operations under the CSL will include:
      1. Analytical Services
      2. Research and Development Services
      3. Extraction to Support Analysis and R&D​
      In future, NV Labs™ anticipates the opportunity to amend its license to include:
      4. Extraction service for sale of extracted ingredients
      5. Importation/Exportation

      The table below contains a list of laboratories that have a current Dealers Licence under the Narcotic Control Regulations and who are licensed to conduct activities with cannabis. This may include analytical testing for persons who fall under the following Section 56 exemption



      Analytical Services
      Potency Testing
      Determining composition and concentration of various cannabinoid compounds.
      Moisture Analysis and Foreign Matter Testing
      Microbiological Testing
      Ensuring the safety of products by testing for levels of mold and bacteria.

      In partnership with the BC Institute of Technology (BCIT), Northern Vine Labs™ has been working to develop new and improved methods for the analysis of cannabis. This work is expected to be published by BCIT positioning NV Labs™ as the industry expert in analytical services which are substantially faster and more reliable than any other in Canada. Utilizing these proprietary methods, Northern Vine Labs™ will offer for sale its analytical reference standards enabling market participants to check quality and metrological traceability of products, to validate analytical measurement methods, and/or to support the proper calibration of instruments.

      Link: https://www.abattis.com/northern-vine
      Avatar
      schrieb am 26.04.17 22:52:16
      Beitrag Nr. 274 ()
      ABATTIS (ATTBF) SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT FOR PROPRIETARY EXTRACTION TECHNOLOGY
      April 26, 2017 l Abattis Bioceuticals Corp. l Vancouver, BC
      Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT) (OTCQB: ATTBF) is pleased to announce it has signed an exclusive distribution agreement effective April 20, 2017 (the “Agreement”) with Suzhou Raybot Material Tech Corp. (“Raybot”). The Agreement allows Abattis to use Raybot’s proprietary extraction technology and to exclusively sell the extraction equipment and services.

      Raybot has developed a proprietary technology which utilizes industrial column chromatography to extract and separate a wide range of materials, in a continuous, closed loop system. This method, which is currently used in the mass production of extracts such as Ginkgo Biloba, Stevia and Ginsenosides among others, has been specifically designed for the extraction of legal cannabis derivatives such as Cannabidiol (“CBD”),Tetrahydrocannabinol (“THC”) and Cannabigerol (“CBG”) from Marijuana or Hemp. The technology has excellent processing capacity, high extraction yield and significant cost advantages over traditional methods.

      The proprietary technology is capable of extracting CBD from Hemp to above a 99% purity level. The current methods using multi-staged CO2 extraction are significantly more expensive and limited in production scale. Raybot’s extraction machines can be customized to any factory production scale. A factory with 5,000 kg per day processing rate is able to produce CBD at $0.20 per gram.

      “This technology has the potential to revolutionize the extraction process for THC, CBD, CBG and other cannabis derivatives globally,” stated Robert Abenante, President and CEO of Abattis.
      “Raybot’s proprietary extraction method is currently one of the only toll processing technologies that can extract high purity CBD on an industrial scale. Furthermore, it could lead to the full separation of individual compounds and derivatives at significantly lower costs than today’s widely used methods.”

      “We are eager to bring this technology to Abattis to verify its capabilities in our labs,” says Dr. Will Panenka, Director of Abattis. Dr. Panenka, MD, is an assistant professor, neurologist, and psychiatrist with a pre-clinical and clinical academic research program focused on substance use and brain injury at the University of British Columbia.

      Pursuant to the terms of the Agreement, Abattis has obtained exclusive rights to sell the machines, receive royalties and service licensed producers by offering toll processing and extraction. The distribution is exclusively licensed to Abattis in the territories of North America and Europe.

      “This is the only extraction technology capable of processing industrial scale volumes of biomass and separation of individual compounds to any target purity levels,” said Dr. Shuang Xie, Director of Abattis. “With this technology, products containing phyto-cannabinoids can become more cost-effective which would enable the production of affordable natural, functional products for consumers.”

      Northern Vine Update: The Company is also pleased to announce that its subsidiary, Northern Vine Canada Inc. (“Northern Vine”) has now been added to the Health Canada websites’ list of Licensed Dealers (see below for details). This further contributes to the Company’s positive momentum as Northern Vine completes the final installations and calibrations of its state of the art machinery capable of analytical testing for a variety of medicinal marijuana products.

      Mr. Abenante commented: “We have taken a big step forward in becoming a full service provider to Licensed Producers and end-consumers of medicinal marijuana products. The agreement with Raybot puts the Company in a position to be the leading provider of phyto-cannabinoid extraction products and services, and the launching of our lab will enable us to immediately generate revenue through providing analytical testing services to the Canadian medical Cannabis market and the future Recreational market.”

      About Abattis Bioceuticals Corp.
      Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.

      About Northern Vine Canada Inc.
      Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.
      For a listing of Health Canada’s Licensed Dealers see:
      https://www.canada.ca/en/health-canada/services/list-license…
      For more information, please contact info@northernvinelabs.com

      About Suzhou Raybot Material Tech Corp.
      Suzhou Raybot Material Tech Corp., is a technology company with offices in Suzhou Jiangsu, PRC and Vancouver, BC, focused on the development of proprietary methods and processes for applications in nutraceuticals, bioceuticals, botanicals and other derivatives from biomass on a commercial scale. Raybot is founded by a group of engineers and technologists who had successfully built over thirty mass production lines to extract high purity ingredients such as Ginkgo Biloba, Coenzyme Q10, Stevia, Ginsenosides, Paclitaxel, EGCG and other extracts for use in commercial nutraceuticals, functional foods and cosmetics. For more information, visit the Company's website at: www.abattis.com

      Link: https://www.abattis.com/single-post/2017/04/26/ABATTIS-SIGNS…
      Avatar
      schrieb am 05.05.17 13:49:08
      Beitrag Nr. 275 ()
      Abattis Bioceuticals (ATTBF) Announces the Official Launch of Northern Vine Laboratory
      Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT) is pleased to announce that its subsidiary, Northern Vine Canada Inc. (“Northern Vine”), has officially launched its flagship laboratory, having completed its first successful test analysis.

      Link: https://www.abattis.com/single-post/2017/05/03/ABATTIS-ANNOU…

      Northern Vine obtained a Health Canada Dealers’ License pursuant to the provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations. On November 30, 2016, the Task Force on Cannabis Legalization and Regulation published a report which emphasized the importance of independent lab testing of all cannabis products.

      Northern Vine has already begun taking samples from select Licensed Producers (“LPs”) and is building a sales force to aggressively grow its client base. Located in the valley of Langley, BC, amongst a consortium of MMAR and ACMPR license holders, Northern Vine aims to establish itself as a first class testing and analytics facility by offering a convenient location, efficient turnaround times, unparalleled customer service and the highest quality testing program.

      The Company’s Northern Vine laboratory solidifies another central piece in its vision to become a fully integrated medicinal marijuana company. Abattis continues to grow as a well-rounded biotechnology company now able to provide analytical research, development, extraction and testing services. Northern Vine has signed an agreement with a company in the last stages of becoming an LP and continues to entertain other joint-venture opportunities with LPs in Canada and abroad to further expand its reach in the cannabis market.



      Abattis recently announced that it has signed an exclusive distribution agreement with Suzhou Raybot Material Tech Corp ("Raybot"). Raybot has developed a technology capable of extracting legal cannabis derivatives such as Cannabidiol (“CBD”), Tetrahydrocannabinol (“THC”) and Cannabigerol (“CBG”) from marijuana or hemp. Per the exclusive agreement with Raybot, the Company is able to sell the machines, receive royalties and service LPs by exclusively offering toll processing and extraction services of their technology. Raybot has provided results whereby CBD was extracted from hemp to an above 99% purity level. This is currently the only technology capable of producing industrial scale extraction at this purity level, without the use of CO2. Harnessing economies of scale, Raybot claims their technology is capable of extracting CBD at $0.20 per gram.

      With these two significant milestones achieved, Abattis can begin to re-ignite its formulation division, which once boasted over 100 Natural Product Numbers (“NPN’s”). The Company has a sales division, Vergence Visionary Bioceuticals, (“Vergence”), that has a sales and marketing group with established distribution channels ready to market, sell and distribute newly formulated products from the Company’s Northern Vine lab. Vergence aims to promote healthy living through natural remedies and is developing new cannabis lifestyle products with plans to develop and distribute these products to global markets.

      "There are revolutionary advancements in the medicinal community stemming from research into natural cures from the cannabis plant," said Dr. David Galvez, Senior Science Advisor at Northern Vine. "Abattis is uniquely positioned to formulate and distribute innovative, high quality products which could potentially revolutionize the way we treat patients for a variety of pains and illnesses as well as to develop advanced nutraceutical and cosmetic products for high-end markets." Dr. Galvez has a PhD. in Plant Physiology and a B.Sc. in Botany.

      “I would like to thank our loyal shareholders and many stakeholders for working with the Company over the past three years to achieve this very significant milestone,” says Mr. Abenante. “I believe this marks the beginning of new growth for the Company as it now transforms from a development company to a revenue and profit generating entity.”

      About Abattis Bioceuticals Corp.
      Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.

      About Northern Vine Canada Inc.
      Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.

      About Vergence Visionary Bioceuticals Corp.
      Vergence Visionary Bioceuticals, dba Vergence Sales and Marketing Group, is a wholly owned subsidiary of Abattis, based in Vancouver, B.C., Canada. The Vergence team are bioceutical marketing specialists focused on health products to penetrate the fast-growing market for natural, safe and effective natural products that meet unmet wellness needs. For more information, visit the Company's website at: www.abattis.com.
      Avatar
      schrieb am 21.08.17 15:39:54
      Beitrag Nr. 276 ()
      Abattis Bioceuticals (ATTBF) – Partnerfirma EXPERION als Cannabis Produzent lizensiert (Licensed Producer)
      Experion Biotechnologies Inc. ("Experion") hat am 18. August 2017 die offizielle Lizenz zum Anbau von medizinisch genutzten Cannabis von der Kanadischen Gesundheitsbehörde Health Canada erhalten. Die sogenannte Cannabis for Medical Purpose Regulations License – auch ACMPR-Lizenz genannt – erlaubt Experion nun, medizinisches Marihuana in seiner neu eröffneten Anlage in Mission BC anzubauen.

      Die Abattis Bioceuticals Inc., ist der Mehrheitseigentümer der Firma Northern Vine, die wiederum eine Beteiligung von 18,75% an Experion hält. Aufgrund des Erhalts der Lizenz, wird Experion nun offiziell von Health Canada als lizenzierter Produzent (LP) geführt - bisher gibt es nur 13. lizenzierte Cannabis-Produzenten in British Columbia.
      Siehe Liste aller lizensierter Produzenten: https://www.canada.ca/en/health-canada/services/drugs-health…


      Die Anbaulizenz erfolgte nach Fertigstellung einer, den strengen gesetzlichen Auflagen entsprechenden, sicheren Lager- und Verarbeitungsanlage. Diese Anlage, die auch als Mission Site bezeichnet wird, ist insgesamt etwa 8.300 Quadratmeter gross. Experion hat bereits angekündigt, seine Produktionsstätte auf 40.000 Quadratmeter zu erweitern, vorbehaltlich einer weiteren Zulassung durch Health Canada.

      Quelle: https://globenewswire.com/news-release/2017/08/21/1090526/0/…
      Avatar
      schrieb am 24.08.17 15:27:02
      Beitrag Nr. 277 ()
      Abattis Subsidiary, Northern Vine, Provides Update on Growth Targets
      Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE: ATT / OTC: ATTBF) is pleased to provide an update on its subsidiary, Northern Vine Canada Inc. (“Northern Vine”), which specializes in the legal testing and analysis of cannabis products and is expected to soon commence extraction of cannabinoid derivatives for commercial applications.

      “Northern Vine is ramping up for a busy finish to 2017,” said Northern Vine and Abattis President and CEO, Robert Abenante.

      “We are very pleased with the progress of Northern Vine and are working hard to become a premiere cannabis laboratory and extraction processing center. Northern Vine is now poised for further growth and expansion. Given the progress of Northern Vine’s development, we anticipate that we will be ready for larger volume licensed producer (LP) clients by next quarter.”

      Improved Capacity and Turn-Around Times
      Northern Vine continues to successfully accept cannabis flower, oil and edible samples at its lab in Langley, BC. The team of scientists has improved their methods and procedures and are aiming to provide a full cannabinoid profile with the most efficient turnaround times in the market.

      Additionally, Northern Vine has successfully submitted an application to Health Canada regarding enhancing its security from Level 3 to Level 6. Approval of this security level enhancement will increase the amount of controlled substances Northern Vine can hold and process in its lab to up to 25 kgs. This is expected to enable Northern Vine to exponentially increase the volume of services it can provide to LPs and ACMPR patients.

      Arrival of Raybot Team
      Northern Vine also welcomed the extraction team from Suzhou Raybot Material Tech Corp. (“Raybot”). Raybot’s contribution to Abattis’ and Northern Vine’s operations includes provision of Raybot’s proprietary extraction technology to Abattis and Northern Vine, and the granting of exclusive rights to sell and service Raybot’s extraction equipment. Delivery of two Raybot extraction machines is expected in the fall of 2017.
      Strategically located in Langley, BC, Northern Vine is expected to be in the hub of major future testing and formulation activity. As Northern Vine streamlines its methods and customer service efforts, it plans to be a main service provider to the AMPCR market.

      With the integration of Raybot’s technology and Northern Vine’s extraction and testing capabilities, Northern Vine is in the final stages of validating its various methods for a full array of services that include testing for potency, pesticides and heavy metals.

      The arrival of the new machines will mark the beginning of the Company’s large-scale cannabinoid extraction business plan, which it hopes to replicate across Canada and globally.

      New Additions to Northern Vine Lab Team
      Northern Vine is pleased to announce the addition of scientists, Dr. Anika Singh and Akshita Puri, to its laboratory staff.

      Dr. Singh holds a PhD in Food Science and Agricultural Chemistry from McGill University. Her projects have been funded by the Natural Sciences and Engineering Research Council of Canada (NSERC). She has composed several reviewed papers in various international journals of food science and nutrition.

      Ms. Puri holds a Masters degree in Biochemistry from McMaster University, with 7 years of research experience in the field of microbiology. Her experience includes managing multiple projects leading a team of 12 biotech professionals, and contributing to securing $2M in grant funding from the Canadian Institute of Health Research.

      New Products
      Science advisor, Dr. David Galvez, and the team at Northern Vine, are formulating a proprietary cannabinoid-infused product for strategic marketing and sales, with the goal of targeting Canadian, Australian, European and California markets. Product completion is anticipated for as early as fall 2017.

      The team has identified an array of unique ingredients and delivery methods for maximum bioavailability and product efficacy and has begun brand development and marketing efforts around this initiative.

      Link: https://www.abattis.com/single-post/2017/08/23/Abattis-Subsi…
      Avatar
      schrieb am 30.08.17 21:10:19
      Beitrag Nr. 278 ()
      Abattis Bioceuticals (ATTBF) – Powering up the Cannabis Industry
      Abattis Bioceuticals Corp (CSE: ATT) (OTC: ATTBF) is powering up the cannabis industry with downstream services for legal producers including testing, extraction and formulation. Led by Rob Abenante, a seasoned public company executive with an impressive track record, Abattis is a vertically integrated biotechnology company that is strategically positioned to be an industry leader in cannabis services and botanical drug development. Everything from patented and proprietary formulations, proprietary extraction technology and toll processing methods to world-class analytics and testing facilities. Abattis consistently works towards providing strategic and operational support to a portfolio of great companies.

      Link: http://stocksyndicate.com/blog/powering-cannabis-industry-ab…
      Avatar
      schrieb am 06.09.17 17:39:48
      Beitrag Nr. 279 ()
      Abattis Bioceuticals (ATTBF) – Powering up the Cannabis Industry


      Quelle: https://twitter.com/abattis
      Avatar
      schrieb am 13.09.17 19:02:07
      Beitrag Nr. 280 ()
      Abattis Bioceuticals (ATTBF) provides important update on Northern Vine and Sales Division
      “We are very pleased with the continued progress being made to strengthen to the sales, marketing and distribution arm of Abattis and Northern Vine,” said Rob Abenante, President and CEO of Abattis. “We believe that the major value to be derived from the legal cannabinoid space will come from all downstream products and services derived from the cannabis plant. Vergence will be a direct gateway to sell products formulated at our labs in Northern Vine as well as others products which we are able to infuse with customized cannabinoid formulas. Abattis is equipped to service both of these rapidly evolving market’s and be fully prepared to be a market leader when recreational laws are passed.”

      Website Launch and Online Retail Opportunity
      Abattis is pleased to announce the official launch of the Vergence retail website, www.VergenceNaturals.com
      The website is designed to streamline availability of the Vergence’s product lines, both developed in-house by Northern Vine and Abattis, as well as third-party products with which Vergence has distribution agreements. VergenceNaturals.com is a full-suite natural health products online store, through which all of Vergence’s products will eventually be featured and for sale.

      “We’re very excited to launch VergenceNaturals.com, which should deliver not only sales revenue, but also important data on customer metrics for our carried lines,” said Mark Mansfield, VP of Sales at Vergence. “We see this sales portal as our Amazon, driving our goal is to be the go-to online retail location for natural health products. We look forward to the potential of incorporating Northern Vine’s CBD-infusion capabilities with not only the products we develop in-house, but with those we’ve signed distribution and marketing agreements with.”

      Brands currently featured on the website include:
      Mogiana Coffee
      Jonny Hetherington
      Natrihealth
      Planet Hemp
      Beyond Silver
      Real Aloe
      Styrian Gold
      Maui Vera


      In congruence with the launch of the website, Abattis is proud to announce the following sequence of distribution agreements signed by Vergence Naturals with high-quality third parties:

      Distribution Agreement with Styrian Gold BC Inc.

      Vergence has reached a global distribution agreement with Styrian Gold BC Inc., makers of the award-winning, 100% pure and unrefined Styrian Gold Pumpkin Seed Oil.

      Styrian Gold Pumpkin Seed Oil delivers healthy antioxidants, vitamins and minerals vital for bodily functions. Consumption of the oil helps to aid the liver, bladder, urinary tract, and prostate, as well as having anti-inflammatory, anti-parasitic, and anti-diabetic benefits. Along with the oils, Styrian Gold also sells seeds and protein powder that it imports directly from an established and reputable oil pressing company in Styria.

      Vergence will use its distribution and marketing channels to properly spread Styrian Gold products to global markets, and is proud to incorporate the line in its portfolio of products.

      Distribution Agreement with Cascadia Soap Company
      Vergence has reached a major North American distribution agreement with Cascadia Soap Company (or “Cascadia”), makers of natural skin care products under the same brand name.

      Cascadia’s soaps, remedies, and infusions are made using classic artisan methods used for generations in the South of France. Along with all-natural ingredients such as rose hips, and dandelions to make the required salves and balms, Cascadia’s founder Joel Morassutti developed a technique to incorporate goat milk in the production of the company’s rich, long-lasting, and moisturizing cleansing bars. Goat milk is used to increase the health benefits of the milk’s liposomes in the soap.

      Vergence has already listed the Cascadia Soaps best sellers on its new website, and is set to begin working on global distribution with partnered distributors.

      Distribution Agreement with Naturally Canadian Foods
      Vergence has signed a global distribution deal with Naturally Canadian Superfoods Inc., direct importers, distributors, and brokers of several products including Real Aloe, Maui Vera, and the hemp superfood line Planet Hemp.

      “Key to the deal is the potential to co-develop products with Naturally Canadian Superfoods’, through our subsidiary, Northern Vine,” said Rob Abenante, President and CEO of Abattis. “We believe there is major potential for synergistic product lines still-to-be developed between Northern Vine and our new partners, through enhancement of formulas with the medical benefits of CBD oils.”

      Naturally Canadian Superfoods’ product lines include natural and organic aloe vera sun care and lotion product lines Real Aloe and Maui Vera, as well as hemp superfood line Planet Hemp, a natural buckwheat seaweed product line, a spice line from India, and an organic garden hose line, among other products.

      Distribution Agreement with Smartpep Canada Biological Tech (DBA Natrihealth)
      Vergence has signed a global distribution agreement with Smartpep Canada Biological Tech (DBA) Natrihealth (or “Smartpep”), for the “Natrihealth” brand of collagen supplements. Smartpep brings with it previously forged partnerships in North America, Asia, Japan, Korea, and Hong Kong among its markets, and boasts only the best, high-quality ingredients in its products.

      The “Natrihealth” brand produces several collagen supplements, utilizing tripeptide technology. Unlike most collagen supplements on the market which are mass produced cheaply using beef and poultry, Natrihealth has focused on a higher quality fish-based formula.

      “We are adding new brands to the website every week," adds Andrea Bates, COO of Vergence Naturals, “…and we are very excited about the development of our own high end Vergence product lines. For example, we are currently working on a line of premium wild BC honeys, a luxury all natural, organic plant based cosmetic line and a CBD sunscreen which is being developed by our lab, Northern Vines.”

      Link: https://globenewswire.com/news-release/2017/09/13/1120379/0/…
      Avatar
      schrieb am 23.09.17 22:47:12
      Beitrag Nr. 281 ()
      Abattis Bioceuticals (ATTBF) - Prepares for Growth in Extracts
      Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte analysts, driven by the legalization of recreational cannabis next year. While many licensed producers are focused on expanding capacity, the best opportunities may be those that can add value for existing licensed producers. These opportunities include those companies focused on higher value cannabis extracts.

      In this article, we will look at Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) and why its proprietary extraction technology represents an important breakthrough that investors shouldn’t ignore.



      Proprietary Extraction Technology

      Abattis recently signed an exclusive distribution agreement with Suzhou Raybot Material Tech Corp (“Raybot”). Under the terms of the agreement, Abattis will use Raybot’s proprietary extraction technology in its own operations and have the exclusive rights to sell the extraction equipment and services to other companies. The agreement could open the door to mass produced cannabinoid products as well as licensing opportunities with other producers.

      Raybot’s proprietary technology utilizes industrial column chromatography to extract and separate a wide range of materials in a continuous closed loop system. While the method is already used to mass produce extracts like Ginkgo Biloba and Stevia, the technology has been altered to extract legal cannabis derivatives like cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) from marijuana or hemp.

      The proprietary technology uses a process known as low pressure preparatory column chromatography, which involves passing a pressurized liquid through a proprietary and exclusive polymer. Each component of the sample material interacts slightly differently with the polymer, causing different frequencies depending on the polarization for each component, which leads to the separation of the components as they flow out of the pressurized column.



      Significant Advantages

      Raybot’s proprietary extraction technology is capable of extracting CBD from hemp at a greater than 99% purity level. While the current methods use multi-staged CO2 extraction, the Raybot technology is significantly more cost-effective and can be customized to any factory production scale. For example, a processing center with a 5,000 kilograms per day processing rate could produce CBD at just $0.20 per gram using the technology. Raybot is able to achieve these cost advantages due to their ability to reuse and replenish the polymers for the columns. Abattis has exclusive distribution and service rights to replenish the polymers for extractions machines sold in North America and Europe.

      In addition to these cost and scalability benefits, the technology can be used with both wet and dry products, which eliminates the need to dry cannabis products. Drying of the cannabis flower is not only expensive and time consuming, but could also lead to loss of terpenes and other active ingredients. The Raybot technology isolates only the desired active ingredients and removes all impurities, such as pesticides, without chemically altering the cannabinoids that are extracted, resulting in the purest formulations.

      “This technology has the potential to revolutionize the extraction process for THC, CBD and other cannabis derivatives globally,” said Abattis CEO Robert Abenante in a recent press release announcing the licensing agreement. “Raybot’s proprietary extraction method is currently one of the only extraction technologies that can extract high purity CBD on an industrial scale. Furthermore, it could lead to the full separation of individual compounds and derivatives at significantly lower costs than today’s widely used methods.”

      Link: http://www.cannabisfn.com/abattis-prepares-growth-extracts/
      Avatar
      schrieb am 18.10.17 10:39:47
      Beitrag Nr. 282 ()
      Abattis Bioceuticals (ATTBF) - NEW Investor Presentation 2017 PDF
      Die neue Firmenpräsentations-Broschüre von Abattis Bioceuticals 2017:
      http://testsiteservers.com/abattis/wp-content/uploads/2017/1…

      Avatar
      schrieb am 27.10.17 12:46:24
      Beitrag Nr. 283 ()
      Abattis Bioceuticals (ATTBF) - Industrial Scale Processing Centers
      Abattis is in negotiations with strategic partners with large cultivation operations – https://globenewswire.com/news-release/2017/10/26/1154386/0/…. In the industrial scale processing model, the cultivators will provide the biomass, Abattis will provide the extraction technology and processing expertise and together they will process and sell full spectrum oils and isolates to the market.

      Of notable importance, Northern Vine’s LD status allows it to not only export/import cannabis, as LPs are permitted to do under ACMPR, but to also export/import cannabis oils.



      Abattis intends to build out its first pilot "XLAB" in British Columbia with capabilities to test, extract, formulate, process, package and create market-ready cannabis based products. Once the initial pilot lab is operational, Abattis will fund and stamp out "XLABS" across the country in even major province.
      Emerald Health Therapeutics Inc. (“Emerald”) (TSXV:EMH) (OTCQX:EMHTF) announced that it has signed a definitive agreement (the “Agreement”) with Northern Vine Canada Inc. (“Northern Vine”) and Abattis Bioceuticals Corp. (“Abattis”) (CSE:ATT) (OTC:ATTBF) to invest $2.5 million into Northern Vine to acquire 53% of the company and appoint three of its four directors. Abattis will continue to hold the remaining 47% of Northern Vine - https://globenewswire.com/news-release/2017/10/26/1154251/0/….

      Avatar
      schrieb am 02.11.17 01:27:30
      Beitrag Nr. 284 ()
      Abattis Bioceuticals (ATTBF) - Emerald Health Expands Capabilities with Northern Vine Labs Deal
      SEATTLE, WA--(Marketwired - Nov 1, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Emerald Health Therapeutics Inc.'s (TSX VENTURE: EMH) (OTCQX: EMHTF) recent deal with Abattis Bioceuticals Corp. to acquire a controlling interest in Northern Vine Labs. The agreement could grow Northern Vine into a thriving center for analytical testing, genetic research and development, tissue culture, and proprietary medicinal and therapeutic formulations. As a Licensed Dealer, Northern Vine will also be able to export and import cannabis oils around the world, unlike ACMPR licensed producers. Under the agreement, Emerald Health will invest $2.5 million to acquire 53% of Northern Vine and appoint three of four directors. Abattis will continue to hold the remaining 47% equity stake in Northern Vine and benefits from the deal in a variety of other ways. Meanwhile, Emerald Health plans to utilize Northern Vine for cannabis testing, product innovation, and potentially import/export capabilities for cannabis oils.

      Broadening Licensing Capabilities
      Emerald Health benefits from a Licensed Dealer that has much broader capabilities than a Licensed Producer when it comes to carrying out research and development, importing and exporting cannabis oils, and related activities. Northern Vine also provides exposure to the cannabis testing industry, as it currently provides LPs and registered patients with complete microbiology and chemical analyses to ensure product is safe and efficacious. "Our acquisition of control of Northern Vine will set the wheels in motion on a number of strategic business opportunities that we have been nurturing," said Emerald Health Executive Chairman Avtar Dhillon, MD, in a press release announcing the deal. "We see tremendous synergies and opportunities to work with Abattis both on extraction and research and development of medicinal and therapeutic products." In addition to the Northern Vine transaction, Emerald Health has been working to dramatically expand its cannabis production capacity with a new facility on its 32-acre property in Metro Vancouver and its partnership with Village Farms, which utilizes an existing 25-acre greenhouse complex that is being retrofitted to grow cannabis. The company is focused on high-quality product innovation particularly for wellness and medical benefit to set it apart from many licensed producers in the space that are focused on scale.

      Opening the Door to the Future
      Abattis Bioceuticals benefits from Emerald Health's wealth of scientific knowledge, pharmaceutical connections, and access to capital, as well as a $2.5 million capital infusion into the subsidiary. The strong relationship between Abattis and a rapidly growing and respected licensed producer in Canada also paves the way for future joint ventures for its extraction technology and adds credibility to its ability to create laboratories - which is essential to its business model moving forward. "This is an important turning point for Abattis," said Robert Abenante, President and CEO of Abattis and Northern Vine. "The company has always desired a strategic partner for its laboratory and has now partnered with one of the most experienced LPs in Canada. As we commence rolling out our business model for extraction, attracting a partner like Emerald is proof that we have an extremely talented team." In addition to Northern Vine, Abattis has licensed a proprietary extraction technology with a patented counter-current layering system that yields 98% of cannabinoids -- 18% better than today's leading methods. A continuous system of columns can either remove impurities and pesticides from full spectrum oil or individual cannabinoids and terpenes to 99% purity levels. And, it's at a lower cost than traditional CO2 extraction methods. Abattis believes that a major growth area of the industry moving forward lies in the extraction of active ingredients from cannabis to create products such as edibles and the company's previously announced CBD-based sunscreen. The new relationship with Emerald Health should provide the company with products to test and biomass to convert to those products, utilizing the patented extraction tech to further the company's stated goal of becoming a key downstream service and products provider.

      Please follow the link to read the full article: http://www.cannabisfn.com/emerald-health-expands-capabilitie…
      Avatar
      schrieb am 07.11.17 17:34:28
      Beitrag Nr. 285 ()
      Abattis Bioceuticals (ATTBF) - Interview mit CEO Robert Abenante
      Ein sehr aufschlussreiches Interview mit Herrn Rober Abenante, CEO der Abattis Bioceuticals Inc. (CSE: ATT) (OTCQB: ATTBF).
      CFN Media spoke with Mr. Robert Abenante, CEO of Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) to discuss the company’s cannabis testing and product development strategy in light of the recently announced partnership with Emerald Health Therapeutics.
      Link: http://www.cannabisfn.com/exclusive-ceo-interview-abattis-va…

      Aktuelle Abattis Firmen Präsentation vom September 2017:
      Avatar
      schrieb am 28.11.17 23:42:07
      Beitrag Nr. 286 ()
      ABATTIS BIOCEUTICALS – ATTBF – Die Cannabis Aktie der Woche
      Der Marihuana-Experte Jeffrey Friedland, Autor des Buches "Cannabis: The World's Most Misunderstood Plant" stellt in diesem YouTube-Video seine Aktien-Favoriten der Kalenderwoche 48 vor:

      Avatar
      schrieb am 04.12.17 14:22:37
      Beitrag Nr. 287 ()
      ABATTIS BIOCEUTICALS – ATTBF – Prognose des Analyse- und Testmarktes für Cannabisprodukte
      Eine Vorausschätzung des weltweiten Analyse- und Testmarktes für Cannabisprodukte bis zum Jahre 2025:



      Quelle: www.inkwoodresearch.com
      Avatar
      schrieb am 13.12.17 02:37:41
      Beitrag Nr. 288 ()
      ABATTIS BIOCEUTICALS – ATTBF – Abattis Confirms Breakthrough Extraction Technology Capabilities
      Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE: ATT / OTC: ATTBF) is pleased to announce the successful completion of experiments confirming column chromatography extraction technology.

      The experiments assessed the feasibility of applying the technology for the extraction of CBD, THC and THCA from industrial hemp and cannabis. Throughputs, yields, purity and terpene profiles were also part of the scope of work performed at our facility, Northern Vine Labs. Bench scale runs were carried out in conjunction with confirmatory larger scale runs of up to 75 kilograms of biomass per day. The technology is already being used in an industrial scale capacity of up to 50,000 kilograms of biomass per day. The developer of the technology is now preparing to work with key partners to start isolating cannabinoids for the upcoming Canadian legalized market.

      “The extraction method using proprietary polymers has very distinct competitive advantages over traditional methods,” said Rob Abenante, President and CEO of Abattis. “The technology is capable of extraction on an industrial scale, which delivers significant cost advantages. It is also capable of separating cannabinoids on a molecular level which allows for the extraction of pure isolates such as CBD and THCA and even the separation pesticides from the biomass.”

      Proof of Concept

      Abattis confirms the following results from performed by the technology owner, Frank Zhu and his team:

      – The quantitative recovery measurement showed 99% recovery of all cannabinoids from the biomass material. These yields are better than conventional methods that generally only yield up to 80%.
      – Confirmed separation of THC, THCA and CBD from a series of cannabis strains.
      – Confirmed separation and production of pure 98%+ THCA in crystallized form.
      – The technology successfully removes all traces of any pesticides or harmful residues from the cultivation and transportation process.
      – Once commercialized, a factory running at a 500 kg-per-day processing rate can process CBD at less than $0.20/gram.
      – The cost of capital equipment and overall cost of operation is less than half of conventional CO2

      “We have enjoyed our collaboration with Mr. Zhu. It has been an honor to have someone of his expertise and ingenuity here to show the capabilities of his technology and methodologies. The technology has the potential to revolutionize the extraction process for most cannabis derivatives for the entire sector,” stated Mr. Abenante. “His extraction method and use of his key IP is currently one of the only toll-processing technologies that can extract high purity CBD on an industrial scale. We’re happy to have confirmed that it can fully separate individual compounds such as THCA.”

      “We believe the implementation of this extraction technology has the ability to give Abattis a competitive advantage in the extraction industry. It is our intention to position the extraction technology with the largest producers and oil manufacturers in North America to provide the market with the highest quality distillate and isolates, at the lowest cost. We feel the evolution of the industry will lead to the commoditization of marijuana and hemp, at which point downstream services such as extraction will become the primary focus of the industry as companies compete to create thousands of new products based on the numerous derivatives,” added Mr. Abenante.

      Validation and Demonstration of Technology

      Frank Zhu, the key developer and owner of the technology, was brought in to supervise the arrival and assembly of the machines.

      Mr. Zhu has installed the demonstration apparatus at Abattis’ faculties, its subsidiaries, as well as several producers to confirm the technology. He setup a working model of the technology to demonstrate its capabilities to separate and isolate compounds with very little capital, consumables and operating requirements.

      “I am very pleased to finally demonstrate some of the capabilities of the column chromatography technology, when applied to cannabinoid extraction.” stated Frank Zhu, the key scientist behind the technology. This visit and demonstration has been two years in the making with key members of the Abattis team. My extraction technology is capable of processing industrial scale volumes of biomass and separation of individual compounds to any target purity levels. Products containing phyto-cannabinoids can become more cost-effective which would enable the production of affordable natural, functional products for consumers. I believe that by using my extraction technique, Abattis could obtain a competitive cost advantage the high growth concentrates market. I look forward to setting up my North American program in 2018 and feel that I am in great hands working with Abattis to set up facilities in Canada and United States to start,”

      Link: http://abattis.com/index.php/2017/12/12/abattis-confirms-bre…
      Avatar
      schrieb am 13.12.17 02:50:49
      Beitrag Nr. 289 ()
      ATTBF – Abattis looks to become a leader in extraction with proprietary Raybot extraction technology
      Raybot has repurposed its industrial Preparative Chromatography Separation System, previously used in Tobacco, Pharma and Natural Food industries, specifically for implementation in the Cannabis industry. Let us explain...




      Notable Products Created with Raybot Technology:
      Resveratrol | 98% purity
      5-HTP | 99% purity
      Ginkgo Biloba Extract | 24% purity
      Inositol | 99% purity
      Co-Enzyme Q10 | 98.5% purity

      Quelle: https://www.raybottech.com
      Avatar
      schrieb am 15.12.17 17:41:59
      Beitrag Nr. 290 ()
      Emerald Healt Therapeutics Partnerschaft.
      Da bin ich doch mal mit dabei.
      Mal sehen wo die Reise hin geht.
      Avatar
      schrieb am 01.02.18 10:38:37
      Beitrag Nr. 291 ()
      Lohnt der Einstieg jetzt noch?
      Avatar
      schrieb am 02.02.18 02:30:58
      Beitrag Nr. 292 ()
      Warum nicht. :laugh: ist doch schön gefallen! :cool:
      Avatar
      schrieb am 10.02.18 09:26:05
      Beitrag Nr. 293 ()
      Avatar
      schrieb am 10.02.18 09:29:21
      Beitrag Nr. 294 ()
      Avatar
      schrieb am 12.02.18 12:27:17
      Beitrag Nr. 295 ()
      um diesen Wert herum ist es auch noch relativ ruhig. Ich persönlich finde dieses Kursniveau sehr interessant. werde mir wohl ein paar Stücke gönnen.
      Avatar
      schrieb am 21.02.18 12:34:31
      Beitrag Nr. 296 ()
      Gab es hier News?
      Avatar
      schrieb am 27.02.18 07:47:16
      Beitrag Nr. 297 ()
      Weiß jemand mehr über den Trading Halt gestern bei Abattis - nach den 10 % Minus abverkauf auf 0,25 US $

      Eigentlich könnte es eine gute Meldung werden.
      Avatar
      schrieb am 27.02.18 13:09:44
      Beitrag Nr. 298 ()
      1 Antwort
      Avatar
      schrieb am 27.02.18 16:08:44
      Beitrag Nr. 299 ()
      Antwort auf Beitrag Nr.: 57.131.910 von grayWOLF am 27.02.18 13:09:44Um 16 Uhr - hoher Umsatz bei Abattis bei 0,28 US $ - ca. 11 % plus
      Nur die Händler in Deutschland haben das noch nicht bemerkt.

      evtl. wird Abattis auch wieder billiger in dem Minus-Umfeld
      kurz nach 16 Uhr bei 0,255 - 026 US $ = 0,21 €

      Die anderen Canabiswerte die meisten starten im Minus 3 - 6 % -

      Tradegate verkauft noch zu 0,193 - gestriger Schlußkurs.
      Avatar
      schrieb am 28.02.18 00:38:05
      Beitrag Nr. 300 ()
      Bin in Abattis gut investiert und sitze es jetzt aus bis es endlich über den €/$ geht....:laugh:....bin ja auch bei Terra Tech, aber die griegen auch den Arsch nicht hoch, obwohl sie auch gut aufgestellt sind und mit "Blüm" schöne Verkaufstellen haben.
      Avatar
      schrieb am 02.03.18 07:30:02
      Beitrag Nr. 301 ()
      heute morgen zwei Meldungen von Abattis - auf www.finanznachrichten.de -
      der link zu einer Meldung - zur anderen geht der link nicht.

      http://www.finanznachrichten.de/nachrichten-2018-03/43156585…
      2 Antworten
      Avatar
      schrieb am 02.03.18 08:05:38
      Beitrag Nr. 302 ()
      Antwort auf Beitrag Nr.: 57.166.053 von urpferdchen am 02.03.18 07:30:02Sind nur Erklärungen zu den jüngsten erhöhten Marktaktivitäten.
      Von täglich ein paar wenigen Aktien auf mehrere Millionen ist nicht unerheblich.

      Aber der Chart zeigt jetzt schön nach oben.
      1 Antwort
      Avatar
      schrieb am 02.03.18 08:12:59
      Beitrag Nr. 303 ()
      Antwort auf Beitrag Nr.: 57.166.311 von teresas am 02.03.18 08:05:38Vielen Dank für die Info.
      Da müssten demnächst die Quartalszahlen kommen. - evtl. schon nächste Woche.
      Auch bei Aequus und Delivra.
      Avatar
      schrieb am 02.03.18 08:16:50
      Beitrag Nr. 304 ()
      Die kostenlose Tagesprognose von Rocco Gräfe auf www.godmode-trader.de
      der link
      https://www.godmode-trader.de/analyse/dax-tagesausblick-flag…

      seine Prognose
      --------------------

      Freitag, 02.03.2018 - 08:09 Uhr
      DAX Tagesausblick: Flagge aufgelöst! 12000 im Fokus!
      Dax - normaler logischer Verlauf, einfache Routine! Nach einer Flagge kommen überfallartig neue Tiefs! Das ist höchst gewöhnlich und war tagelang anzukündigen. Die Frage ist nur, ok es der Dax bei 12000/11850 belässt oder ob er bis 15.3. auch noch 11150/11000 in Anspruch nimmt.
      ----
      DAX: 12191 

      Widerstände: 12190/12200 + 12280 
      Unterstützungen: 12000 + 11865 + 11150/11000 

      DAX Tagesausblick:
      Die Flagge der letzten Tage löste sich regelkonform nach unten auf. Der DAX brach nach unten nachbörslich bis 12000 weg.
      Warnungen dafür gab es genug, auch die, dass das obere Idealziel 12650 aufgegeben wird (seit Mi, 17 Uhr).
      Von 12000 könnte der DAX kurzzeitig etwas steigen, z.b. bis 12200/12260.
      Dann sind weitere Tiefs zu favorisieren, vor allem bei 11865.
      Unter 11850 wäre sogar 11150/11000 das Ziel bis 15.3.18.


      Übrigens: Falls Sie jetzt direkt "loshandeln" möchten, kann ich Ihnen die Consorsbank nur wärmsten empfehlen. Seit der Anbindung an Guidants funktioniert das blitzschnell – mit nur einem Klick, ohne die Plattform zu verlassen. Ich selbst bin schon über 15 Jahre Kunde bei der Consorsbank und immer noch überzeugt ... Lassen auch Sie sich überzeugen. Alle wichtigen Infos finden Sie hier.

      DAX Alternativen? Etwas "Entspannung" erfolgt nur nach Stundenschluss über 12300 und etwas mehr noch über 12515.

      Viel Erfolg!
      Rocco Gräfe
      Avatar
      schrieb am 13.03.18 15:21:43
      Beitrag Nr. 305 ()
      Wenn die 0,30 C$ fallen, ist die nächste Unterstützung erst bei 0,20 ?!
      Avatar
      schrieb am 14.03.18 12:44:01
      Beitrag Nr. 306 ()
      Antwort auf Beitrag Nr.: 57.264.118 von Toni666 am 13.03.18 15:21:43Warum sollte sie fallen ?
      Avatar
      schrieb am 14.03.18 13:36:57
      Beitrag Nr. 307 ()
      Abattis - es wäre langsam Zeit, daß die Zahlen kommen - bzw. der Kurs nach oben dreht.

      So lange die Zahlen - Umsatz - Gewinn / Minus je Aktie - nicht kommt, geht es eher Seitwärts.
      Oder Meldung über die Testanlage mit 50 / 500 kg tägliche Verbeitung - und die Zukäufe. usw.

      8 Antworten
      Avatar
      schrieb am 14.03.18 13:43:28
      Beitrag Nr. 308 ()
      Antwort auf Beitrag Nr.: 57.275.158 von urpferdchen am 14.03.18 13:36:57Vielleicht kommen die Zahlen ja heute.
      Es wurden schon über 300 T Aktien in D gekauft.
      7 Antworten
      Avatar
      schrieb am 14.03.18 13:57:37
      Beitrag Nr. 309 ()
      Antwort auf Beitrag Nr.: 57.275.236 von teresas am 14.03.18 13:43:28Das ist Auffällig und ohne Meldung bisher. Das gab es schon lange nicht mehr in Deutschland.

      Dann werden wir ab 14 Uhr 30 - bis heute Abend mehr wissen.

      Mal immer wieder bei den -www.finanznachrichten.de - nachsehen, ob da was gemeldet wird.

      Überfällig wäre der Ausbruch bei Abattis.
      6 Antworten
      Avatar
      schrieb am 14.03.18 14:10:33
      Beitrag Nr. 310 ()
      Antwort auf Beitrag Nr.: 57.275.425 von urpferdchen am 14.03.18 13:57:37
      300 000...
      ... habe ich zwar nicht gekauft, aber einen Bruchteil davon. Gefallen hat mir die Geschichte mit den Northern Vine Labs, dort hat sich eine deutlich höher bewertete "Emerald" beteiligt. Zusammen mit den korrigierten Kursen ist das einen Zock wert. Denke schon, dass irgendwas von der Cannabis-Story seinen Weg in den medizinischen Bereich finden wird....
      Avatar
      schrieb am 15.03.18 08:34:07
      Beitrag Nr. 311 ()
      Antwort auf Beitrag Nr.: 57.275.425 von urpferdchen am 14.03.18 13:57:37Hhhmmm...eine Etage tiefer.
      War vor dem letzten Anstieg auch so.
      Aber muss nichts heißen.
      4 Antworten
      Avatar
      schrieb am 15.03.18 08:40:44
      Beitrag Nr. 312 ()
      Antwort auf Beitrag Nr.: 57.284.095 von teresas am 15.03.18 08:34:07Der Abverkauf gestern - heftig auf 0,185 € - bei Abattis - mit dem allgemeinen DOW-Cannabis-Trend.

      Es wird Zeit daß die was Melden.
      Meistens kommt der Sell-Off-Abverkauf vor der Meldung - Anstieg -Trendwende.
      Evtl. nächste Woche ?
      3 Antworten
      Avatar
      schrieb am 15.03.18 09:41:43
      Beitrag Nr. 313 ()
      Antwort auf Beitrag Nr.: 57.284.140 von urpferdchen am 15.03.18 08:40:44Durch allerlei Vereinbarungen, Übernahmen und Absichtserklärungen ist Abattis sehr gut aufgestellt.
      Das alles kommt erst in die Gänge, wenn ein genauer Zeitplan für die Legalisierung steht. Der bisherige wurde gecancelt, einen neuen gibt es nicht. Der immer wieder genannte 22. März 2018 habe ich nirgends gefunden. Es wird wie mit der Bildung der Bundesregierung laufen: irgendwann klappt's.
      Und dann sind auch bei Abattis einige 100% vom jetzigen Niveau drin.
      2 Antworten
      Avatar
      schrieb am 15.03.18 10:38:58
      Beitrag Nr. 314 ()
      Antwort auf Beitrag Nr.: 57.284.944 von teresas am 15.03.18 09:41:43Abattis hat extrem Abverkauft - zu den anderen Aphria - Aurora - Canopy -
      weil die noch keine Finanz- oder Ergebnismeldungen brachten - weder das 4. Quartal 2017 - noch
      sonst was - Und da müsste von den Übernahmen einiges in der Kasse sein.

      Die Verschiebung der Freigabe sehen die 3 Marktführer nicht als Problem, weder am Börsenumsatz,
      noch am Kurs.
      Aurora kommt wegen dem Umsatz nun sogar in den S&P500.

      Also Fehler oder Absicht bei Abattis :(
      1 Antwort
      Avatar
      schrieb am 15.03.18 19:04:31
      Beitrag Nr. 315 ()
      Antwort auf Beitrag Nr.: 57.285.562 von urpferdchen am 15.03.18 10:38:58hi,
      reizvoller Kurs................habe verbilligt und verdoppelt...........
      M.
      Avatar
      schrieb am 15.03.18 20:37:09
      Beitrag Nr. 316 ()
      So lange jeden Tag tiefer abverkauft wird, warte ich mit dem verbilligen.
      um 20 Uhr 30 bei 0,22 US $ - Tief bei 0,18 $ - noch kein Schlußkurs -
      2 cent tiefer als gestern.
      Wenn es so weiter fällt, wäre das Tief morgen ? oder Anfang nächster Woche
      erreicht.

      Der extremste Cannabis-Wert - vor 10 Tagen noch über 30 % höher.
      Abverkauf ohne Grund - nur -Charttechnisch -


      zum Teil werden grösssere Blöcke gehandelt an der OtC - sieht aus wie sammeln.
      Avatar
      schrieb am 16.03.18 16:40:23
      Beitrag Nr. 317 ()
      Heute bisher kein tieferes Minus - es werden größere Blöcke gehandelt.
      Wenn es bis Schlußkurs über die 0,22 US $ steigt - sieht es nach Bodenbildung aus.
      Chart um 16 Uhr - noch kein Schlußkurs


      Avatar
      schrieb am 20.03.18 08:52:33
      Beitrag Nr. 318 ()
      Abattis - gestern mit einer Meldung - sieht nach Bodenbildung aus. Der verrückteste Cannabis-wert.
      Ob das mit der Übernahme des Bitcoin Wertes zusammenhängt ?
      Die Vermutung liegt nahe. Anderst ist das fundamental nicht erklärbar.


      4 Antworten
      Avatar
      schrieb am 20.03.18 09:23:01
      Beitrag Nr. 319 ()
      Antwort auf Beitrag Nr.: 57.326.363 von urpferdchen am 20.03.18 08:52:33Ich glaube, die haben einfach zu viel von dem Zeugs geraucht.

      Deshalb kann der Kurs an einem Tag auch mal 100% steigen.

      DARAUF warte ich gerne.
      3 Antworten
      Avatar
      schrieb am 20.03.18 10:05:10
      Beitrag Nr. 320 ()
      Antwort auf Beitrag Nr.: 57.326.744 von teresas am 20.03.18 09:23:01Das letzte mal stieg es nach dem Ausverkauf an 1 Tag um 200 % plus nach oben. bei Abattis.
      Da muss nur die passende Meldung kommen. z.B. was ist mit der Testanlage die 500 kg am Tag
      an Cannabis verarbeiten kann. lt. Meldung vom 13.12. - könnte das der Fall sein, sobald es was zum
      ernten gibt in den Treibhäusern - im Kanada Frühling.

      Und die Ergebnisse des letzten Quartals - fehlt auch noch - und die der Übernahmen.

      Canopy macht den steigenden Trend vor - als einer der 3 - Cannabis-Leithammel.
      mit 300 % plus im letzten halben Jahr.
      2 Antworten
      Avatar
      schrieb am 20.03.18 14:39:22
      Beitrag Nr. 321 ()
      Antwort auf Beitrag Nr.: 57.327.248 von urpferdchen am 20.03.18 10:05:10schon plus 10%

      kommen heute die 100 % ??
      1 Antwort
      Avatar
      schrieb am 20.03.18 14:53:59
      Beitrag Nr. 322 ()
      Antwort auf Beitrag Nr.: 57.330.716 von teresas am 20.03.18 14:39:22mal die ersten Stunden abwarten - so haben die schon öfters stark angefangen und dann stark nachgelassen.

      im Moment um 14 Uhr 50 bei 0,18 € - 0,19 - mit 6 % im plus -

      Gut wäre erst mal die Trendwende über 0,18 € bis Schlußkurs - schön wären die 0,19 € paari
      Avatar
      schrieb am 20.03.18 15:17:23
      Beitrag Nr. 323 ()
      Comdirect - diese Knalltüten :( - zeigen erste Kurse bei 0,30 Can $ an - reines Wunschdenken.
      Der erste Umsatz war bei 0,23 € - und in dem Bereich ist er auch um 15 Uhr 15 -

      Nur zur Zwischen-Info- noch kein Schlußkurs.

      und der nächste Widerstand 0,24 - 0,25 Can. $ -
      Das wäre schön, wenn es diese Woche darüber geht.


      3 Antworten
      Avatar
      schrieb am 20.03.18 18:32:06
      Beitrag Nr. 324 ()
      Antwort auf Beitrag Nr.: 57.331.274 von urpferdchen am 20.03.18 15:17:23um 18 Uhr 30 - Kurs mit 9 % im plus bei 0,234 US $ - paari 0,191 €

      In den ersten 15 Minuten wurden für 2 Mio. Aktien bei Abattis gehandelt - und die 0,30 Can. $ waren
      da auch dabei mit einigen Stück.
      Ein Ausbruch die nächste Woche über die 0,30 US-$ - würde ein starkes Kaufsignal nach oben geben.

      Schön wäre der Schlußkurs über 0,19 € - als Wendesignal -
      2 Antworten
      Avatar
      schrieb am 21.03.18 08:49:04
      Beitrag Nr. 325 ()
      Antwort auf Beitrag Nr.: 57.334.019 von urpferdchen am 20.03.18 18:32:0612% plus, reger Handel.
      Angesichts der zu erwartenden Berichte eine gute Vorgabe.
      1 Antwort
      Avatar
      schrieb am 21.03.18 08:55:07
      Beitrag Nr. 326 ()
      Antwort auf Beitrag Nr.: 57.338.171 von teresas am 21.03.18 08:49:04Das sieht gut aus für Abattis - mit Wendesignal nach oben.
      Wenn es evtl. die nächste Woche über die 0,30 US $ geht - dann ist eine Rally nach oben zu erwarten.
      -charttechnisch- und -Fundamental.
      Da fast jede Woche von Abattis eine Meldung kommt, könnte es im Laufe der nächsten Woche los gehen.

      Avatar
      schrieb am 02.04.18 17:21:07
      Beitrag Nr. 327 ()
      hi,
      ABATTIS...............16% weniger wert heute OTC...................stehen laut Meinung eines Users von Reditt kurz vor einem Aus.................
      der Chart spricht Bände...................
      M.
      1 Antwort
      Avatar
      schrieb am 05.04.18 18:33:17
      Beitrag Nr. 328 ()
      Antwort auf Beitrag Nr.: 57.443.588 von manffreddoo am 02.04.18 17:21:07Abattis - nach brutalem Abverkauf mit 50 % Verlust seit der Finanzierung vor 1 Woche mit 5 Mio. US $ bei ca.0,24 $
      gestern das Absolute Tief bei 0,118 US - $
      heute bis 18 UHR 30 bei 0,165 US $ - Tradegate zeigt 0,132 zu 0,14 €
      Um den Finanzierungslevel zu erreichen muss es um 100 % steigen auf die 0,24 US $.
      Der Umsatz ist heute sehr hoch.
      Über 0,18 $ wäre es der -charttechnische Ausbruch aus dem fallenden Trend.

      NOCH kein Schlußkurs.


      Avatar
      schrieb am 17.04.18 11:09:47
      Beitrag Nr. 329 ()
      Es sieht so aus, als ob Abattis mit den anderen Cannabiswerten nach oben läuft -
      mal sehen ob demnächst noch gute Meldungen kommen, die den Kurs nach oben treiben
      mit den anderen Cannabiswerten.
      Nach der Freigabe des Cannabis in den USA und ab 1.7. in Kanada - könnten die Cannabiswerte
      bis Herbst - Dez. weiter nach oben laufen. -

      2 Antworten
      Avatar
      schrieb am 17.04.18 11:43:27
      Beitrag Nr. 330 ()
      Antwort auf Beitrag Nr.: 57.561.594 von urpferdchen am 17.04.18 11:09:47Nach Deiner 3-Linien-Theorie müsste Abattis demnächst nach oben schiessen.....
      100% bis 0,38 USD ist das mindeste ;)
      1 Antwort
      Avatar
      schrieb am 17.04.18 13:02:24
      Beitrag Nr. 331 ()
      Antwort auf Beitrag Nr.: 57.561.960 von teresas am 17.04.18 11:43:27Das sind nur die vorherigen Unterstützungen bei 0,24 und 0,37 US $ - und jetzt sind es die Widerstände
      beim Anstieg.
      Der fallende Trend ist überwunden - Gut ist, daß Abattis mit dem Cannabis-Markt mit steigt.
      Es kommt darauf an, was Abattis in den nächsten Wochen meldet an Zahlen usw.
      Avatar
      schrieb am 19.04.18 08:57:13
      Beitrag Nr. 332 ()
      gestern mit der Meldung - bei Abattis - Kurs fast gleich wie zum Vortag bei 0,181 US $ = 0,146 € paari

      http://www.finanznachrichten.de/nachrichten-2018-04/43564051…
      Avatar
      schrieb am 08.05.18 16:06:11
      Beitrag Nr. 333 ()
      Am 8. Mai - ist der Kurs bei Abattis zum Handelsbeginn mit 4 - 5 % im plus bei 0,18 US $ - bei Tradegate
      bei 0,146 zu 0,153 -
      Gestern auch schon 4 - 5 % plus -

      mal sehen ob es bis Schlußkurs im plus bleibt - und der Plus - Trend anhält.
      2 Antworten
      Avatar
      schrieb am 08.05.18 16:11:50
      Beitrag Nr. 334 ()
      Antwort auf Beitrag Nr.: 57.718.342 von urpferdchen am 08.05.18 16:06:11Link für Kanada:

      https://ih.advfn.com/stock-market/CNSX/ATT/chart
      1 Antwort
      Avatar
      schrieb am 08.05.18 16:19:15
      Beitrag Nr. 335 ()
      Antwort auf Beitrag Nr.: 57.718.405 von teresas am 08.05.18 16:11:50Bei den -www.finanznachrichten.de - kommt die Meldung 3 mal - das ganze ist aufgeschoben - die
      nächste Runde am 15. Juni. - Dann wird sich bis 15. Juni nicht viel am Katanga Kurs ändern.
      Ob es dann entschieden wird ?

      einen Teil übersetzt -

      --------
      Die erste Anhörung der Oberste Gerichtshof ist am 15. Juni 2018 geplant.

      Das Unternehmen ist weiterhin entschlossen, eine einvernehmliche Lösung der Streitigkeiten mit Gécamines und hofft, wird die Partnerschaft zwischen KCC und Gécamines beleben und erhebliche Vorteile mit sich bringen. Zu Gécamines und alle Akteure in der Demokratischen Republik Kongo zu finden.
      Avatar
      schrieb am 22.05.18 13:51:27
      Beitrag Nr. 336 ()
      Abattis Bioceutica­ls kündigt die Einführung­ einer neuen Linie von Verdampfer­n an.
      VANCOUVER,­ British Columbia, 22. Mai 2018 (GLOBE NEWSWIRE) - Abattis Bioceutica­ls Corp. (das "Unternehm­en" oder "Abattis")­ (CSE: ATT) (OTC: ATTBF) freut sich, die Einführung­ von drei neuen Vaporizern­ bekannt zu geben seine Produktlin­ie. Seit der Übernahme von Green Tree Therapeuti­cs ("Green Tree") durch das Unternehme­n in diesem Jahr hat Abattis daran gearbeitet­, seine Einzelhand­elspräsenz­ und Produktpal­ette zu erweitern und ist nun bereit, seine ersten drei Vaporizer,­ VB-1, VB-2 und der KB-1.
      Abattis Bioceutica­ls Corp.
      Bild 1


      Abattis Bioceutica­ls Corp.
      Bild 2


      Abattis Bioceutica­ls Corp.
      Bild 3


      Abattis Bioceutica­ls Corp.
      Bild 4


      Die "VB-1" ist mit einem 280mAh Akku ausgestatt­et und feuert automatisc­h, indem sie ihre Batterie basierend auf dem Luftstrom aktiviert.­ Das Gerät verfügt über ein ultra-schl­ankes und dezentes Design und eine Arbeitsspa­nnung von 3,3V bis 4,2V. Der VB-1 enthält einen universell­en USB-Anschl­uss, der das Wiederaufl­aden erleichter­t.

      Die "VB-2" verwendet eine kompakte 350mAh-Bat­terie mit variabler Spannung, die mit integriert­en Schutzfunk­tionen gegen Kurzschlus­s und Überhitzun­g ausgestatt­et ist. Sie verfügt über eine herkömmlic­he Vorheizfun­ktion, die der Benutzer mit nur zwei Mausklicks­ aktiviert.­ Das Gerät verwendet Arbeitsspa­nnungen von 3,4 V, 3,7 V und 4,0 V und enthält einen USB-Anschl­uss zum Aufladen.

      Fotos zu dieser Ankündigun­g finden Sie unter
      http://www­.globenews­wire.com/N­ewsRoom/..­.-e7c5-4f9­8-8b22-f1a­5f12f5c55

      http://www­.globenews­wire.com/N­ewsRoom/..­.-c0a7-47e­a-a8fd-a81­57b8a1d82

      Der "KB-1" ist mit einem innovative­n Akku ausgestatt­et, der wie ein Luxusauto aussieht und ideal für diejenigen­ ist, die auf der Suche nach einem diskreten Gerät oder unterwegs sind. Das hochmodern­e Gerät verfügt über eine 510-Gewind­e-Verbindu­ng, die für Hausinstal­lationen geschlosse­n werden kann und über ein integriert­es USB-Ladeka­bel, einen langlebige­n integriert­en 350-mAh-Li­thium-Ione­n-Akku, einen Schlüssela­nhänger und eine LED-Leucht­anzeige verfügt. Das Gerät unterstütz­t die meisten Anhängeger­äte bis 1,2 Ohm und arbeitet mit 3,7 V.

      Fotos zu dieser Ankündigun­g finden Sie unter
      http://www­.globenews­wire.com/N­ewsRoom/..­.-c52e-435­4-9965-11b­f0f62cd33

      http://www­.globenews­wire.com/N­ewsRoom/..­.-235c-4d7­9-a950-669­4e37c12d6

      "Wir glauben, dass die Zukunft des Cannabis-V­aporizer-M­arktes in Branding, Konzentrat­en und Zusatzprod­ukten liegt", erklärte Rob Abenante, President und CEO von Abattis. "Die Nutzer in den Verkaufsrä­umen suchen nach funktional­en, diskreten und langlebige­n Produkten und wir sind der Meinung, dass unsere neue, kitzelnde Produktlin­ie all diese Anforderun­gen erfüllen wird. Wir freuen uns darauf, einen weiteren Schritt in Richtung unseres Ziels zu machen, ein Komplettan­bieter von Downstream­-Cannabis-­Lösungen zu werden ", fügte Herr Abenante hinzu.

      Über Abattis Bioceutica­ls Corp.

      Abattis ist ein Biowissens­chafts- und Biotechnol­ogieuntern­ehmen, das Cannabiste­chnologien­ und Biotechnol­ogiedienst­leistungen­ für die legale Cannabisin­dustrie, die sich in Kanada entwickelt­, aggregiert­, integriert­ und investiert­. Das Unternehme­n hat erfolgreic­h natürliche­ Gesundheit­sprodukte,­ Medikament­e, Extraktion­en und Inhaltssto­ffe für den biologisch­en, nutrazeuti­schen, bioceutisc­hen und kosmetisch­en Markt entwickelt­ und lizenziert­. Das Unternehme­n versucht auch, exklusive Rechte an geistigem Eigentum für landwirtsc­haftliche Technologi­en zu erwerben, die bei der Extraktion­ und Verarbeitu­ng von botanische­n Inhaltssto­ffen und Verbindung­en eingesetzt­ werden.
      Im Namen des Vorstandes­ von
      ABATTIS BIOCEUTICA­LS CORP.,
      "Rob Abenante"
      Robert Abenante, Präsident und CEO
      https://we­b.tmxmoney­.com/...d=­7580535761­086533&qm_sym­bol=ATTBF:­US
      1 Antwort
      Avatar
      schrieb am 22.05.18 18:56:44
      Beitrag Nr. 337 ()
      Antwort auf Beitrag Nr.: 57.807.221 von Hanfblatt am 22.05.18 13:51:27der link klappt zu den Abbildungen

      http://www.globenewswire.com/news-release/2018/05/22/1509844…
      Avatar
      schrieb am 23.05.18 18:53:27
      Beitrag Nr. 338 ()
      Nutritiona­l High erweitert die Infrastruk­tur von Calyx in Südkalifor­nien durch den Kauf einer Long Beach Distributi­on Facility.
      TORONTO, 22. Mai 2018 (GLOBE NEWSWIRE) - Nutritiona­l High Internatio­nal Inc. (CSE: EAT) (OTCQB: SPLIF) (FRANKFURT­: 2NU) freut sich, die Erweiterun­g von Die Präsenz von Calyx Brands, Inc. ("Calyx") in Südkalifor­nien durch den Kauf einer Liegenscha­ft in Long Beach (die "Einrichtu­ng"). Die Einrichtun­g wird als Vertriebsk­notenpunkt­ für die Tochterges­ellschaft Calyx in Südkalifor­nien genutzt.

      Die Einrichtun­g ist ein 7.000 Quadratfuß­ großes Gebäude, von dem 3.000 an eine Cannabis-T­estanlage vermietet werden, wobei der Rest von Calyx genutzt wird. Die Fazilität erfüllt die aktuellen lokalen und staatliche­n Vorschrift­en zur Cannabisli­zenzierung­ vollständi­g und das Management­ des Unternehme­ns erwartet daher einen beschleuni­gten Lizenzieru­ngsprozess­.

      Die Einkaufsbe­dingungen lauten wie folgt (alle Angaben in USD $):

      Gesam­tkaufpreis­ von 1.900.000 $;
      $ 250.000 Barzahlung­ bei Abschluss bezahlt werden;
      $ 801.000 in 3 gleichen Raten von $ 267.000 zu zahlen, zahlbar 6 Monate, 12 Monate und 18 Monate ab dem Closing;
      Der Restbetrag­ des Kaufpreise­s in Höhe von 800.000 USD, der vom derzeitige­n Eigentümer­ der Fazilität mit einer jährlichen­ Rate von 4% in Form eines Schuldsche­ins mit Fälligkeit­ am oder vor dem 1. Juni 2021 zu tragen ist. In Anbetracht­ des Schuldsche­ins wird die Gesellscha­ft monatlich leisten Zahlungen in Höhe von 23.619,19 US-Dollar,­ die durch monatliche­ Leasingzah­lungen in Höhe von 13.000 US-Dollar ausgeglich­en werden, die das Unternehme­n durch die Mieter-Can­nabis-Test­einrichtun­g erhält, was zu einer Nettozahlu­ngsbelastu­ng von 10.619,19 US-Dollar pro Monat führt.

      Jim Frazier, CEO von Nutritiona­l High, kommentier­te: "Wir freuen uns sehr, unsere erweiterte­ Infrastruk­tur in Südkalifor­nien ankündigen­ zu können, um das Wachstum der Vertriebsk­apazitäten­ von Calyx in diesem hochwertig­en Markt zu unterstütz­en. Indem wir unseren Shareholde­r Value weiter ausbauen Die Chancen stehen eindeutig im Einklang mit unserer Vision, aggressiv Marktantei­le zu erobern und die Grundlage dafür zu schaffen, ein bedeutende­s Stück des kalifornis­chen Cannabisma­rktes zu kontrollie­ren. "

      Dakota Sullivan, CEO von Calyx, fügte hinzu: "Diese zusätzlich­e Infrastruk­tur wird es Calyx ermögliche­n, unseren Fußabdruck­ in Südkalifor­nien weiter zu erhöhen, da sich der Markt aufgrund der fortgesetz­ten staatliche­n Regulierun­gstätigkei­ten schnell ändert Wir werden unsere aggressive­n Expansions­bestrebung­en fortsetzen­, um Marktantei­le zu gewinnen. "
      https://we­b.tmxmoney­.com/...d=­6468394088­079780&qm_sym­bol=SPLIF:­US
      Avatar
      schrieb am 23.05.18 18:55:08
      Beitrag Nr. 339 ()
      Falscher Chat, wie kann man einen Beitrag löschen?
      Avatar
      schrieb am 25.05.18 07:39:17
      Beitrag Nr. 340 ()
      News von gestern:

      WINSTON RESOURCES VERÖFFENTLICHT GEMEINSAME ANTEILE VON ABATTIS BIOCEUTICALS AN WINSTON RESOURCES-AKTIONÄRE
      Nach einer früheren Pressemitteilung beabsichtigt Winston Resources Inc., seine 15 Millionen Stammaktien von Abattis Bioceuticals Corp. anteilig an die Inhaber von Stammaktien von Winston, die am 23. Januar 2018 eingetragen sind, zu verteilen. Die Abattis-Aktien unterliegen einer Haltefrist bis zum 25. Mai 2018.
      Winston erwarb die Abbatis-Aktien gemäß den Bedingungen eines Abtretungsvertrags vom 10. Januar 2018 (der "Abtretungsvereinbarung") zwischen Winston und Abbatis im Zusammenhang mit dem Erwerb der GT Therapeutics Corporation, dba Green Tree Therapeutics ("GTT"). Im Zusammenhang mit dem Abschluss der Übernahme von GTT durch Abattis am 25. Januar 2018 wurden der Gesellschaft die Abattis-Aktien ausgegeben.
      Nach reiflicher Überlegung hat der Board of Directors von Winston (der "Board") der vorgeschlagenen Distribution zugestimmt und ist der Ansicht, dass die vorgeschlagene Distribution den Winston-Aktionären zwei separate Investments bieten wird und den Winston-Aktionären somit eine Investitionsflexibilität bieten wird Interesse an zwei Unternehmen, die sich jeweils auf unterschiedliche Ziele konzentrieren. Dies ermöglicht den Winston-Aktionären gezielte Investitionsentscheidungen für jede Art von Anlage zu treffen.
      Die in dieser Pressemitteilung enthaltenen Informationen sind nicht als Rechts-, Geschäfts- oder Steuerberatung für einen bestimmten Winston-Aktionär oder eine andere Person auszulegen und sollten auch nicht als solche ausgelegt werden, und in dieser Pressemitteilung wird in Bezug auf den Datenschutz keine Erklärung abgegeben Steuerfolgen für einen bestimmten Winston-Aktionär oder eine andere Person. Winston-Aktionäre sollten sich mit ihren eigenen Steuerberatern hinsichtlich der steuerlichen Konsequenzen der vorgeschlagenen Verteilung unter Berücksichtigung ihrer besonderen Umstände beraten.
      Avatar
      schrieb am 07.06.18 08:51:16
      Beitrag Nr. 341 ()
      Gestern schönes Plus - evtl. die Trendwende mit den anderen Canabiswerten -
      nach dem starken Abverkauf bei Abattis
      Wichtig wäre der Anstieg über die 0,18 Can. $ - charttechnisch-

      Evtl. läuft es ähnlich wie im Dezember mit den anderen nach oben.


      1 Antwort
      Avatar
      schrieb am 07.06.18 08:58:16
      Beitrag Nr. 342 ()
      Antwort auf Beitrag Nr.: 57.928.380 von urpferdchen am 07.06.18 08:51:16Die 0,18 CAN wurden schon geschafft, Du meinst sicherlich die 0,18 USD

      Die müssten bei positivem Bescheid in CAN heute drin sein.

      Von der WHO bzgl. Freigabe konnte ich bis jetzt nichts finden.
      Avatar
      schrieb am 29.06.18 17:14:45
      Beitrag Nr. 343 ()
      Stehen hier in naher Zukunft News an? Andernfalls rechne ich mit fallenden Kursen.
      Avatar
      schrieb am 12.07.18 07:23:07
      Beitrag Nr. 344 ()
      Der Kurs bei 0,10 $ - die Fianzierung bei 0,17 $ - die trauen dem Laden was zu
      der gnze Text bei www.finanznachrichten.de
      -------------------

      ABATTIS PROVIDES CORPORATE UPDATES

      Abattis Bioceuticals Corp. has provided the following corporate updates.

      Completion of private placement

      Abattis Bioceuticals has completed a non-brokered private placement for gross proceeds of $2.25-million through the issuance of 13,235,294 common shares of the company at 17 cents per share. The company anticipates that the proceeds will be used to organically grow its existing downstream service division and for general working capital purposes.
      ------------------
      2 Antworten
      Avatar
      schrieb am 12.07.18 08:23:18
      Beitrag Nr. 345 ()
      Antwort auf Beitrag Nr.: 58.193.168 von urpferdchen am 12.07.18 07:23:07Habe jetzt von flatex einen Brief erhalten mit einer 5-seitigen Liste der bald nicht mehr handelbaren Cannabis-Aktien. Darunter auch Abattis.
      Flatex versucht eine Lösung zu finden. Sie weisen aber auch darauf hin, dass „....die Wertpapiere möglicherweise in absehbarer Zeit nicht mehr handelbar sind. Deshalb ersuchen wir Sie, auch eigenständige Überlegungen bezüglich einer möglichen Verwertung bzw. Ausbuchung vorzunehmen.“

      Werde den Rest entsorgen.
      1 Antwort
      Avatar
      schrieb am 12.07.18 09:07:04
      Beitrag Nr. 346 ()
      Antwort auf Beitrag Nr.: 58.193.621 von teresas am 12.07.18 08:23:18Der Handel geht noch bis Ende September - bis dahin finden die eine Lösung -
      Die Deutsche Börse die den Mist verzapft - kommt sowieso unter Druck,wegen überhöhter Gebühren. - das sollte man bei der BAFIN melden -

      Nach der Unsinns-Logig wäre der bisherige Handel demnach illegal - was hat eine Aktie mit dem
      dem Handel von Rauschgift zu tun ? - GAR NIX.

      Evtl. kommt Abattis auch noch in den Bereich der Fiananzierung bei 0,17 $ -
      oder sind das Canadische $ ?
      Avatar
      schrieb am 18.07.18 09:56:54
      Beitrag Nr. 347 ()
      oh weh
      Mein Invest in Abattis war vermutlich eine Fehlentscheidung, allerdings ist die Frage, ob es zumindest nochmals kurz eine Erholung gibt. Wenn man das nur wüsste...

      Seid ihr noch dabei oder schon raus aus diesem Titel?
      1 Antwort
      Avatar
      schrieb am 20.07.18 03:23:29
      Beitrag Nr. 348 ()
      Antwort auf Beitrag Nr.: 58.240.272 von liquidx am 18.07.18 09:56:54Abattis nicht betroffen von der Handelsaussetzung. :cool: https://www.wallstreet-online.de/nachricht/10731984-breaking…. Scheint aber trotzdem ein Fehlinvestment zu bleiben. 😤
      Avatar
      schrieb am 23.07.18 17:09:43
      Beitrag Nr. 349 ()
      Beim nächsten Anstieg, sofern es einen geben wird, bin ich raus hier.
      1 Antwort
      Avatar
      schrieb am 01.08.18 09:52:22
      Beitrag Nr. 350 ()
      Antwort auf Beitrag Nr.: 58.279.793 von liquidx am 23.07.18 17:09:43
      in Hamburg sagt man Tschüüss
      ... dann mal schnell raus :-)
      Avatar
      schrieb am 01.08.18 20:51:47
      Beitrag Nr. 351 ()
      Bin heute raus in der Tat :)
      Avatar
      schrieb am 05.08.18 12:29:08
      Beitrag Nr. 352 ()
      Die Zeit der steigenden positiven Bekiffungen sollen jetzt dann kommen. https://www.stockwatch.com/News/Item.aspx?bid=Z-C:ATT-263970…. Bleibe mal noch dabei :cool:
      Avatar
      schrieb am 10.09.18 13:10:24
      Beitrag Nr. 353 ()
      Abattis - ATT / ATTBF ist Betrug – Aussteigen solange es noch möglich ist
      :eek: :eek: :eek: 18 MILLIONEN DOLLAR für Management- und Berater-Gehälter in 9 Monaten !!! :eek: :eek: :eek:

      2,7 MILLIONEN DOLLAR für Marketing :laugh: :laugh: :laugh:

      :laugh: :laugh: :laugh: und in den letzten 9 Monate NUR 5000,-- Dollar Umsatz !!! :laugh: :laugh: :laugh:



      Diese Firma betrügt vorsätzlich die Anleger die ihnen vertrauen!
      Raus solange es geht!


      Quelle: https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo…
      2 Antworten
      Avatar
      schrieb am 15.09.18 12:29:04
      Beitrag Nr. 354 ()
      Antwort auf Beitrag Nr.: 58.660.323 von webmimi am 10.09.18 13:10:24 Hi,
      JAAAAAA, das ist schon seit längerem bekannt dass hinter ABATTIS eine "operative Luftnummer" steckt deren Geschäftsmodell aus Pump and Dump besteht.......Wollte es vor Monaten auch nicht glauben.........diese Form der Realitätsverweigerung hat mich nicht das ganze Invest, aber einen Dausender gekostet................. Vieleicht hilft dein Post einigendie Augen zu öffnen..........Danke
      M.
      1 Antwort
      Avatar
      schrieb am 16.09.18 01:32:17
      Beitrag Nr. 355 ()
      Antwort auf Beitrag Nr.: 58.707.240 von manffreddoo am 15.09.18 12:29:04
      Abattis Bioceuticals die große Abzocke und Luftnummer
      Hi manffreddoo, mir geht es ähnlich wie Dir. Ich habe vor allem viel Zeit – und durch das gebundene Kapital wohl auch Geld? – verloren. Von den sichtbaren Zahlen her bin ich bereits Anfang des Jahres mehr oder weniger glatt aus dieser Nummer heraus gekommen.
      Man lernt nie aus :look:

      Es grüßt die webmimi


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      Abattis Bioceuticals -- warum nicht